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Synthesis of azatriquinacene Abstract 
Abstract 
" Azatriquinacene (10-Azatricyclo[5.2.1.0"10]deca-2,5,8-triene) and azatriquinadiene 
(10-Azatricyclo[5.2.1.01"0]deca-2,8-diene) have been synthesised in respectively eight 
and seven steps from pyrrole. 27 Woodward dimerisation4 of azatriquinacene has been 
attempted although no evidence of diazadodecahedrane has yet been found. 
"A unique nonacyclic species (10-Azatricyclo[5.2.1.0''10]-2,9-bis[1-azatricyclo 
[5.2.1.01'10]decane]dec-l-ene) has been obtained by trimerisation of an enamine. 19 Its 
structure and extraordinarily high basicity (pKa 25.1) make it a new class of "proton 
sponge". 
" During this study thirteen new substituted azatriquinanes and four new substituted 
azabicycles have been synthesised, and nine crystal structures have been solved, 
providing valuable insights into the chemistry and structure of this novel heterocyclic 
system. 
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1. Introduction 
1.1 Dodecahedrane 
A great deal of effort has been focused on the synthesis of dodecahedrane 1 during the 
past three decades' due to its symmetric and beautiful structure. It comprises 12 five- 
membered rings, formed from 20 identical spa-hybridised carbon atoms with ideal 
tetrahedral character, generating an impressive level of symmetry (Ih). 
Y 
I 
The possibility of including an atom or ion inside the dodecahedrane cavity has been 
investigated computationally2 and it has been proposed that this process is 
energetically unfavourable except perhaps in the case of Bee+. 3 
1.2 Retrosynthetic analysis of dodecahedrane construction 
Many ways exist in principle to plan a dodecahedrane total synthesis, and the number 
of potential functional groups that could be used is very large. It is important to know 
in this synthesis that every new carbon incorporated into the structure has the 
hydrogen atom specifically situated at the molecular exterior. 
Scheme 1 illustrates three possible routes to 1 in which the white circles represent the 
sites where functionality is necessary, while the black circles indicate the location of 
complementary functional groups. For a triquinane structure, such as 2, the second 
structural component is an identical tricyclic Clo molecule and in this case it is very 
important to analyse the steric and entropic factors, due to the congested approach 
between the two triquinane units. 
1 
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Scheme 1 
1.3 Dimerisation schemes 
--ý 
-, 
A photochemical [2+2+2+2+2+2]n cycloaddition reaction is a theoretically allowed 
process. Woodward synthesised triquinacene 3, a tricyclic hydrocarbon CIOH1o, with 
the aim of dimerising it to form dodecahedrane 1. This strategy, developed 
independently by both Woodward4 and Jacobson more than 30 years ago, remains to 
be realised (Scheme 2). The overall process is expected to be exothermic (OH= -97 
kcalmol) as a result of the formation of six C-C a bonds and loss of six C-C it bonds. 
However, this cycloaddition has not been achieved thermally, photochemically, by 
means of transition-metal catalysis or using high pressure. 
2Gj 
3 
Scheme 2 
ýýýýý- 1 
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Although triquinacene 3 has been shown to react with Mo(CO)6 to give 4 and with 
(CH3CN)3W(CO)3 to give the tricarbonyl tungsten analogue, 6 the small size of the 
dodecahedrane cavity prevents the dimerisation of such molecules. 
4 
In a different approach to the synthesis of a dodecahedrane, Serratosa prepared the 
known C3-triketone 6 in an enantioselective manner starting from the optically pure 
lactone 5 (Scheme 3) 7 This achievement represented the first assignment of the 
absolute configuration of an optically active triquinacene. In the dimerisation of 
triketone 6, three regioselective aldol condensations have to occur, however the 
reaction did not give dodecahedrane 7 due to the multiple condensation possibilities. 
5 
00 
s 
Scheme 3 
7 
Scheme 4 shows another strategy for the synthesis of 1 using the triquinane dimer 8. In 
this case, the idea was to try a dehydrogenative closure of 8, but it has not succeeded, 
perhaps because the conformation 8' is strongly favoured (as shown by X-ray 
analysis). 8 
3 
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Scheme 4 
To avoid the problem mentioned above a triquinane dimer 12 was synthesised with the 
appropriate reactive conformation. Deslongchamps et a!. 9 prepared (+)-triquinacene-2- 
carboxylic acid 9 which was transformed into the (+)-2-formamido derivative 10. 
Condensation of 10 with the acid chloride of (+)-9 gave the secondary amide 11 which 
was converted into the cyclic imidate salt 12. However cyclisation of 12 to the 
dodecahedrane 13 was not successful (Scheme 5). 
COON NHCHO 
9 10 
11 
v 
BFq 
/\O 
r-n 0 
12 13 
Scheme 5 
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Coupling of dibromide 14 with dimercaptan 15 gave a mixture of the anti- and syn- 
triquinacenophanes 16 and 17. These isomers were separated chromatographically and 
their identities established by X-ray crystal structure. Although cyclisation of a 
molecule such as 16 appears possible on the basis of molecular modelling, again this 
process has not been observed (Scheme 6). b0 
BrH2C 
\ CH2Br 
--" 
HSH2C CH2SH 
14 15 
16 17 
Scheme 6 
Jayaraman et All have also attempted the synthesis of dodecahedrane 1 by 
dimerisation of triquinacene 3 under high pressure. Triquinacene 3 is a liquid at room 
temperature but freezes to a clear crystalline solid at about 18°C. The molecules in the 
crystal are positioned in layers perpendicular to the c-axis, and contacts between 
molecules are top-to-top (convex faces) and bottom-to-bottom (concave faces) in 
alternate layers (Figure 1). The idea was that by the application of high pressure to a 
triquinacene crystal the two molecules could move the small distance required for 
proper overlap. However, compression of triquinacene to nearly 20 GPa in a diamond 
5 
Synthesis of azatriquinacene Introduction 
cell and exposure to 248 nm and 308 nm ultraviolet radiation at 5 GPa failed to 
produce any detectable dodecahedrane 1. 
Figure 1 
Dodecahedrane 1 was synthesised by Paquette et a1.12 in 1982 in 23 steps, but a direct 
synthesis from triquinacene has not as yet been realised. The key steps of the synthesis 
of dodecahedrane 1 are presented in Scheme 7. 
C 
18 
i) Li, NH3 
PhOCH2C 
Pd(C) 
A 
19 
h i) by ii) TsOH 
iii) HN=NH 
iv) Dibal-H 
v) PCC 
i) KOH 
ii) by 
iii) TsOH 
iv) H2NNH2, 
H202 
h 
20 i) by 
ii) Li, NH3 
iii) H3O+ 
iv) PCC 
1 22 21 
Scheme 7 
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1.4 Synthesis of azatriquinane: an approach to the synthesis of azatriquinacene 
It could be possible to use, in all the strategies mentioned above, triquinane analogues 
such as azatriquinanes. The parent compound, azatriquinane 28 was prepared by 
Mascal and coworkers in 1996.13 This synthesis, presented in Scheme 8, also provides 
an approach to the synthesis of azatriquinacene 29. 
H 
Me02 C02Me 
23 
º McO2Cýýý,,... N 
84% H 
25 
H H2 Me02C, 
-, 
"//,,,.. N0 
, 
C02Me 
Rh/A1203 
88% 24 
Base Hs 
HH 70% 
L 26 
OH H 
LAH 
N 
--, 
N 
HH 
97% 
HH 
27 28 
Scheme 8. Synthesis of azatriquinane. 
1.5 Aims and objectives 
The main target of this project is the synthesis of azatriquinacene 29, which is a 
potential precursor to 1,16-diazadodecahedrane 30. If triene 29 could be prepared the 
Woodward dimerisation strategy could be re-examined (Scheme 9). 
2/N\ 
---ý 
29 
f N(fr 
30 
Scheme 9 
7 
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There are two main differences between 3 and 29 which could favour the dimerisation 
of the aza-analogue 29: 
(i) The aza-analogue 29 would be expected to possess some aqueous solubility, 
particularly as the hydrochloride. When substances with non-polar regions are 
dissolved in water, they tend to associate so as to diminish the hydrocarbon-water 
interfacial area. Thus, by attempting the dimerisation of the aza-analogue 29 in 
aqueous solution it may adopt the "reactive conformation" in which the concave endo 
faces of two molecules are in close contact. A similar phenomenon has already been 
described for [4+2] cycloaddition reactions, where substantial acceleration of 
cycloaddition rates in aqueous verses organic media were observed. '4 
(ii) There is a possibility that the incorporation of either an amine or quaternary 
ammonium centre, could favourably affect the electronic properties of the triquinane 
relative to 3 and facilitate dimerisation. 
8 
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2. Results and discussion 
2.1 Enamine 26 reactivity: a key compound in this study 
With the synthesis of azatriquinane 28 in hand, a possible route to azatriquinacene 29 
based on a substitution-elimination strategy was proposed as presented in the 
following scheme: 
HH 
Me02C N CO2Me H2 Me02C,,,,, 
-/,,,,.. N C02Me 
X 
"IX 
31 
McO2Cý/'ý,,,.. N+ 
33 34 
32 
Me Base 
e 
yyyy 
+2Y+ N+N 
_ý N+N 
HHHHHHHH 
. IX "X ,X ýX 
35 36 37 38 
HH 
-2H N+NN -HX N 
HHHHHHH_H 
?X 
39 40 41 29 
Scheme 10 
This synthesis starts with pyrroles in which the 3-substituent could be eliminated to 
give the bottom double bond. Up to the formation of the enamines 35 and 36 this 
synthesis is analogous to that of azatriquinane itself (Scheme 8). The two top double 
9 
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bonds could be introduced by disubstitution of the azatricycles 35 and 36, bis- 
elimination and isomerisation. 
For the purpose of the disubstitution of the double bond in 35 and 36, model reactions 
involving 26 were studied. 
The X-ray crystal structure of azatriquinane13 shows that these molecules have the 
912 expected convex geometry due to the rigid tricyclic structure. Therefore, 
8N 3 the double bond of 26 could be considered part of an enamine or as a 74 
s 
26 
5 bridgehead alkene. Experimentally, it has been observed that the 
nitrogen in crystalline enamines varies from tetrahedral (sp 3 hybridized) to planar (sp 2 
hybridized) geometry. 15 It would be conformationally unfavourable for the nitrogen in 
26 to adopt spe hybridization due to the rigid nature of the tricyclic framework. So it 
was supposed the double bond would behave like a bridgehead alkene rather than an 
enamine. 
Two different reactions were attempted: a dibromination and a dihydroxylation of the 
double bond. The dibromination using N-bromosuccinimide-tetraethylammonium 
bromide16 gave the monobrominated product 42 (Scheme 11) and the dihydroxylation 
reaction was attempted using potassium permanganate and triethylbenzylammonium 
chloride, '7 giving a mixture of starting material and the hemiaminal 27 (Scheme 11). 
In earlier attempts to synthesise 26, vigorous agitation with water during work up gave 
only hemiaminal 27 suggesting that 26 is water sensitive and was partially hydrolysed 
in the work up. Attempts to dehydrate hemiaminal 27 to obtain 26 using aluminum 
trichloride, phosphorus pentoxide, neutral alumina or boron trifluoride etherate's 
failed. Compound 26 is synthesized by a cyclisation/distillation method13 and it was 
possible to avoid the hemiaminal formation by introducing dry ethyl ether and freshly 
10 
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activated powdered 4A molecular sieves in the collection flask to maintain anhydrous 
conditions and eliminating the aqueous work up. 
An attempt to further purify 26 by short path distillation in vacuo gave mostly the 
compound 43 (Scheme 11), 19 the structure and interesting features of which will be 
discussed in detail in Section 2.2. 
Br 
NBS KMnO4 
N4 
Et4NBr 
HNH Et3BnNCI H 
60% 
42 
H 
43 
Scheme 11 
OH 
N+ SM 
HH 
27 
The product obtained in the bromination of 26, its unsuccessful dihydroxylation, its 
hydrolysis to give hemiaminal 27 and the formation of trimer 43 all suggested that this 
compound behaves as an enamine and not as a bridgehead double bond as it was 
assumed at the beginning. The enamine character of 26 is also supported by a 
characteristic high field chemical shift of the olefinic proton in 'H-NMR spectrum 
(4.32 ppm) and the C2 in 13C-NMR spectrum (93.2 ppm). It also shows a characteristic 
strong absortion at 1660 cm'' in the infrared spectrum. 
11 
26 
30% e 
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H 4.32 ppm 
N 
CH3. 
'CH3 N 
H 4.36 ppm 
26 44 
Figure 2. Comparison of the 'H-NMR chemical shift of the vinylic protons in enamine 26 and the 
classical enamine 44. 
A correlation exists between enamine reactivity and 'H-NMR chemical shift: the 
greater the degree of p-n overlap, the greater the electron density at the ß-carbon atom, 
and consequently, the greater the magnetic shielding of the vinylic proton. 15 The 
reactivity of an enamine depends on the degree of substitution at the a- and ß- 
positions. Alkyl substituents at C-a increase the electron density and reactivity at C-ß 
by hyperconjugative and inductive effects, while substitution at C-ß decreases the 
reactivity at this position due to steric and electronic effects. '5 
Figure 3. A) Bond angle values around Cl of 26. B) View of the convex geometry of 26. Structure 
obtained using semiempirical calculations which were performed with the PM3 method implemented in 
Spartan 4.0. 
12 
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In the case of enamine 26, it is substituted at C-a and mono-substituted at C-ß which 
renders it highly reactive. For 26 the chemical shift of the vinylic proton is 4.32 ppm, 
which is a significantly high field shift characteristic of a reactive enamine. For 
example, a classical enamine as 44 has a chemical shift for the vinylic proton of 4.36 
ppm as shown Figure 2. The high reactivity could also be attributed to the location of 
the double bond at a strained bridgehead position in which the bond angles: N-C1-C9, 
N-Cl-C2 and C9-C1-C2 have unusual values (Figure 3). 
If compound 26 is thus considered as an enamine, it is possible to explain the results 
obtained above. Bromoenamine 42 is the result of the bromination of the enamine 26 
with N-bromosuccinimide and the hemiaminal 27 formation is the consequence of 
enamine hydrolysis which does not require the presence of acid due to its high 
reactivity (Scheme 12). The formation of the species 43 is another consequence of the 
enamine character of 26 and the mechanism for its trimerisation will be discussed in 
the next section. 
Brr 
:NO 
10 
26 
HCO'H 
:N 
-»- 
26 
Br Br 
-H + N 
+O 
42 
=OH2 
H OH 
N 
e 
27 
Scheme 12 
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2.2 Trimer 
The solid residue from the enamine 26 after heating was purified by column 
chromatography to afford the nonacyclic structure 43 in 30% isolated yield. 19 Crystals 
of it were grown by diffusion of ether into a dichloromethane solution of 43 and the X- 
ray crystal structure of this compound is shown in Figure 4. 
ON c 
0) 2 
4W 
Figure 4. X-ray crystal structure of 43 (C27H40N3C1 x 4H20). 
-H+ 
-ý 
. 
H+ 
-> 
43 
Scheme 13 
ncN 
ON 
14 
CI' 
N H+ 
26 
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In Scheme 13 is shown a possible mechanism of the trimer 43 formation. The crude 
enamine 26 was contaminated with dichloromethane and the small amount of HCl 
present in this solvent could act as a catalytic proton source. To test this hypothesis, 
the formation of the trimer was attempted with crude enamine 26 which came from an 
ethereal solution. By heating 26 at 140°C no reaction took place until two drops of 
dichloromethane were added. 
The exotic species 43 has three tricycles, three basic centres and an enamine moiety. 
In the crystal structure (Figure 4) the most interesting feature is the conformation of 
the two terminal azatricycles due to an intramolecular hydrogen bond between the 
proton on Ni and the N3. Nitrogens Ni and N3 face each other separated by a distance 
of 2.745 A with a N1-N1H-N3 angle of 177° and this indicates the existence of a 
strong intramolecular hydrogen bond. 
,. 
Figure 5. X-ray structure of 43. 
Another view of the trimer 43 is presented in Figure 5 which shows the hydrogen 
bonds between the nitrogens, chloride ions and water molecules in the crystal. In the 
middle of it is observed an infinite column of hydrogen bonded water molecules. The 
15 
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molecules of 43 are linked to these columns by hydrogen bonds via water molecules 
and chloride ions. 
An attempt was made to abstract the proton on Ni of trimer 43 using the same 
methodology that was successful in the deprotonation of azatriquinane salts (KOH 2 
M). However, the deprotonation was not possible using this base probably due to an 
increase in the pKa of 43 by stabilisation of the protonated form by the high quality 
intramolecular hydrogen bond between the proton on Ni and the N3. This fact makes 
43 a new class of "proton sponge". 
By comparison of the 'H-NMR of the trimer 43 with those of 26 and azatriquinane 28, 
the five signals between 4.12 ppm and 3.44 ppm have been assigned as being the six 
protons a to nitrogen. The Ni proton was successfully abstracted using KHMDS and 
this fact was supported by a characteristic high field shift of the protons a to nitrogen 
in the 'H-NMR spectrum. However, re-protonation by atmospheric water was 
observed suggesting that compound 43 had an extraordinary basicity. 
An investigation of the basicity of 43 was thus undertaken using both chemical and 
computational approaches. The experimental value of the pKa of 43 using 
potentiometric titration in acetonitrile solution, and its protonation energy (DEprot) 
using the HF/6-31G(d)//HF/6-31G(d) theoretical model, were calculated by L. 
Chmurzynski et al. The pKa in acetonitrile was experimentally determined to be 25.1 
which showed that the molecule was in fact highly basic, about seven orders of 
magnitude more than 1,8-bis(dimethylamino)naphthalene ("proton sponge") and 4- 
dimethylaminopyridine (DMAP). This result was supported by the calculation of its 
theoretical pKa value which was 26.0.19 
The extraordinary basicity of 43 is attributed to the relief of lone pair repulsion 
between the nitrogens Ni and N3 in enforced proximity (Figure 6). The establishment 
16 
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of a high quality H-bond on protonation, and the extensive resonance stabilisation of 
the HB+ ion can also be the responsible facts of the high pKa as happens in other 
known proton sponges. ° 
Figure 6. Possible conformation of trimer 43 in the deprotonated state. The semiempirical QM 
calculations were performed with the PM3 method as implemented in Spartan 4.0. 
To investigate the possibility of different conformations of the two terminal tricycles 
of trimer 43, crystallisation experiments using the deprotonated trimer were attempted 
but unfortunately, due to its solubility in apolar solvents it was not possible to grow 
them under similar conditions to those used with the di-protonated trimer. Other 
attempts to grow crystals of 43 were made without success. 
With the idea mentioned above of obtaining a different conformation of trimer 43, a 
protonation reaction was carried out. Due to the positive charges on the Ni and N3 a 
conformation in which the two terminal azatricycles are not facing each other could be 
obtained induced by similar electrostatic effects as in the deprotonated state. 
Therefore, the protonation was attempted treating the trimer with trifluoroacetic acid 
to afford a compound in which a downfield shift of the protons a to nitrogen in the 'H- 
NMR spectrum indicated a possible protonation. Unfortunately, the conformation of 
17 
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this species was not determined because crystals of this compound again could not be 
grown. 
The reduction of the double bond in 43 was attempted with the aim of synthesising the 
saturated trimer 45. Catalytic hydrogenation, 21 sodium borohydride in acid, 22 sodium 
cyanoborohydride in acid23 and formic acid24 were all tried but unfortunately, in all the 
cases starting material was recovered. Catalytic hydrogenation failed, probably due to 
steric considerations. Poor reactivity of the enamine moiety in the trimer due to the 
bulky substituent in the ß-carbon, could be the reason for the resistance to reduction in 
the case of the hydride reactions. 15 
45 46 
An asymmetric structure was formed by hydrolysis with aq HCl to afford the trans- 
trimer-hemiaminal 46 in which the protonation took place on the less sterically 
hindered exo face. The proposed structure is supported by the peak in the mass 
spectrum of 424 and the trans-stereochemistry suggested by the presence of the two 
different multiplets at 3.00 ppm and at 2.88 ppm corresponding to the protons on the 
C2 and C9 of the central azatricycle. 
18 
Synthesis of azatriquinacene Results and discussion 
2.3 Synthesis of azatriquinadiene 
As was seen in the substitution-elimination strategy in Section 2.1, compound 26 
should be considered an enamine. So, it was proposed that it might be possible to 
functionalise the 2- and 9-positions of the azatriquinane system by taking advantage of 
its enamine character. Then, by reduction and bis-elimination, two of the three double 
bonds of azatriquinacene could be introduced. 
The following substitution-elimination strategy was therefore proposed: 
+N... 
2Y+ 
HHHH 
N 
35 36 
YHY 
[H] 
-2HY 
HH 
49 
YYYY 
N+N 
HHHH 
s; XX 
47 48 
HH 
N 
--- 
HX 
N 
HHHH 
'X 
41 29 
Scheme 14 
It was decided to carry out model reactions using the readily available enamine 26 to 
examine the possibility of forming the C2-C3 and C8-C9 double bonds. 
Three different electrophiles were examined: methylchloroformate (Y=COZMe), 
paraformaldehyde (Y=CH2OH), and bromine (Y=Br)25 These reagents were chosen 
due to the possibility of performing an elimination with consequent alkene formation. 
This could be achieved by oxidative decarboxylation26 in the first two cases or 
elimination of HBr in the case of bromine. 
19 
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Treatment of enamine 26 with methylchloroformate gave a mixture of products in 
which trimer 43 was the mayor compound formed in this reaction. When 
paraformaldehyde was used as the electrophile a mixture of products was again 
obtained which was not possible to purify. Pleasingly, using bromine a molecule 
substituted at the 2- and 9-positions was obtained. Furthermore, treatment of enamine 
26 with two equivalents of bromine gave not dibromoazatriquinane, but a 
tetrabrominated derivative (Scheme 15)27 Due to the high reactivity of molecular 
bromine, it was impossible to stop the bromination at the dibromo stage and, although 
only two equivalents of bromine were used, the tetrabromo product 50 was obtained. 
When four equivalents of bromine were used 50 was formed in 37% yield. The 
hydroxy group results from the hydrolysis of the iminium salt during aqueous work- 
up. 
Br OH @r 5 eq Br2 Br - Br 
5 eq TEA 
NI 
HH H2O HH 
37% 
26 50 
Scheme 15 
The tetrabromo compound 50 is a highly crystalline solid and single crystals were 
obtained by slow evaporation of dichloromethane. Interestingly, the X-ray crystal 
structure of this compound (Figure 7) shows that the molecule is asymmetric in the 
solid state. Its convex geometry is deformed due to steric requirements of the bromines 
which instead of adopting an eclipsed conformation, they are offset with respect to 
each other, giving a highly strained azatriquinane structure. 
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Figure 7. X-ray crystal structure of 50. 
Tetrabromide 50 is a possible precursor of azatriquinadiene 52 via bis-elimination and 
reduction of the resulting vinylbromides and the hemiaminal function, therefore the 
strategy outlined in Scheme 16 was examined. 
B. OH or 
Br Br 
HH 
Br OH Br H 
N ........ N 
HHHH 
50 51 52 
Scheme 16 
2.3.1 Studies on bis-elimination from tetrabromide 50 
The first attempt at bis-elimination was made using potassium tert-butoxide in THE at 
0°C which gave a crystalline solid. 'H-NMR did not show the presence of olefinic 
protons and surprisingly, a strong band characteristic of a carbonyl group appeared in 
the infrared spectrum proving that the azatricycle was opened to give bicycle 53. This 
compound was obtained in 59% yield and a possible mechanism for this ring opening 
is presented in the Scheme 17.28 
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Scheme 17 
After this unsuccessful experiment, the elimination was attempted with DBU, a base 
commonly used for the elimination of HBr. 29 Thus, treatment of the tetrabromo 
compound 50 with DBU in THE at room temperature led mainly to decomposition 
plus a small amount of the bicycle 54 (4% yield) whose structure was determined by 
X-ray crystallography (Figure 8). 28 
Figure 8. X-ray crystal structure of 54. 
A probable mechanism for this reaction, starting from the product of the first ring 
opening 53 is shown in Scheme 18. In this case two subsequent eliminations of HBr 
have taken place after the ring opening, followed by attack on the resulting iminium 
salt by water. 
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Scheme 18 
Attempts at elimination using DBU at lower temperatures (0°C and 
-78°C) afforded 
yet another new compound 55 in 23% yield, in which the azatricyclic structure is 
maintained. 28 It was possible to grow single crystals of this compound and its X-ray 
crystal structure is presented in Figure 9. 
Figure 9. X-ray crystal structure of 55. 
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In Scheme 19 a possible mechanism for the formation of 55 is proposed. An 
elimination of HBr takes place during the reaction to give an alkene, then the oxygen 
is transposed from the bridgehead position to the adjacent carbon via an intramolecular 
nucleophilic displacement followed by ring opening of the resulting epoxide. The 
carbonyl group is formed by the displacement of a third bromide, and finally, the 
enaminone moiety is obtained by the loss of a proton. It is important to mention that a 
number of variations in the sequence of events are possible. 
Br OH Br Br . OH Br 
Bras'... 
.., ýººBr B .. 
Bra., Br 
-HBr N -HBr 
HHHHHH 
50 
Br p Br [B]ý 
-Br' I 
HHHH 
HO Br pH Br 
HH 
HO Br 
N 
-H 
O 
HH 
55 
Scheme 19 
The enaminone moiety in 55 displays interesting reactivity which makes it a possible 
precursor for the synthesis of the triene 29, as will be discussed in Section 2.4.2. 
The lack of success in these bis-elimination reactions could be attributed to the 
strained nature of the tetrabromo 50 in which the presence of four bulky bromines 
makes it a highly strained tricyclic structure which readily undergoes various 
rearrangements and/or eliminations simply by treatment with base. It was thus decided 
to attempt the synthesis of a less strained molecule. 
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One possibility was iodination of enamine 26 instead of bromination. In this case, due 
to the greater size of the iodine atom in comparison with bromine, the halogenation 
might stop at the diiodinated state. The iodination of the enamine 26 was attempted 
using the same conditions as for the bromination but unfortunately, the reaction gave a 
complex mixture and no diiodinated compound could be detected by mass 
spectrometry. 
The next reaction attempted was the substitution of the bromines in 50 with chlorines 
with the aim of reducing the strain in the system as a result of the smaller size of 
chlorine. Thus, heating tetrabromide 50 in a 1: 1 mixture of acetonitrile and aqueous 
saturated NaC1,29 resulted in no halogen exchange, but another new product 56 was 
obtained in 30% yield 28 Single crystals of this compound were grown and its X-ray 
structure is presented in Figure 10. 
01 CBr2 
02 
C2 
C9 g C1 
C3 
C4 
CS 
C7 
C5 (T ) C6 
Figure 10. X-ray crystal structure of 56. 
In this case the same transposition of the oxygen appears to have taken place as in the 
formation of enaminone 55. However, due to the presence of water in the reaction, the 
iminium salt is hydrolysed without further rearrangement to give 56 (Scheme 20). 
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Another attempt to diminish the strain in the tetrabromide 50 was by reduction of the 
two gem-dibromo moieties to give dibromoazatriquinane 57 using diphenyl phosphite 
and triethylamine, a method which is used for the reduction of gem- 
dibromocyclopropanes. 30 This reaction afforded 57 in 38% yield, the mass spectrum of 
which indicated the presence of two bromines in the molecule. The 'H-NMR and13C- 
NMR spectra of this product showed that it was symmetrical suggesting a syn- 
disposition of the two bromines. The exo stereochemistry assigned to the two 
bromines in 57 is based on the probable mechanism of this reaction. The formation of 
the anions is responsible for the final stereochemistry of the molecule in which an exo 
disposition of the bromines is more stable than the endo orientation due to steric 
requirements (Scheme 21). 
The above hypothesis was supported by the fact that, on treating the dibromo 
compound 57 with DBU in THF, it was necessary to heat at reflux overnight to 
achieve any elimination. A mixture of starting material and the monoeliminated 
product 58 was obtained. The difficulties with this elimination are attributed to the fact 
that the base has to abstract a proton from the more sterically hindered endo face due 
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to the exo disposition of the bromines. In the case of the formation of enaminone 55, 
one elimination was observed with DBU at 0°C and this is probably due to the fact 
that, in that case, the abstraction took place from the less sterically hindered exo face. 
0 
Br OH Br \ 11 Br OH Br Br OH Br 
Bdn,.. 
. 
mgr O -OR BBtli,,,.. OF OR 
N 
Oo UNI> H+ N I\OR 
HHLHHHH 
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[BQHBr] 
N 
HH 
Br OH Br 
H+ 
100 N 
HH 
57 
OH Br 
D» 
57 +N 
AHH 
58 
Scheme 21 
Due to the difficulties encountered in bis-elimination with 57, we continued to 
investigate the elimination of HBr with the tetrabromo compound 50 using other 
bases. 
The elimination of HBr from 50, without any further reaction, was finally achieved 
using KHMDS. It is noteworthy that it was possible to obtain the monoelimination 
product 59 or the bis-elimination product 51 in 83% and 85% yields, respectively, 
using different conditions (Scheme 22). It was possible to grow crystals of both 
elimination products and their X-ray crystal structures are presented in Figure 11.28 
Br OH Br Br OH Br Br OH Br 
,... 
Br Bai,,. 
. taBr 
N 
KHMDS 
N 
KHMDS 
N OCHH 7815 5 
min HH -7812h HH 
59 83% 50 85% 51 
Scheme 22 
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Br2 
A B 
Figure 11. A) X-ray crystal structure of 59. B) X-ray crystal structure of 51. 
A possible explanation for the different rates of the first and second eliminations is 
that, due to the deformation of the convex geometry of tetrabromo compound 50, each 
side of the molecule has only one antiperiplanar disposition of atoms for the 
elimination of HBr. However, on one side the elimination of HBr is strongly favoured 
due to the base abstracting a proton from the less sterically hindered exo face 
compared to the other side of the molecule, where the base has to abstract a proton 
from the more hindered endo face. 
The crystal structure of 59 (Figure 1 1A) shows that there is not an antiperiplanar 
disposition close to 180° between either of the two protons at C8 with Brl or M. 
This could explain why the second loss of HBr whether the base approaches via the 
endo or exo face, requires longer reaction times and higher temperatures. Thus, on 
treating the tetrabromo compound 50 with KHMDS at 
-78°C, an elimination of HBr 
takes place within 15 min but it is necessary to maintain these basic conditions for 12 
h and also allow the mixture to warm up to room temperature to achieve the second 
elimination. 
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2.3.2 Approaches to the synthesis of monoene 60 
With 59 in hand the synthesis of 60 was examined (Scheme 23). 
H 
N 
HH 
60 
Br OH Br 
Brun, 
N 
HH 
59 
Scheme 23 
The reduction of the gem-dibromo moiety was attempted using tributyltin hydride? and 
superhydride. 8 In both cases compound 61 was obtained, illustrating the difficulty in 
reducing the two bromines in C9 (Scheme 24). 
Br OH Br 
B nn,.. 
N 
HH 
59 
5 eq Bu3SnH 
(23%) Br OH Br 
or 
bl. N 
5 eq LiEt3BH HH 
(26%) 
Scheme 24 
61 
As seen in Section 2.1, bromination of the enamine 26 with NBS gave 42. It was 
possible to get the monobromo compound 62 exposing 42 to hydrolysis conditions 
(Scheme 25). 
Br OH Br 
1.3 eq NBS N 
HCI/H20 
N n 
HHHHHH 
26 42 62 
11 % over two steps 
Scheme 25 
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Attempts to eliminate HBr from compound 62 towards the synthesis of 60 using 
tBuOK, KHMDS and NaH failed, giving recovered starting material. This difficulty 
was attributed to the exo stereochemistry of the bromine atom which forces the base to 
abstract a proton from the more sterically hindered endo face (Figure 12)28 
Figure 12. X-ray crystal structure of 62. 
The iodo-analogue compound 63 was synthesised with the aim of introducing the 
double bond of 60. Based on literature precedents, 33 a syn-elimination of HIO could 
take place after oxidation of the iodine atom (Scheme 26). Unfortunately, the 
elimination did not take place and only starting material was recovered. 
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2.3.3 Synthesis of azatriquinadiene 52 by reduction of 51 
The reduction of 51 to synthesise the diene 52 was attempted and pleasingly, using the 
conditions for the reduction of the hemiaminal OH with LiAIH4,13 it was also possible 
to reduce both vinyl bromides in the same step, affording diene 52 in almost 
quantitative yield?? The final steps in the synthesis of azatriquinadiene 52 are 
presented in Scheme 27. 
Br OH Br Br OH Br H 
Brmn,,... 
.,, 
%Br 
N 
KHMDS LAH 
N 
HH -7812 
to it HHA, 
36h HH 
50 85% 51 95% 52 
Scheme 27 
The free base of the diene 52 is a volatile oily solid which was isolated and purified as 
its trifluoroacetate salt. Its structure was supported by the presence of two double 
doublets at 5.82 ppm and 5.69 ppm in the 'H-NMR spectrum, corresponding to the 
four olefinic protons in which the major coupling constant (6.3 Hz) is characteristic of 
that of the olefinic proton coupling constants in cyclopentene derivatives. The 
presence of a singlet at 5.46 ppm confirmed the reduction of the hemiaminal OH. Its 
13C-NMR spectrum has five peaks, supporting the presence of a mirror plane in the 
molecule in which the peaks at 127.9 ppm and 127.8 ppm correspond to the olefinic 
carbons. 
2.3.4 Hydrogen bonded dimers 
Figure 13 shows that in the solid state, the four structures shown below, the 
tetrabromo, tribromo, dibromo and monobromo compounds 50,59,51 and 62, 
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respectively, form dimers via two intermolecular hydrogen bonds between the proton 
of the hemiaminal OH of one molecule and the nitrogen of the other. 
Br OH Br Br OH Br Br OH Br OH Br 
Br",,,... 
. 
%%Br Br",,,... 
NNNN 
HHHHHHHH 
50 59 51 62 
Figure 13. Top left: tetrabromo 50, bottom left: tribromo 59, top right: dibromo 51, bottom right: 
monobromo 62. 
The distances and angles of the intermolecular hydrogen bonds are shown in Table 1. 
O-H"""N (A) O"""N (A) O-H""N angle (°) 
Tetrabromo 50 2.08 2.89 161.1 
Tribromo 59 2.00 2.80 159.4 
Dibromo 51 2.01,1.99a 2.85,2.82' 172.8,169 oa 
Monobromo 62 1.99 2.80 163.0 
Table 1. Distances and angles of the intermolecular hydrogen bonds of dimers 50,59,51 and 62. ' Two 
values are shown due to its asymmetric character. 
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2.4 Synthesis of azatriquinacene 
2.4.1 Substitution-elimination strategy: attempts to introduce the bottom double 
bond 
With the synthesis of diene 52 in hand, we hoped to employ the strategy outlined in 
Section 2.3 to introduce the bottom double bond of azatriquinacene 29. 
One possibility we have already seen is to start with a substituent on the 3-position of 
pyrrole which is capable of undergoing elimination later in the synthesis. Thus, 
hydrogenation of 2,3,5-trisubstituted pyrroles should give 2,3,5-trisubstituted 
pyrrolidines with the three substituents on the same side. It is also necessary that the 
substituent at the 3-position may not be removed under the hydrogenation conditions 
and for this purpose, the following 3-substituted pyrroles were synthesised: 
H 
N 
McO2C 
\/ 
CO2Me 
CI 
66 
H 
McO2C CO2Me 
CO2Me 
67 
Chloropyrrole 66 was prepared by reacting dimethyl-1H-pyrrole-2,5-dipropanoate 23 
with N-chlorosuccinimide in chloroform. The 3-methoxycarbonyl analogue 67 was 
obtained using methylchloroformate and catalytic aluminium chloride. 
An attempted hydrogenation of 3-chloropyrrole 66 showed that hydrogenolysis of the 
halogen unfortunately occurred faster than hydrogenation of the pyrrole ring to give 
dimethyl-cis-2,5-pyrrolidine dipropanoate 24. 
The hydrogenation of the 3-methoxycarbonyl analogue was also attempted, but was 
not achieved possibly due to the electron withdrawing nature of the ester at the 3- 
position. Various attempts to hydrogenate 67 by increasing the hydrogen pressure, 
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temperature, amount of catalyst, and also using other conditions (PtO2 / AcOH) were 
all unsuccessful. 
The synthesis of the two different pyrroles and the results of their respective 
hydrogenation attempts are presented in Scheme 28. 
H 
N H2 
Me02C C02Me 
CI 
23 66 
H 
N H2 
McO2C 
"ýCOC02Me 
CO2Me 
67 
Scheme 28 
H 
Me0 
ý 
`-' 2 CO2Me 
24 
No reaction 
The synthesis of 3-pyrroline 69 was attempted by reduction of pyrrole 23 with the idea 
of synthesising a cyclisation precursor which contains a bottom double bond instead of 
a substituent. The 3-pyrroline 69 should cyclise to give enamine 68 which after 
bromination, elimination and reduction by the same protocol used for the synthesis of 
azatriquinadiene 52 (Section 2.3) might give azatriquinacene 29 (Scheme 29). 
H 
29 '''< ''' 23 
H-H McO2C ý CO2Me 
68 69 
Scheme 29 
Thus, treating pyrrole 23 with Zn and HC1,35 the bicycle 71 was obtained (Scheme 30). 
Surprisingly, the first cyclisation took place in situ without heating whereas in the case 
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of the pyrrolidine 24, heating at reflux for 10 days in toluene was necessary to achieve 
the same cyclisation. This first cyclisation could be promoted by the activation of the 
ester under the acidic reaction conditions or due to an enhanced nucleophilic character 
of the nitrogen in 70 relative to 24. 
Acid catalysed esterification of 71 with methanol provides 72, however, when the 
second cyclisation was attempted, some decomposition occurred and only starting 
material was isolated from the reaction. To explain this result, it has been assumed that 
the pyrrolizinone 72 has trans-stereochemistry and this fact has been reinforced by the 
absence of an NOE interaction between the protons shown in Scheme 30. Due to the 
cis, cis, cis-geometry of the azatriquinane structure it is necessary to use pyrrolizinones 
with a cis-stereochemistry as the precursors, to achieve the second cyclisation. 
H 
Zn/HCI N CH3OH/H+ 23 I ''', " )No 
HO2C - 
/ýH C02H 17% 0 
'11/'H 82% 
2 
70 
Me02C HHH 
72 
Scheme 30 
2.4.2 New strategies using enaminone 55 
71 
McO2 
0% 
72 
After failing to introduce the bottom double bond, we started to consider the 
enaminone 55 as a precursor to azatriquinacene 29. 
As seen in Section 2.3, treating tetrabromide 50 with DBU at 0°C gave 55 (Scheme 
31). 
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Scheme 31 
The enaminone moiety displays very interesting reactivity. The nucleophilic reactions 
of conjugated enaminones are classified into the four types shown in Scheme 32.36 
E (type 11) YPe IV) 
-CC 
ý 
C-CH ý-- CC C 
co 
N< E (type I) 
cI 
E (type 111) H 
Scheme 32 
Using type II reactivity it might be possible to introduce four bromine atoms in the 
enaminone 55 as with the enamine 26. In this case it is probably necessary to reduce 
the carbonyl group of the enaminone to remove its conjugation with the double bond 
(Scheme 33). 
H 
N 
HH 
29 
Br H OH Br H OH Br HO 
N Br Br 
H OH HH 
Br är 
73 74 55 
Scheme 33 
It was possible to selectively reduce the carbonyl group of 55 by treatment with 
sodium borohydride37 to obtain the enaminol 74. As seen in Section 2.1, the chemical 
shift of the vinylic proton of the parent enamine 26 in the 'H-NMR is 4.32 ppm. The 
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chemical shift of the analogous proton in the enaminol 74 is 4.58 ppm which 
suggested enamine character. This slight downfield shift also indicated that 74 may be 
less reactive than 26. The bromination of the enaminol 74 was attempted using the 
same conditions as those used with enamine 26. However, the reaction afforded 
starting material and a complex mixture of brominated products, despite longer 
reaction periods compared with the enamine 26. 
Another strategy relying upon enaminone type IV and type III reactivities was 
proposed and is presented in Scheme 34. 
Br H OTf 
N 
HHH OH 
29 75 
Br HO Br HO 
NN 
HH 
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Scheme 34 
Br H OTf 
/N\ 
H OH 
Br 
76 
Type IV reactivity of the enaminone moiety suggests that treatment of enaminone 55 
with a base and then with NBS would introduce a bromine atom at C5 to give 77. It 
could be possible to introduce the double bond in position C2-C3 using type III 
reactivity, 38 thus treating brominated enaminone 77 with trifluoromethanesulfonic 
anhydride should form the vinyltriflate 75 as shown Scheme 35. From this point, 
azatriquinacene could be synthesised by elimination of HBr and consequent reduction 
of the I substituents with Pd°Bu3SnH and/or LiAIH4.39 
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Scheme 35 
Two different bases, KHMDS and "BuLi, were used to try to abstract the proton at C5 
of 55. NBS was then added to afford, in both cases, the a-brominated product 78 
instead of the desired y-brominated product 77. This can be explained by the fact that 
the base did not abstract the y-proton and the a-bromination was the result of type II 
reactivity of the enaminone. To test this theory, the enaminone 55 was treated with 
NBS in absence of a base and after 10 min the bromination in the a-position took 
place to afford 78. In the crystal structure of the enaminone (Figure 9, Section 2.3) is 
possible to see that the convex geometry of these compounds prevents carbon atoms 
C2, C3, C4 and C5 from adopting a coplanar disposition. Coplanarity is necessary for 
orbital overlap, responsible for the acidic characteristics of the y-protons of 
enaminones 36 
A selective bromination of an enaminone, in the a or in the a and y positions with 
NBS, has been reported in the literature. 0 Based on this precedent, enaminone 55 was 
exposed to the bromination conditions and fortunately was observed that it underwent 
regioselective bromination using NBS. Exclusive a-bromination was obtained using 
one equivalent of NBS to give 78 in 96% yield, whereas the a, y-dibrominated product 
79 was formed in 94% yield when 55 was treated with two equivalents of NBS 
(Scheme 36). It is noteworthy that bromination at the C8-C9 double bond was not 
observed due to the lower reactivity of NBS compared with bromine. 
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Scheme 36 
After this important result, which constitutes the first example of substitution of the 
bottom ring in enaminone 55, a model reaction to introduce the double bond in 
position C2-C3 was attempted. Pleasingly, treatment of 55 with 
trifluoromethanesulfonic anhydride at 
-78°C followed by hydrolysis of the resulting 
iminium salt afforded vinyltriflate 80 in 72% yield (Scheme 37). 
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Tf2O 
N/ 
H 
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+ý 
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/N\ 
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Scheme 37 
However, when the reaction shown in Scheme 37 was attempted using 79, it failed. 
This unsuccessful result was probably due to the presence of the a-bromine atom 
which makes the enaminone poorly reactive through electronic and steric effects 4' 
With the aim of recovering the original reactivity of the system, the reduction of both 
vinyl bromides of 79 by hydrogenolysis42 was attempted. Unfortunately the non- 
conjugated double bond was reduced under the reaction conditions and this fact was 
indicated by the absence in the 'H-NMR of the olefinic proton at C8. 
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It was then decided to eliminate HBr from the bottom ring of 79. This was to be 
followed by reduction of the enaminone, then dehydration to give azatriquinacene 29. 
The elimination reaction was attempted using DBU and KHMDS but unfortunately, 
decomposition occurred in both cases suggesting that 79 was unstable in the presence 
of strong bases. 
Both the reduction and elimination strategies are presented in Scheme 38. 
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Scheme 38 
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2) [H] 
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" 
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Bromination of the bottom ring of the iminium salt 85 was attempted. This would give 
a compound with the two top double bonds and the potential to form the third by 
elimination (Scheme 39). Unfortunately, treatment of the iminium salt 85 with a 
variety of bases (NEt3, DBU and tBuOK) or a system of two bases 
(BuNH2/KHMDS)43 followed by NBS did not give any bromination of the 5-position. 
This unsuccessful result could be due to the fact that the presence of the double bonds 
at the 2- and 8-positions led to the product 86 being more strained than the parent 
enamine 26, thus preventing deprotonation. 
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2.4.3 Synthesis of azatriquinacene by reduction of 87 
Following the problems and setbacks encountered with the substitution-elimination 
strategy and the difficulties in working with the a, y-dibromoenaminone 79, new 
strategies were considered. 
The nonachloroazatriquinacene 87, prepared by Mascal and coworkers' 3 from the 
saturated azatriquinane 28 by radical chlorination with sulfuryl chloride, constituted 
the first and unique example of the synthesis of an azatriquinacene structure (Scheme 
40). However, all previous attempts to dechlorinate it by reduction in an anologous 
fashion to perchlorotriquinacene 88 failed 
.5 
H 
light 
HH S02CI2 
28 
N Cl 
Cl 
Cl 
87 
Scheme 40 
In the final step of the synthesis of the diene 52 (Section 2.3), two vinyl bromides and 
the hydroxyl group of the hemiaminal were reduced in one step. This result suggested 
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that the reduction of the chlorine substituents in perchloroazatriquinacene 87 might be 
possible and should therefore be re-examined. 
The reduction of a vinyl chloride is more difficult to achieve than that of a vinyl 
bromide. In the synthesis of triquinacene 3, Hoffman used lithium in tert-butanol to 
reduce perchlorotriquinacene 88.5 In 87 the bridgehead chlorines are a to a nitrogen 
and this fact makes these three chlorines easier to reduce than the bridgehead chlorines 
in 88. In the case of the reduction of the hydroxyl group of the hemiaminal, the slow 
step is the formation of the iminium salt by expulsion of hydroxide by the electron 
lone pair of the nitrogen. This fact suggested that the reduction of the chlorines a to 
nitrogen should be easier than the reduction of the hydroxyl group of the hemiaminal 
as chloride is a better leaving group than hydroxide. Thus, the strong conditions 
required to remove the vinyl chlorides and the mild conditions proposed to reduce the 
bridgehead chlorines suggested that the reduction of the nine chlorines of 
perchloroazatriquinacene 87 could be achieved in two steps (Scheme 41).. 
87 
1St reduction 
............... 
0- 
89 
Scheme 41 
H 
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.............. 
N 
HH 
29 
Pleasingly, treating perchloroazatriquinacene 87 with tributyltin hydride at room 
temperature for 16 h44 reduced the three chlorines a to nitrogen to afford 2,3,5,6,8,9- 
hexachloroazatriquinacene 89 in 53% yield. This fact was supported by the presence 
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of a singlet at 4.75 ppm in the `H-NMR spectrum which corresponded to the three 
protons a to nitrogen. 
Due to the absence of a radical initiator and the temperature at which the reduction 
was carried out (room temperature), this reaction cannot be explained by a radical 
mechanism and must proceed via hydride transfer as shown in the Scheme 42. In this 
mechanism, chloride, a Lewis base, forms a pentacoordinated tin species that can act 
as a strong hydride donor. 45 
87 
CI 
Scheme 42 
CI Cl Cl 
CI CI N CI 
CI H 
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With 89 in hand, the reduction of the remaining six chlorines was attempted using 
lithium and tert-butanol5 and pleasingly, azatriquinacene 29 was obtained in 32% 
yield. 27 As in the case of the synthesis of diene 52 (Section 2.3), triene 29 was isolated 
as its trifluoroacetate salt as the free base is highly volatile. 
The final steps in the synthesis of azatriquinacene 29 are presented in the Scheme 43. 
CI. CI 
N Cl nBu3SnH 
CI Cl benzene, rt 
cl CI 16 h 
87 53% 89 
H 
Li, tBuOH N 
THF, reflux HH 
2.5 h 
32% 29 
Scheme 43 
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The 'H-NMR and 13C-NMR data of its trifluoroacetate salt and the free base form are 
shown in Table 2. 
'H-NMR(8/ppm) 13C-NMR (5/ppm) 
H2 H1 C2 C1 
Azatriquinacene 29"HBF4 5.87 (S)a 5.69 (s)a 127.8b 78.6b 
Azatriquinacene free base 5.79 (s)a 4.87 (s)a 130.3c 78.6° 
Table 2. In all the cases the solvent used was CDC13. '400 MHz, b125 MHz, c67.5 MHz. 
The hydrochloride salt of this compound is very soluble in water whereas the 
trifluoroacetate salt is very soluble in organic solvents. The tetrafluoroborate salt is 
partially soluble in both, which makes it the most suitable salt for crystallisation 
studies. Crystals of the tetrafluoroborate salt of 29 grew as light yellow cubes by slow 
diffusion of ether into dichloromethane solution of 29, and its X-ray crystal structure is 
presented in Figure 14. The tricycle and its counterion lie across a crystallographic 
mirror plane, which in the cation passes through C1 and N and bisects the C5-C5A 
double bond. An N-H F hydrogen bond (N F 2.77A and N-H°"F 178°) links the cation 
and the anion, which pack in alternating corrugated layers (Figure 15). 
Figure 14. X-ray crystal structure of 29"HBF4. The counterion is omitted for clarity. 
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Figure 15. Packing of 29"HBF4. 
2.4.4 Dimerisation attempts 
c 
00 
As seen in the introduction, a great deal of effort has been focused on the dimerisation 
of triquinacene 3 to form dodecahedrane 1 via a [2+2+2+2+2+2]n cycloaddition 
reaction. 1,4,5 With azatriquinacene 29 in hand this strategy could be re-examined 
(Scheme 44). 
2(S 
29 30 
Scheme 44 
Figure 15 shows that, in the tetrafluoroborate salt of 29 there is no close approach 
between the endo faces of two molecules which makes topochemical dimerisation 
unlikely. However, it had been speculated that the aqueous solubility of 29 and its 
45 
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perturbed electronics relative to 3 might prove advantageous in the photochemical 
[2+2+2+2+2+2]zc dimerisation reaction which would give diazadodecahedrane 30 
(Scheme 44). Thus, it was decided to do this study in solution and the conditions and 
outcomes of the preliminary attempts are summarised in Table 3. 
Substrate Irradiation Source Solvent Time Photosensitiser Salt Metal 
29"CF3CO2H 300 W Sun lamp H2O 48 h No Yes No 
29"CF3CO2H HV Mercury lamp H2O 3.5 h No Yes No 
29"CF3CO2H HV Mercury lamp Acetone 3.5 h Yes No No 
29"CF3CO2H HV Mercury lamp H2O 3.5 h Yes No No 
29"CF3CO2H HV Mercury lamp THE 144 h No No No 
29 Free Base HV Mercury lamp H2O 144 h Yes No Yes 
Table 3. In all the cases acetone was used as the photosensitiser, LiC1 as the inorganic salt and 
CuOTf Benzene as the coordinating metal. 
Starting material was recovered in all the entries except using the free base of 29 after 
a long period of irradiation in which decomposition was observed. Neither 29 nor its 
salt are more reactive than 3 in this capacity, and no evidence of diazadodecahedrane 
30 has yet been found. In fact, compound 29 appears to be curiously inert, failing to 
react at all under conditions known to induce various photochemical transformations 
in 3,46 but efforts will continue. 
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3. Experimental 
General Details. 
- 
Melting points determinations were made on a Reichert Kofler 
micro hot-stage or in a Box 6402 Holliston MA 01746-6402 apparatus and are 
uncorrected. IR spectra were obtained using a Perkin-Elmer 1600 series FT-IR 
instrument as dilute solutions in spectroscopic grade chloroform. UV spectra were 
recorded as solutions in spectroscopic grade ethanol using a Philips PU 8700 
spectrophotometer. Unless stated otherwise solutions in deuteriochloroform were used 
for the determination of NMR spectra. Shifts are expressed in ppm downfield from 
Me4Si, as internal standard. The 1H and 13C NMR spectra were obtained using a 270 
MHz Jeol EX-270,400 MHz Bruker AM400,400 MHz Bruker AV400, or a 500 MHz 
Bruker DRX500 instrument. Multiplicities of signals are assigned using the following 
abbreviations: s= singlet, d= doublet, t= triplet, q= quartet, quint = quintet, m= 
multiplet, br = broad, app = apparent. Coupling constants (J) are given in Hertz. 
Assignments in the 'H spectra were consistent with signal intensities, and in the 13C 
spectra with the results of the DEPT pulse sequence. Signals corresponding to OH 
protons were not observed in the 1H NMR spectra. Mass spectra were recorded on a 
MM-701 CF instrument using electron impact ionisation at 70 eV, fast atom 
bombardment (FAB) or electrospray (ES) techniques. Microanalytical data were 
obtained on a Perkin-Elmer 24013 elemental analyser. Flash chromatography was 
performed using Merck silica gel 60. "Ether" refers to diethyl ether and "petrol" to the 
fraction bp 40-60 °C. All reactions were monitored by TLC using Merck silica gel 60 
F254 precoated aluminum plates which were visualised with ultraviolet light and then 
with basic potassium permanganate solution. Organic extracts were dried over 
anhydrous magnesium sulfate prior to solvent removal using a Büchi rotary 
evaporator. Tetrahydrofuran was distilled from sodium benzophenone ketyl and 
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dichloromethane was distilled from calcium hydride before use in reactions. Other 
organic solvents and reagents were purified by the accepted literature procedures. 
Where necessary, reactions requiring anhydrous conditions were performed in a flame 
or oven dried apparatus under a nitrogen or argon atmosphere. 
rel-(4R, 7S, 9R)-10-Azatricyclo[5.2.1.01"0]-2,9-bis [1-(10r, 13S, 16R)-azatricyclo 
[5.2.1.01"°]decane]dec-l-ene 43. 
H 
DCM (1 mL) was added to the freshly distilled enamine 
2613 (0.781 g, 5.78 mmol) and the mixture was then heated 
at 140°C with stirring for 12 h. The reaction was cooled to 
RT and the resulting brown solid was purified by column 
chromatography (DCM: MeOH 10: 1) to give the 
monohydrochloride salt of 43 (0.254 g, 30%) as a pink crystalline solid, mp 127- 
130°C; (Found: (HRMS FAB) M++H 406.3223, C27H39N3 requires 406.3222); 
vm,,, /cm' 3696,2935,1678,1602,1459,1348,1068,962,892; 811(400 MHz) 4.12 
(IH, m), 4.04 (IH, m), 3.73 (1H, m), 3.58 (2H, m), 3.44 (IH, m), 2.99 (IH, dd, J 15.0, 
7.5), 2.87 (1H, m), 2.41 (1H, d, J 15.1), 2.37-1.67 (25H, m), 1.62-1.50 (3H, m), 1.32- 
1.24 (2H, m); 8ß(125 MHz) 147.6 (C), 112.9 (C), 81.8 (C), 76.1 (C), 67.7 (CH), 67.2 
(CH), 66.8 (CH), 66.7 (CH), 62.3 (CH), 60.4 (CH), 43.1 (CH2), 42.6 (CH2), 36.9 
(CH2), 36.8 (CHZ), 36.3 (CHZ), 32.8 (CH2), 32.2 (CH2), 31.8 (CH2), 31.0 (CH2)) 30.4 
(CH2), 30.2 (CH2), 30.0 (CH2), 29.9 (CH2), 29.8 (CH2), 29.7 (2 x CH2), 28.7 (CH2); 
m/z (FAB) 406 (M++H, 53) 406 (53), 307 (26), 155 (32), 154 (100), 138 (36), 137 
(67), 136 (86), 107 (26), 91 (29), 90 (24), 89 (20), 77 (22), 73 (68), 69 (23), 57 (32), 
55 (29). 
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To obtain the free base of 43 a solution of KHMDS in toluene (0.5 M, 2.6 mL) was 
added dropwise to a stirred solution of the monohydrochloride salt (43"HCl) (0.191 g, 
0.432 mmol) in THE (7 mL) at 
-78°C under argon. The mixture was stirred 2h at - 
78°C and then 30 min at RT. The solvent was removed under argon and the residue 
extracted with dry ether (3 x 10 mL). The combined organic phase was filtered and the 
solvent removed under argon to give 43 (0.170 g, 97%) as a pale brown oil; (Found: 
(HRMS ES) M++H 406.3239, C27H39N3 requires 406.3222); v,,, a,, /cm-1 3652,3155, 
2947,2866,2253,1817,1794,1651,1458,1382,1348,1320,1299,1094,1064,1022, 
988,947,892,644; 8H(400 MHz) 3.52-3.40 (4H, m), 3.32 (1H, m), 3.25 (1H, m), 3.05 
(1H, d, J 8.3), 2.80 (1H, dd, J 14.4,7.3), 2.36 (1H, m), 2.30-2.20 (2H, m), 2.01 (1H, 
m), 1.95-1.18 (26H, m), 0.85 (1H, m); 8ß(100 MHz) 148.5 (C), 115.6 (C), 78.3 (C), 
74.2 (C), 66.2 (CH), 66.0 (CH), 65.9 (CH), 65.3 (CH), 64.0 (CH), 60.4 (CH), 44.5 
(CH2), 40.3 (CH2), 39.2 (CH2), 37.5 (CH2), 34.5 (CH2), 33.8 (CH2), 33.7 (CH2), 32.8 
(CH2), 31.6 (CH2)2 30.9 (CH2)2 30.8 (CH2), 30.3 (CH2), 30.2 (2 x CH2), 30.0 (CH2), 
29.9 (CH2)2 28.6 (CH2). 
(1r, 4S, 7R)-2,3,5,6,8,9-Hexachloro-10-azatricyclo[5.2.1.01'lo]deca-2,5,8-triene 89. 
CI` H CI Tributyltin hydride (0.756 g, 2.60 mmol) was added dropwise to a 
N,, ý-CI stirred solution of 87 (0.265 g, 0.601 mmol) in benzene (20 mL) 
i'"H 
under nitrogen at RT. After 16 h the mixture was concentrated in Cl Cl 
vacuo and the residue purified by column chromatography (Petrol: AcOEt 10: 1) to give 
89 (0.108 g, 53%) as a white solid, mp 152-154°C; (Found: (HRMS EI) M+, 334.8407, 
C9H3NC16 requires 334.8397); vta,, /cm 1 1636,1073,905; 811(400 MHz) 4.75 (3H, s); 
5C(100 MHz) 128.4 (C), 76.8 (CH); m/z (EI) 334 (M+, 20) 341 (16), 340 (16), 339 
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(39), 338 (38), 337 (54), 336 (49), 335 (21), 334 (20), 304 (56), 302 (100), 300 (60), 
267 (33), 265 (26), 232 (21), 230 (21). 
(1r, 4S, 7R)-10-Azatricyclo[5.2.1.01'loldeca-2,5,8-triene 29. 
H Lithium metal (0.234 g, 33.7 mmol) and tert-butanol (1.40 g, 18.9 
N mmol) were added to a stirred solution of 89 (0.338 g, 1.00 mmol) in 
H-H 
THE (40 mL) at RT. A slow stream of nitrogen was passed over the 
mixture which was stirred for 20 min and then heated at reflux for 2.5 h. The mixture 
was allowed to cool to RT and poured into a mixture of ice / water / HCl (30 g/ 20 
mL /5 mL) and stirred for 20 min. The mixture was washed twice with DCM and the 
aq layer basified with aq NaOH (2 M). The aq layer was extracted with DCM (3 x 40 
mL) and trifluoroacetic acid (0.34 g, 3.0 mmol) was added to the organic phase which 
was then dried and the solvent was removed in vacuo to give the trifluoroacetate salt 
of 29 (79 mg, 0.31 mmol, 32%) as white crystals, mp 178-180°C; (Found: (HRMS EI) 
M+ 131.0735, C9H9N requires 131.0735); v.,, /cm 1 2925,1666,1140,973; %,.,, /run 
202 (c, 4074), 253 (1585); 6n(400 MHz) 5.87 (6H, s), 5.69 (3H, s); Sß(100 MHz) 
127.8 (CH), 78.6 (CH) (the signals corresponding to the trifluoroacetate were not 
observed); 8F(282 MHz) -76.1; m/z (EI) 131 (M+, 100) 131 (100), 130 (76), 105 (55), 
104 (26), 45 (32). 
The crystalline tetrafluoroborate salt (29. HBF4) was prepared for X-ray analysis in 
essentially quantitative yield by dissolving 29-CF3CO2H in a 20-fold molar excess of 
saturated aq NaBF4 followed by extraction with DCM. 
To obtain the free base of 29, the trifluoroacetate salt (29-CF3CO2H) (0.102 g, 0.416 
mmol) was introduced into a mixture of DCM (5 mL) and aq KOH (2 M, 1 mL). After 
vigorous agitation for 2 min, the layers were separated and the aq phase extracted with 
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DCM (2 x5 mL). The combined organic phase was dried and the solvent cautiously 
removed in vacuo to give 29 (49 mg, 94%) as a volatile colourless solid; (Found: 
(HRMS EI) M+ 131.0735, C9H9N requires 131.0735); ,, /nm 205 (c, 9772); SH(400 
MHz) 5.79 (6H, s), 4.87 (3H, s); Sc(67.5 MHz) 130.3 (CH), 78.6 (CH); m/z (EI) 131 
(M+, 97) 131 (97), 130 (76), 105 (49), 69 (92), 55 (54). 
(1r, 4S, 7R)-2,2,9,9-Tetrabromo-10-azatricyclo[5.2.1.01'l0] decan-1-o150. 
Br OH Br 
A solution of 26 (1.24 g, 9.17 mmol) in DCM (5 mL) was added 
Bra,,. 
. 
Br 
dropwise to a stirred solution of bromine (7.40 g, 46.3 mmol) in 
N 
HH DCM (30 mL) at 
-78°C under nitrogen. After 5 min, a solution of 
triethylamine (4.66 g, 46.1 mmol) in DCM (12 mL) was added dropwise, and the 
mixture was stirred for an additional 5 min. The -78°C bath was then replaced by an 
ice-acetone bath (-5°C) and stirring was continued for 10 min. Water (9 mL) was 
added and the mixture was stirred for a further 20 min. The layers were then separated 
and the aq phase extracted with DCM (3 x 60 mL). The combined organic phase was 
washed with aq sodium hydrogencarbonate (1 M, 80 mL) and water (3 x 60 mL) and 
dried. The solvent was removed in vacuo to leave a brown solid which was triturated 
with DCM (20 mL) to give 50 (0.843 g) as a white crystalline solid, mp 132-134°C. 
The DCM triturate could be purified by column chromatography (Petroleum 
ether: AcOEt 4: 1) to give more 50 (0.748 g) as a yellow solid, total yield 37%; (Found: 
C, 23.0; H, 2.3; N, 2.9). C9H11NOBr4 requires C, 23.2; H, 2.4; N, 3.0); (Found (HRMS 
ES) M++H 465.7543 C9H12NOBr4 requires 465.7652); vn, ax/cmt 3694,3540,2977, 
2874,1601,1463,1383,1297,1111,976,894,613; 811(400 MHz, DMSO-d6) 3.71 
(2H, m), 3.32-3.20 (4H, m), 2.20 (2H, m), 1.93 (2H, m); 8ß(67.5 MHz, DMSO-d6) 
51 
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103.3 (C), 70.3 (C), 61.4 (CH), 53.8 (CH2), 29.1 (CH2); m/z (ES) 465 (M++H, 18) 473 
(1), 471 (40), 469 (100), 467 (96), 465 (18). 
(1 r, 4S, 7R)-2,9-Dibromo-10-azatricyclo [5.2.1.01'10] deca-2,8-dien-1-o151. 
Br OH Br A solution of KHMDS in toluene (0.5 M, 20 mL) was added dropwise 
N to a stirred solution of 50 (1.17 g, 2.50 mmol) in THE (125 mL) at - 
HH 78°C under nitrogen. The mixture was stirred 12 h during which it was 
allowed to warm to RT. Water (150 mL) and DCM (150 mL) were added and stirring 
was continued for 5 min. The layers were separated and the aq phase extracted with 
DCM (2 x 150 mL). The combined organic phase was dried and the solvent removed 
in vacuo to give 51 (0.649 g, 85%) as colourless crystals, mp 110-112°C; (Found: 
(HRMS ES) M++H 305.9142, C9H10NOBr2 requires 305.9129); v,,, a,, /cml 3571,3153, 
2967,2898,2795,1626,1457,1338,1307,1295,1150,1129,1105,1081,1070,985, 
950,908; 8H(400 MHz) 6.09 (2H, s), 4.18 (2H, m), 2.09 (2H, m), 1.80 (2H, m); 
äc(67.5 MHz) 134.9 (CH), 122.1 (C), 106.3 (C), 68.4 (CH), 31.8 (CH2); m/z (ES) 306 
(M++H, 29) 310 (25), 308 (100), 306 (30). 
(1r, 4S, 7R)-10-Azatricyclo[5.2.1.01"o]deca-2,8-diene 52. 
HA solution of lithium aluminum hydride in THE (1.0 M, 14 mL) was 
N added to a stirred solution of 51 (0.611 g, 2.00 mmol) in THE (40 mL) at 
HH RT under nitrogen. The mixture was then heated at reflux for 36 h, 
cooled to 0°C and water (2 mL) was cautiously added followed by aq NaOH (2 M, 10 
mL). The resulting slurry was stirred at RT for 30 min and solid potassium carbonate 
(10 g) was added. The mixture was stirred for a further 1h at RT and then filtered. 
The solid residue was washed with DCM and aq HCl (0.5 M, 150 mL) was added to 
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the combined filtrate. The layers were separated and the aq phase washed with DCM 
(150 mL). The aq layer was then basified with aq NaOH (2 M) and extracted with 
DCM (3 x 150 mL). Trifluoroacetic acid (0.68 g, 6.00 mmol) was added to the 
combined organic phase which was then dried. The solvent was removed in vacuo to 
give the trifluoroacetate salt of 52 (29 mg, 95%) as white crystals, mp 179-181°C; 
(Found: C, 53.4; H 5.0; N, 5.4. C1 1H12NO2F3 requires C, 53.4; H, 4.9; N, 5.7 %); 
(Found: (HRMS EI) M+ 133.0894, C9H11N requires 133.0892); vX/cm 1 2951,1666, 
1140,1056,838; 
, max/nm 207 (c, 1023), 260 (78); 6H(400 MHz) 5.82 (2H, dd, J 6.3, 
1.5), 5.69 (2H, dd, J 6.3,1.5), 5.46 (1H, s), 4.90 (2H, br s), 2.35 (2H, m), 1.90 (2H, 
m); 6c(100 MHz) 162.3 (q, 2JCF 36.3) (C), 128.0 (CH), 127.9 (CH), 116.4 (q, 1JcF 
290.9) (C), 77.7 (CH), 64.8 (CH), 32.3 (CH2); m/z (EI) 133 (M+, 28) 133 (28), 105 
(100), 104 (24), 45 (27). To obtain the free base 52, the trifluoroacetate salt 
52"CF3CO2H (0.152 g, 0.615 mmol) was introduced into a mixture of DCM (2 mL) 
and aq KOH (2M, 2 mL). After vigorous agitation for 2 min the layers were separated 
and the aq phase extracted with DCM (2 x8 mL). The combined organic phase was 
dried and the solvent cautiously removed in vacuo to give 52 as a volatile colourless 
solid, (Found: (HRMS EI) M+ 133.0896, C9H1IN requires 133.0892); vom, (/ cm'1 2937, 
2868,1667,1453,1351,1117,1080,1065,992,964,945; Xmax/nm 205 (E, 2818); 
5H(400 MHz) 5.62 (2H, ddd, J 5.9,1.8,1.8), 5.50 (2H, ddd, J 5.9,1.8,1.8), 4.62 (1H, 
s), 4.00 (2H, m), 1.86 (2H, m), 1.45 (2H, m); öc(100 MHz) 130.5 (CH), 130.0 (CH), 
78.0 (CH), 71.2 (CH), 32.3 (CH2); m/z (EI) 133 (M+, 15)133 (15), 105 (100). 
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rel-(1R, 7S)-9-Bromo-10-azatricyclo[5.2.1.01'lo]deca-3,8-dien-2-one 55. 
Br HOA solution of DBU (2.70 mL, 2.75 g, 18.1 mmol) in THE (5 mL) was 
N/ added dropwise over 15 min to a stirred solution of 50 (2.83 g, 6.04 
H 
mmol) in THE (50 mL) at 
-78°C under nitrogen. Stirring was continued 
for 4.5 h during which the mixture was allowed to warm to RT. The solvent was 
removed in vacuo and the residue partitioned between DCM (50 mL) and water (35 
mL). The mixture was shaken, the layers were separated and the aq phase was 
extracted with DCM (3 x 30 mL). The combined organic phase was washed with water 
(30 mL) and dried. The solvent was removed in vacuo to give a brown solid which 
was purified by column chromatography (AcOEt: Petroleum ether 1: 1) to give 55 (312 
mg, 23%) as orange crystals, mp 100-103°C; (Found: (HRMS EI) M+ 224.9793, 
C9H8NOBr requires 224.9789); v,,, a, Jcm 1 2925,1687,1584,1368,1045,890; SH(400 
MHz) 5.87 (1H, br s), 5.24 (1H, br s), 4.53 (1H, m), 4.32 (1H, m), 2.91-2.72 (2H, m), 
2.68-2.60 (1H, m), 2.02-1.93 (1H, m); 5ß(67.5 MHz) 202.3 (C), 189.9 (C), 132.7 
(CH), 119.1 (C), 101.1 (CH), 77.2 (CH), 65.6 (CH), 28.5 (CH2), 27.3 (CH2); m/z (EI) 
225 (M+, 61) 227 (59), 225 (61), 199 (24), 197 (24), 118 (100), 117 (30), 51 (14). 
rel-(1R, 7S)-3,9-Dibromo-10-azatricyclo[5.2.1.01'lo]deca-3,8-dien-2-one 78. 
Br Hp N-Bromosuccinimide (12 mg, 0.067 mmol) was added portionwise 
N/ Br to a stirred solution of 55 (14 mg, 0.062 mmol) in DCM (2 mL) at 
H RT. The mixture was stirred for 10 min and DCM (10 mL) and 2M 
NaOH (8 mL) were added. After vigorous agitation the layers were separated and the 
aq phase was extracted with DCM (2 x 10 mL). The combined organic phase was 
dried and the solvent removed in vacuo to give 78 (18 mg, 95%) as an oily yellow 
solid; (Found: (HRMS EI) M+ 302.8884, C9H7NOBr2 requires 302.8894); v,,, a, /cm-1 
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2925,1702,1588,1360,1064,1043,964,882; 6H(400 MHz) 5.90 (1H, m), 4.62 (1H, 
m), 4.48 (1H, dd, J 3.4,2.2), 2.88 (2H, m), 2.69 (1H, m), 2.04 (1H, m); Sc(100 MHz) 
194.4 (C), 187.0 (C), 133.2 (CH), 118.9 (C), 97.6 (C), 76.4 (CH), 66.6 (CH), 27.9 
(CH2), 27.0 (CH2); m/z (EI) 303 (M+, 20) 307 (19), 305 (51), 303 (20), 277 (12), 227 
(23), 226 (43), 225 (25), 224 (51), 199 (12), 198 (11), 146 (11), 118 (45), 117 (100), 
79 (27). 
rel-(1R, 5R, 7S)-3,5,9-Tribromo-10-azatricyclo[5.2.1.01,10]deca-3,8-dien-2-one 79. 
Br H0 N-Bromosuccinimide (59 mg, 0.33 mmol) was added portionwise to 
N/ Br a stirred solution of 55 (15 mg, 0.066 mmol) in DCM (2 mL) at RT. 
H The mixture was stirred for 7h and DCM (10 mL) and 2M NaOH 
Br 
(8 mL) were added. After vigorous agitation the layers were separated and the aq 
phase was extracted with DCM (2 x 10 mL). The combined organic phase was dried 
and the solvent removed in vacuo to give 79 (24 mg, 94%) as an oily orange solid; 
(Found: (HRMS ES) M++H 381.8044, C9H7NOBr3 requires 381.8078); vna,, /cm t 
2926,2852,1715,1594,1359,1048; 811(400 MHz) 5.91 (1H, dd, J2.2,1.8), 4.98 (1H, 
dd, J7.3,1.3), 4.82-4.77 (1H, m), 4.57 (1H, ddd, J3.1,2.2,0.6), 2.99 (1H, ddt, J 15.3, 
7.6,1.0), 2.74 (1H, ddd, J 15.3,7.3,5.2); 8ß(67.5 MHz) 193.9 (C), 182.6 (C), 132.1 
(CH), 118.7 (C), 92.8 (C), 75.5 (CH), 65.3 (CH), 40.8 (CH2), 36.4 (CH); m/z (ES) 382 
(M++H, 11) 388 (8), 386 (79), 384 (100), 382 (11). 
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rel-(1R, 4R, 7S)-5-Bromo-3-trifluoromethanesulfonoxy-10-azatricyclo[5.2.1.01,1o] 
deca-2,5-dien-1-ol 80. 
Br H OTf Triethylamine (30 µL, 22 mg, 0.22 mmol) was added dropwise to a 
N stirred solution of 55 (15 mg, 0.066 mmol) in DCM (2 mL) at -78°C 
H OH 
under nitrogen. A solution of trifluoromethanesulfonic anhydride (33 
µL, 55 mg, 0.20 mmol) in DCM (2 mL) was added dropwise and the mixture was 
stirred at 
-78°C for 30 min. The reaction was allowed to warm to RT and DCM (10 
mL) and water (8 mL) were added. Stirring was continued for an additional 5 min and 
the layers were separated. The organic phase was washed with aq sodium 
hydrogencarbonate (8 mL), dried and the volatiles removed in vacuo to give 80 (18 
mg, 72%) as unstable white crystals; (Found: (HRMS ES) M++H 375.9427, 
Ci0H10NO4BrF3S requires 375.9466); v.,, / cm 1 3429,2946,1661,1588,1434,1341, 
1322,1138,1060,998,961,867,839,638; 6u(400 MHz) 5.92 (1H, d, J 1.4), 5.90 
(1H, t, J 1.8), 4.70 (1H, app quint, J 1.7), 4.33 (1H, ddd, J 5.1,3.1,1.7), 2.40 (1H, m), 
2.15 (1H, ddd, J 12.8,6.7,2.0), 1.97 (1H, m), 1.68 (1H, ddd, J 12.5,12.5,7.3); Sß(100 
MHz) 146.4 (C), 133.1 (CH), 118.5 (q, 1JCF 320.5) (C), 118.1 (CH), 116.9 (C), 103.1 
(C), 75.2 (CH), 70.3 (CH), 36.7 (CH2), 30.1 (CH2); m/z (ES) 378 (M++H, 100) 378 
(100), 376 (62). 
rel-(1R, 4S, 7R)-2,9,9-Tribromo-10-azatricyclo[5.2.1.0" °Jdeca-2-en-1-o159. 
Br OH Br A solution of KHMDS in toluene (0.50 M, 1.63 mL, 0.82 mmol) was Br's.. 
N added dropwise to 'a stirred solution of 50 (101 mg, 0.215 mmol) in 
HH THE (10 mL) at 
-78°C over 5 min. The mixture was stirred for an 
additional 15 min and allowed to come to RT. DCM (20 mL) and water (10 mL) were 
immediately added, the mixture was stirred for 5 min and the layers were separated. 
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rel-(1R, 4R, 7S)-5-Bromo-3-trifluoromethanesulfonoxy-10-azatricyclo[5.2.1.01'l0] 
deca-2,5-dien-1-ol 80. 
Br H OTf Triethylamine (30 µL, 22 mg, 0.22 mmol) was added dropwise to a 
N stirred solution of 55 (15 mg, 0.066 mmol) in DCM (2 mL) at -78°C 
H OH 
under nitrogen. A solution of trifluoromethanesulfonic anhydride (33 
µL, 55 mg, 0.20 mmol) in DCM (2 mL) was added dropwise and the mixture was 
stirred at 
-78°C for 30 min. The reaction was allowed to warm to RT and DCM (10 
mL) and water (8 mL) were added. Stirring was continued for an additional 5 min and 
the layers were separated. The organic phase was washed with aq sodium 
hydrogencarbonate (8 mL), dried and the volatiles removed in vacuo to give 80 (18 
mg, 72%) as unstable white crystals; (Found: (HRMS ES) M++H 375.9427, 
C10H10NO4BrF3S requires 375.9466); v,,,, / cm' 3429,2946,1661,1588,1434,1341, 
1322,1138,1060,998,961,867,839,638; SH(400 MHz) 5.92 (1H, d, J 1.4), 5.90 
(1H, t, J 1.8), 4.70 (1H, app quint, J 1.7), 4.33 (1H, ddd, J 5.1,3.1,1.7), 2.40 (1H, m), 
2.15 (1H, ddd, J 12.8,6.7,2.0), 1.97 (1H, m), 1.68 (1H, ddd, J 12.5,12.5,7.3); 8ß(100 
MHz) 146.4 (C), 133.1 (CH), 118.5 (q, 1JCF 320.5) (C), 118.1 (CH), 116.9 (C), 103.1 
(C), 75.2 (CH), 70.3 (CH), 36.7 (CH2), 30.1 (CH2); m/z (ES) 378 (M++H, 100) 378 
(100), 376 (62). 
rel-(1R, 4S, 7R)-2,9,9-Trib ro mo-10-azatricyclo [5.2.1.01,1 °] deca-2-en-1-o159. 
Br OH Br A solution of KHMDS in toluene (0.50 M, 1.63 mL, 0.82 mmol) was 
Br"".. 
N added dropwise to a stirred solution of 50 (101 mg, 0.215 mmol) in 
HH THE (10 mL) at 
-78°C over 5 min. The mixture was stirred for an 
additional 15 min and allowed to come to RT. DCM (20 mL) and water (10 mL) were 
immediately added, the mixture was stirred for 5 min and the layers were separated. 
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The aq phase was extracted with DCM (2 x 20 mL), the combined organic phase was 
dried and the solvent removed in vacuo to give 59 (69 mg, 83%) as orange crystals, 
mp 112-114°C; (Found: (HRMS ES) M++H 385.8380, C9H11NOBr3 requires 
385.8391); vmax/cm"13546,2927,1616,1462,1343,1112,1074,949,893,642; SH(400 
MHz) 6.32 (1H, d, J 2.0), 4.22 (1H, m), 3.92 (1H, m), 3.20 (1H, dd, 1 14.1,5.9), 2.73 
(1H, dd, J 14.1,7.5), 2.16-1.99 (3H, m), 1.88 (1H, m); 5ß(100 MHz, DMSO-d6) 138.7 
(CH), 121.2 (C), 105.1 (C), 72.1 (C), 68.6 (CH), 60.9 (CH), 54.3 (CH2), 29.9 (CH2)9 
28.3 (CH2); m/z (ES) 386 (M++H, 5) 392 (2), 390 (85), 388 (100), 386 (5). 
rel-(1R, 4S, 7R)-9,9-Dibromo-l-hydroxy-10-azatricyclo[5.2.1.01'10]decan-2-one 56. 
Br OHO 
Compound 50 (48 mg, 0.10 mmol) was added to a stirred mixture of 
Br".. 
acetonitrile (30 mL) and sat aq sodium chloride (30 mL) and the N 
HH resulting suspension was heated at reflux for 2 h. The reaction was 
cooled to RT and DCM (40 mL) and water (15 mL) were added. The mixture was 
stirred 5 min and the layers were separated. The aq phase was extracted with DCM (2 
x 30 mL) and then the combined organic phase was dried and the solvent removed in 
vacuo to give a solid which was purified by column chromatography 
(AcOEt: Petroleum ether 3: 1) to give 56 (10 mg, 30%) as colourless crystals, mp 97- 
99°C; (Found: (HRMS ES) M++H 323.9210, C9H12NOZBr2 requires 323.9235); 
v,,,,,, /cm' 3696,3533,2946,1760,1698,1601,1463,1354,1146,1125,1098,968, 
894; 8H(400 MHz) 4.09 (1H, m), 3.87 (1H, m), 3.35 (1H, dd, J 14.6,6.6), 2.85 (1H, 
dd, J 18.6,7.3), 2.66 (1H, dd, J 14.6,6.7), 2.45 (1H, dd, J 18.6,7.4), 2.30-2.10 (2H, 
m), 2.01-1.92 (IH, m), 1.85 (IH, m); 6(100 MHz) 209.6 (C), 97.4 (C), 68.1 (C), 62.7 
(CH), 55.8 (CH), 55.6 (CH2), 43.6 (CH2), 32.5 (CH2), 29.0 (CH2); m/z (ES) 324 
(M++H, 30) 328 (25), 326 (100), 324 (30). 
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(1r, 2R, 4R, 7S, 9S)-2,9-Dibromo-10-azatricyclo [5.2.1.01'10] decan-1-o157. 
Br OH Br Diphenyl phosphite (2.37 mL, 2.90 g, 12.4 mmol) was added dropwise 
N to a stirred solution of 
50 (1.02 g, 2.19 mmol) in THE (10 mL) at RT. 
HH The mixture was stirred 5 min and triethylamine (1.23mL, 0.89 g, 8.82 
mmol) was added dropwise. Stirring was continued for 30 min and the volatiles were 
removed in vacuo to give a residue which was partitioned between DCM (40 mL) and 
water (20 mL). The mixture was shaken and the layers were separated. The organic 
phase was washed with brine (60 mL) and water (2 x 50 mL), the solvent removed in 
vacuo and the residue was washed with ether (3 x 20 mL) to give 57 (249 mg, 37%) as 
a white solid, mp 138-140°C; (Found: (HRMS FAB) M++H 309.9420, C9H14NOBr2 
requires 309.9442); v, Y, a, /cm1 3632,3548,2958,2872,1732,1462,1266,1106,1068, 
1016,950; 6H(400 MHz) 4.23 (2H, t, J 6.2), 3.86 (2H, app quint, J 5.6), 2.52 (2H, dt, J 
13.5,6.5), 2.15 (2H, dt, J 13.5,5.6), 1.95 (2H, m), 1.47 (2H, m); 8ß(67.5 MHz) 100.0 
(C), 61.9 (CH), 53.6 (CH), 40.4 (CH2), 29.8 (CH2); m/z (FAB) 310 (M+, 6) 314 (6), 
312 (9), 310 (6), 307 (26), 289 (14), 155 (30), 154 (100), 139 (14), 138 (35), 137 (66), 
136 (72), 124 (12), 120 (12), 107 (23), 105 (11), 95 (10), 91 (15), 90 (14), 89 (18), 77 
(19), 69 (14), 57 (19), 55 (17). 
rel-(1R, 2R, 4R, 7S)-2-Bromo-10-azatricyclo[5.2.1.01'loi decan-1-o162. 
OH Br N-Bromosuccinimide (1.54 g, 8.65 mmol) was added portionwise to a 
N stirred solution of enamine 26 (0.693 g, 5.13 mmol) in DCM (20 mL) at 
HH 
-78°C. When the addition was complete, the -78°C bath was replaced 
by an ice bath and the mixture was stirred for 25 min. The reaction was then allowed 
to warm to RT and the mixture was stirred for a further 10 min. The solvent was 
removed in vacuo and the residue partitioned between DCM (50 mL) and 2M NaOH 
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(30 mL). The mixture was shaken and the layers were separated. The aq phase was 
extracted with DCM (2 x 40 mL) and then, the combined organic phase was dried. The 
solvent was removed in vacuo to give a brown solid which was dissolved in a mixture 
of chloroform (50 mL) and conc-aq HC1 (10 mL) and the mixture was heated for 14 h 
at reflux with stirring. The reaction was cooled to RT and water (30 mL) and DCM (30 
mL) were added. The layers were separated and the aq phase was extracted with DCM 
(2 x 30 mL). The combined organic phase was dried and the solvent removed in vacuo 
to give a solid which was purified by column chromatography (DCM: MeOH 10: 1) to 
give 62 (0.131 g, 11%) as a white solid, mp 118-121°C; (Found: (HRMS ES) M++H 
232.0354, C9H15NOBr requires 232.0337); Vmax/crn 1 3564,2943,2870,1463,1355, 
1293,1140,1106,1078,973; 8H(400 MHz) 4.33 (1H, t, J5.1), 3.87 (1H, m), 3.71 (1H, 
m), 2.40 (1H, m), 2.22-2.12 (1H, m), 2.07 (1H, ddd, J 13.7,7.1,5.5), 2.00-1.72 (4H, 
m), 1.65-1.56 (1H, m), 1.53-1.43 (1H, m), 1.42-1.32 (1H, m); 8ß(67.5 MHz) 101.9 
(C), 64.9 (CH), 61.6 (CH), 58.7 (CH), 40.6 (CH2), 36.0 (CH2), 30.3 (CH2), 30.0 (CH2), 
29.6 (CH2); m/z (ES) 232 (M++H, 100) 234 (84), 232 (100). 
rel-(1R, 2R, 4R, 7S)-2-Iodo-10-azatricyclo[5.2.1.0l'10]decan-1-0163. 
OH I N-Iodosuccinimide (1.50 g, 6.67 mmol) was added portionwise to a 
N stirred solution of enamine 26 (0.593 g, 4.35 mmol) in DCM (30 mL) at 
HH 0°C. The mixture was stirred at 0°C for 10 min and then at RT for 1 h. 
Water (30 mL) and DCM (50 mL) were added and stirring was continued for a further 
5 min. The layers were separated and the aq phase was extracted with DCM (2 x 40 
mL). The combined organic phase was dried and the solvent removed in vacuo to give 
a brown solid which was dissolved in a mixture of chloroform (60 mL) and cone aq 
HCl (40 mL). The mixture was heated at reflux for 15 h the reaction was cooled to RT 
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and water (50 mL) and DCM (40 mL) were added. The mixture was shaken and the 
layers were separated. The aq phase was washed with DCM (2 x 40 mL), basified with 
aq NaOH (2 M) and extracted with DCM (3 x 40 mL). The combined organic phase 
was dried and the solvent removed in vacuo to give a brown oily solid which was 
purified by column chromatography (DCM: MeOH 10: 1) to give 63 (79 mg, 6%) as an 
oily brown solid; (Found: (HRMS ES) M++H 280.0195, C9H15NOI requires 
280.0198); v,,,, /cm-1 3576,2960,2870,1463,1356,1292,1130,1102,1076,1061, 
970; SH(400 MHz) 4.21 (1H, m), 3.73 (2H, m), 2.54 (1H, m), 2.15 (2H, m), 1.94 (2H, 
m), 1.85 (2H, m), 1.60-1.40 (3H, m); 6c(67.5 MHz) 101.9 (C), 64.6 (CH), 63.3 (CH), 
42.0 (CH2), 35.7 (CH2), 35.0 (CH), 31.1 (CH2)030.3 (CH2), 29.4 (CH2). 
rel-(1R, 4R, 7S)-2,9-Dibromo-10-azatricyclo [5.2.1.01'10]dec-2-en-1-0161. 
Br OH Br A solution of 
lithium triethylborohydride in THE (1.0 M, 4.7 mL, 4.7 
N mmol) was added to a stirred solution of 59 (295 mg, 0.761 mmol) 
in 
HH THE (11 mL) at RT under nitrogen. The mixture was then heated at 
reflux for 48 h. The solvent was evaporated and the residue partitioned between water 
(10 mL) and conc aq HCl (8 mL). The mixture was stirred vigorously at RT for 15 
min. The layers were separated and the aq phase was washed with DCM (10 mL). The 
aq layer was then made basic with 2M NaOH and extracted with DCM (3 x 20 mL). 
Trifluoroacetic acid (3.4 mL, 5.0 g, 44 mmol) was added to the combined organic 
phase which was then dried and the solvent removed in vacuo to give the 
trifluoroacetate salt of 61 (83 mg, 26%) as colourless crystals, mp 185-187°C; (Found: 
(HRMS ES) M++H 307.9276, C9Ht2NOBr2 requires 307.9286); v,,, aX/cm-' 3505,2942, 
1624,1458,1355,1101,907; 81, (400 MHz) 6.07 (IH, d, J 1.8), 4.54 (1H, t, J 6.1), 
4.28 (1H, ddd, J 8.0,4.6,1.8), 3.92 (IH, app quint, J 6.1), 2.47 (1H, dt, J 13.6,6.1), 
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2.20 (1H, dt, J 13.6,6.1), 2.11-1.92 (2H, m), 1.75 (1H, m), 1.51 (1H, m); 8ß(67.5 
MHz) 135.9 (CH), 120.5 (C), 103.6 (C), 68.7 (CH), 63.0 (CH), 56.2 (CH), 40.7 (CH2), 
29.4 (CH2), 29.2 (CH2); m/z (ES) 308 (M++H, 42) 312 (28), 310 (100), 308 (42). 
rel-(5R, 8S)-2,2-Dibromo-5-(2,2-dibromoethyl)-pyrrolizidin-3-one 53. 
Br Solid potassium tert-butoxide (69 mg, 0.61 mmol) was added 
0 
., %Br 
portionwise over 15 min to a stirred solution of 50 (101 mg, 
Bra N, 
Br HUH0.215 mmol) in THE (5 mL) at 0°C under nitrogen. After 10 min 
the solvent was removed in vacuo and the residue partitioned between water (10 mL) 
and DCM (15 mL). After vigorous agitation the layers were separated and the aq layer 
was extracted with DCM (2 x 10 mL). The combined organic phase was dried and the 
solvent removed in vacuo to give 53 (59 mg, 58%) as a pale yellow solid, mp 134- 
136°C; (Found: (HRMS EI) M+ 464.7557, C9H11NOBr4 requires 464.7574); vfa,, /cm-1 
2957,2931,2875,1715,1405,1352,1300,908; SH(400 MHz) 6.10 (1H, dd, J 7.1, 
7.1), 3.99 (1H, m), 3.90 (1H, m), 3.38 (1H, dt, J 14.7,5.9), 3.29 (1H, dd, J 13.5,4.7), 
2.69 (1H, dd, J 13.4,8.8), 2.49-2.34 (2H, m), 2.15-2.05 (2H, m), 1.58 (IH, m); 8ß(67.5 
MHz) 164.3 (C), 60.3 (CH), 60.0 (C), 54.1 (CH), 53.0 (CH2), 47.5 (CH2), 42.5 (CH), 
33.6 (CH2), 28.0 (CH2); m/z (EI) 469 (4), 467 (3), 465 (0.3), 392 (7), 390 (19), 388 
(19), 386 (7), 310 (4), 308 (7), 284 (18), 282 (35), 280 (18), 204 (93), 202 (100), 201 
(10), 135 (10), 134 (13), 124 (9), 107 (6), 105 (5), 82 (31), 81 (11), 80 (30), 79 (9), 68 
(17). 
61 
Synthesis of azatriquinacene Experimental 
rel-(5R, 8S)-5-(2,2-Dibromoethyl)-8-hydroxy-5,6,7,8-tetrahydropyrrolizin-3-one 
54. 
O 
DBU (2.80 mL, 2.85 g, 18.7 mmol) was added dropwise over 5 
Br N min to a stirred solution of 50 (1.73 g, 3.69 mmol) in THE (150 
Br H`; OH mL) at RT under nitrogen. After 20 min the solvent was 
removed in vacuo and the residue partitioned between water (40 mL) and DCM (60 
mL). After vigorous agitation the layers were separated and the aq layer was extracted 
with DCM (2 x 50 mL). The combined organic phase was dried and the solvent was 
removed in vacuo to give a brown oil which was purified by column chromatography 
(AcOEt: Petroleum ether 5: 1) to give 54 (49 mg, 4%) as a colourless crystalline solid, 
mp 124-126°C; (Found: (HRMS ES) M++Na 345.9023, C9H11N02Br2Na requires 
345.9054); vn x/cm'1 3579,3400,2947,2876,1711,1593,1458,1366,1347,1296, 
1148,1296,1148,1100,1028,1001,908; 8H(400 MHz) 7.10 (1H, d, J 5.7), 5.96 (1H, 
d, J 5.7), 5.87 (1H, dd, J 9.4,3.8), 3.87 (1H, m), 2.82 (1H, ddd, J 14.7,8.8,3.8), 2.72 
(1H, ddd, J14.7,9.5,3.7), 2.54(1H, m), 2.34(1H, m), 2.17 (1H, dd, J 12.7,6.7), 1.60 
(1H, ddd, J 12.6,12.6,7.9); Sß(100 MHz) 174.4 (C), 150.2 (CH), 126.4 (CH), 98.7 
(C), 54.3 (CH), 53.5 (CH2), 43.0 (CH), 34.3 (CH2), 34.2 (CH2); Wz (ES) 346 
(M++Na, 28) 350 (20), 348 (100), 346 (28). 
3-(rel-(5R, 8S)-5-Oxo-5,6,7,8-tetrahydro-3H-pyrrolizin-3-yl)-propionic acid 71. 
O Pyrrole 23 (0.269 g, 1.12 mmol) was added portionwise to a 
HOiC N stirred suspension of zinc dust (1.11 g, 17.0 mmol) in HCl 
H (20%, 5 mL) at 0°C over a period of 15 min. Conc aq HCl (2 
mL) was added and the mixture was stirred at 0°C for 30 min. The reaction was 
warmed to RT and stirring was continued for a further 3 h. The mixture was filtered 
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and the filtrate basified with aq NaOH (2 M), followed by acidification with dil aq 
HC1. The mixture was extracted with DCM (3 x 80 mL) and then the combined 
organic phase was dried and the solvent removed in vacuo to give 71 (39 mg, 17%) as 
an oily yellow solid; (Found: (HRMS EI) M+ 195.0902, C1oH13NO3 requires 
195.0895); Vmax/crn 12928,1738,1658,1382,1095,671; SH(400 MHz) 5.90 (1H, d, J 
6.1), 5.80 (1H, d, J6.1), 4.69 (1H, m), 4.60 (1H, m), 2.74 (1H, m), 2.48-2.31 (4H, m), 
1.94 (1H, m), 1.80 (1H, m), 1.61 (1H, m); 6c(67.5 MHz) 178.9 (C), 176.7 (C), 131.7 
(CH), 130.6 (CH), 67.1 (CH), 60.9 (CH), 34.0 (CH2), 31.3 (CH2), 29.0 (2 x CH2); m/z 
(EI) 195 (M+, 6) 195 (6), 139 (22), 134 (24), 122 (60), 121 (9), 80 (10), 55 (100). 
3-(rel-(5R, 8S)-5-Oxo-5,6,7,8-tetrahydro-3H-pyrrolizin-3-yl)-methylpropionate 72. 
Two drops of conc sulfuric acid were added to a stirred 
0 
H3CO2C N 
solution of 71 (59 mg, 0.31 mmol) in MeOH at RT. The 
H- "H solution was stirred for 2h and the solvent was removed in 
vacuo to give an orange oil which was dissolved in DCM (10 mL) and treated with aq 
KOH (2 M, 8 mL). The layers were separated and the aq phase extracted with DCM (2 
x 10 mL). The combined organic phase was dried and the solvent removed in vacuo to 
give 72 (48 mg, 82%) as an oily yellow solid; (Found: (HRMS EI) M+ 209.1051, 
C11H15NO3 requires 209.1052); vom,, /cm 12952,2874,1732,1683,1388,1346,1149, 
1015; 8H(400 MHz) 5.87 (1H, d, J 6.0), 5.78 (1H, d, J 6.0), 4.63 (2H, m), 3.62 (3H, s), 
2.69 (1H, m), 2.45-2.25 (4H, m), 1.95 (1H, m), 1.76 (1H, m), 1.62 (1H, m); 8ß(67.5 
MHz) 178.4 (C), 173.9 (C), 131.8 (CH), 130.6 (CH), 67.0 (CH), 61.2 (CH), 51.6 
(CH3), 34.2 (CH2), 30.8 (CH2), 29.7 (CH2), 29.7 (CH2); m/z (EI) 209 (M', 19) 209 
(19), 178 (19), 153 (55), 134 (64), 122 (100), 83 (27), 80 (32), 55 (68). 
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Dimethyl IH-pyrrole-3-chloro-2,5-dipropanoate 66. 
H 
N-Chlorosuccinimide (0.388 g, 2.88 mmol) was 
H3CO2C N CO2CH3 
added to a stirred solution of dimethyl JH- '*'ýý\ Z'**'ý 
CI pyrrole-2,5-dipropanoate 23 (0.621 g, 2.61 
mmol) in chloroform (6 mL) at 0°C under nitrogen. The solution was allowed to warm 
to RT and stirred for 1 h, then heated at reflux for 2 h. DCM (5 mL) was added and the 
mixture was washed with water (3 x3 mL). The layers were separated and the aq 
phase extracted with DCM (3 x3 mL). The combined organic phase was dried and the 
solvent removed in vacuo to give 66 (0.669 g, 94%) as an orange solid, mp 62-64°C; 
(Found: (ES) M++H 274.0821, C12H17C1N04 requires 274.0846); vn,,, x/cml 3412, 
2954,1732,1589,1455,1366,1310,1155,1071,986; 6H(400 MHz) 8.72 (1H, br s), 
5.77 (1H, d, J 3.0), 3.73 (3H, s), 3.72 (3H, s), 2.87 (2H, t, J 6.9), 2.82 (2H, t, J 6.9), 
2.61 (2H, t, J 6.9), 2.60 (2H, t, J 6.9); 8ß(67.5 MHz) 174.2 (C), 173.8 (C), 128.9 (C), 
125.0 (C), 108.4 (C), 105.3 (CH), 51.7 (2 x CH3), 33.9 (CH2), 33.4 (CH2), 22.7 (CH2), 
19.9 (CH2); m/z (ES) 274 (M++H, 100) 276 (18), 274 (100). 
Dimethyl 1H-pyrrole-3-methoxycarbonyl-2,5-dipropanoate 67. 
Methyl chloroformate (0.12 mL, 1.6 mmol) and H 
H3CO2C N C02CH3 
aluminium trichloride (19 mg, 0.15 mmol) were 
CO2CH3 added to a stirred solution of dimethyl IH- 
pyrrole-2,5-dipropanoate 23 (0.153 g, 0.640 mmol) in chloroform (3 mL) under 
nitrogen and the mixture was heated at reflux for 12 h. DCM (2 mL) was added and 
the solution was washed with dil aq sodium hydrogencarbonate (2 mL). The layers 
were separated and the aq phase extracted with DCM (3 x2 mL). The combined 
organic phase was dried and the solvent removed in vacuo to give 67 (0.169 g, 92%) 
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as a pale yellow solid, mp 82-84°C; (Found: C, 56.3; H, 6.4; N, 4.5; C14H19NO6 
requires C, 56.6; H, 6.4; N, 4.7%); (Found: (HRMS EI) M+ 297.1208, C14H19NO6 
requires 297.1212); vr,, /cm 1 3416,2953,1729,1697,1458,1365,1093; SH(400 
MHz) 9.12 (1H, br s), 6.19 (1H, d, J3.0), 3.79 (3H, s), 3.72 (3H, s), 3.67 (3H, s), 3.20 
(2H, t, J 7.0), 2.82 (2H, t, J 6.9), 2.66 (2H, t, J 6.9), 2.59 (2H, t, J 6.9); 8c(67.5 MHz) 
174.8 (C), 174.4 (C), 166.2 (C), 137.7 (C), 129.9 (C), 111.3 (C), 107.4 (CH), 52.3 
(CH3)9 52.2 (CH3)2 51.1 (CH3), 34.3 (CH2), 33.9 (CH2), 22.7 (CH2), 22.2 (CH2); m/z 
(EI) 297 (M+, 3) 297 (3), 237 (3), 224 (8), 192 (9), 164 (5), 132 (6), 88 (7), 86 (39), 84 
(66), 83 (4), 49 (100), 47 (16). 
65 
Synthesis of azatriquinacene References 
4. References 
(1) (a) Eaton, P. E. Tetrahedron 1979,35,2189. (b) Paquette, L. A. Chem. Rev. 1989, 
89,1051. 
(2) Schulman, J. M.; Disch, R. L. J. Am. Chem. Soc. 1978,100,5677. 
(3) Dixon, D. A.; Deerfield, D.; Graham, G. D. Chem. Phys. Lett. 1981,78,161. 
(4) Woodward, R. B.; Fukunaga, T.; Kelly, R. C. J. Am. Chem. Soc. 1964,86,3162. 
(5) Jacobson, I. T. Acta Chem. Scand. 1967,21,2235. 
(6) Codding, P. W.; Kerr, K. A.; Oudeman, A.; Sorensen, T. S. J. Organomet. Chem. 
1982,232,193. 
(7) Almansa, C.; Moyano, A.; Serratosa, F. Tetrahedron 1988,44,2657. 
(8) Clardy, J.; Solheim, B. A.; Springer, J. P.; Itoh, I.; Paquette, L. A. J. Chem. Soc. 
Perkin. Trans. 2 1979,296. 
(9) Deslongchamps, P.; Soucy, P. Tetrahedron 1981,37,4385. 
(10) Roberts, W. P.; Shoham, G. Tetrahedron Lett. 1981,22,4895. 
(11) Bertz, S. H.; Kourouklis, G. A.; Jayaraman, A. Can. J. Chem. 1993,71,352. 
(12) Ternansky, R. J.; Douglas, W. B.; Paquette, L. A. J. Am. Chem. Soc. 1982,104, 
4503. 
(13) Hext, N. M.; Shiskin, 0. V.; Mascal, M. Tetrahedron Lett. 1996,37,131. 
(14) (a) Rideout, 0. C.; Breslow, R. J. Am. Chem. Soc. 1980,102,7816. (b) Grieco, 
P. A.; Yoshida, K.; Garner, P. J. Org. Chem. 1983,48,3137. (c) Breslow, R.; 
Maitra, U.; Rideout, D. Tetrahedron Lett. 1983,24,1901. 
(15) Hickmott, P. W. Tetrahedron 1982,38,1975. 
(16) Rodebough, R.; Debenham, J. S.; Fraser-Reid, B.; Snyder, J. P. J. Org. Chem. 
1999,64,1758. 
(17) Ogino, T.; Mochizuki, K. Chemistry Lett. 1979,443. 
66 
Synthesis of azatriquinacene References 
(18) Bhutani, K. K.; Ali, M.; Atal, C. K. Phytochemistry 1984,23,1765. 
(19) Lera, M.; Blake, A. J.; Czaja, M.; Kozak, A.; Makowski, M.; Chmurzynski, L.; 
Mascal, M. Angew. Chem. Int. Ed. Engl. 2001,40,3696. 
(20) Alder R. A. Chem. Rev. 1989,89,1215. 
(21) Horwell, D. C.; Timms, G. H. Synth. Commun. 1979,223. 
(22) Marshall, J. A.; Johnson, W. S. J. Am. Chem. Soc. 1963,85,421. 
(23) Borch, R. F.; Bernstein, M. D.; Durst, H. D. J. Am. Chem. Soc. 1971,93,2897. 
(24) Madsen, J. 0.; Iversen, P. E. Tetrahedron 1974,30,3493. 
(25) Duhamel, L.; Duharnel, P.; Enders, D.; Karl, W.; Leger, F.; Poirier, J. M.; Raabe, 
G. Synthesis 1991,649. 
(26) Sheldon, K. Org. React. 1972,19,279. 
(27) Lera, M.; Blake, A. J.; Mascal, M. J. Org. Chem. 2000,65,7253. 
(28) Lera, M.; Blake, A. J.; Wilson, C; Mascal, M. J. Chem. Soc. Perkin Trans. 1, 
submitted for publication. 
(29) Oediger, H.; Moller, F.; Eiter, K. Synthesis 1972,591. 
(30) Toda, F.; Akagi, K. Tetrahedron 1971,27,2801. 
(31) Hirao, T.; Masunaga, T.; Ohshiro, Y.; Agawa, T. J. Org. Chem. 1981,46,3745. 
(32) Frutos, M. P.; Fernandez, M. D.; Bernabe, M. Tetrahedron 1992,48,1123. 
(33) Krishnamurthy, S.; Brown, H. C. J. Org. Chem. 1983,48,3085. 
(34) Knapp, S.; Naughton, A. B.; Murali, T. G. Tetrahedron Lett. 1992,33,1025. 
(35) Anderson-McKay, J. E.; Lawlor, J. M. Aust. J. Chem. 1988,41,1013. 
(36) Yoshimoto, M.; Ishida, N.; Hiraoka, T. Tetrahedron Lett. 1973,39. 
(37) Bonacorso, H. G.; Mack, K. E.; Effenberger, F. J. Heterocyclic Chem. 1995,32, 
57. 
(38) Singer, B.; Maas, G. Chem. Ber. 1987,120,485. 
67 
Synthesis of azatriquinacene References 
(39) Scott, W. J.; Crisp, G. T.; Stille, J. K. J. Am. Chem. Soc. 1984,106,4630. 
(40) Ramesh, N. G.; Heijne, E. H.; Klunder, A. J.; Zwanenburg, B. Tetrahedron Lett. 
1998,39,3295. 
(41) Jirkovsky, I. Can. J. Chem. 1974,52,55. 
(42) Kupchan, S. M.; Afonso, A. J. Org. Chem. 1960,25,2217. 
(43) Pearson, W. H.; Lin, K. C. Tetrahedron Lett. 1990,31,7571. 
(44) Easton, C. J.; Hay, M. P.; Love, S. G. J. Chem. Soc. Perkin Trans. 1 1988,265. 
(45) Suwa, T.; Sugiyama, E.; Shibata, I.; Baba, A. Synlett 2000,558. 
(46) Bosse, D.; de Meijere, A. Chem. Ber. 1978,111,2223. 
68 
Part II 
SYNTHESIS OF BACKBONE MODIFIED 
DNA 
USING TRANSITION METAL 
CATALYSIS 
Supervised by Dr Christopher J. Hayes 
Synthesis of backbone modified DNA using transition metal catalysis Abstract 
Abstract 
" The synthesis of a DNA building block containing a linker with an amine has been 
accomplished and its capacity to accommodate interesting molecules in an internal 
position of an oligonucleotide was proved by the attachment of the amino acid 
arginine. 
" 
The coupling of the above dinucleotide with bis(disopropylamino)cyanoethyl 
phosphite has been achieved with the aim of making this material suitable for solid 
support synthesis as used in automated DNA synthesisers. 
"A new methodology for the synthesis of H-phosphonates has been developed based 
upon three nucleophilic substitutions onto phosphorus trichloride in one pot. 
" 
We have developed an easy and efficient way to carry out the palladium catalysed 
cross-coupling reactions using sealed, thick walled reaction vials. 
"A new method for the synthesis of alkynylphosphonates from 1,1-dibromo-l-alkenes 
has been developed and the synthesis of a new alkyne-containing thymidine dimer has 
been achieved. 
" 
Vinylphosphonate-linked dinucleotides have been prepared using an olefin cross- 
metathesis reaction as a key step. 
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1. Introduction 
Even today, despite great advances in technology and knowledge, new drugs are 
usually not discovered by rational drug design, even though this would be highly 
desirable for the medically oriented chemist. On average, it is still necessary to 
synthesise and test about 10,000 new compounds in order to discover a new active 
substance worth developing. In many cases the active substance is directed against 
proteins such as enzymes, receptors, or ion channels, the structure and mode of action 
of which are usually very complicated and often not completely understood. On the 
other hand, therapeutic intervention at the level of the nucleic acid appears to offer a 
number of advantages. 
On transcription, every gene gives rise to a relatively small number of copies of 
messenger ribonucleic acid (mRNA), which are translated into a large number of 
protein molecules. For this reason inhibition of gene expression ought to be more 
efficient than inhibition of the resulting protein product. There is already one drug on 
the market whose activity is based on direct interaction with deoxyribonucleic acid 
(DNA). 
The main goal of this strategy is an efficient gene-specific approach to chemotherapy. ' 
The disease targets can be broadly defined as any diseases that involve the production 
of harmful proteins. This category includes bacterial, viral and fungal diseases, as well 
as certain types of cancer. The basis of this approach is the "antisense method" for 
controlling gene expression (protein synthesis)2 and this is illustrated in Figure 1. The 
antisense method is a naturally occurring3 gene regulation mechanism that relies upon 
the ability of messenger RNA, which is a single-stranded nucleic acid, to be 
recognised in a sequence-specific manner by complementary nucleic acid molecules. 
This recognition occurs by the familiar and highly reliable Watson-Crick base pairing 
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that is responsible for the specificity of the genetic code. The inhibitory effect of 
antisense oligonucleotides was first observed in 1978 by Zamecnik and Stephenson, 
who used a 13-mer oligonucleotide to inhibit the growth of Rous sarcoma virus in cell 
culture. 4 
A 
B 
F, 1ý 
Nucleus Cytoplasm 
Transcription Translation 
VP 
Y'= 
WAN 
DNA mRNA PROTEINS 
/ Nucleus Cytoplasm 
Translation 
Transcription 
NO PROTEINS 
antisense 
oligonucleotide 
DNA mRNA 
Figure 1. (A) Normal process of synthesis of proteins. (B) Inhibition of synthesis of proteins by 
antisense oligonucleotides. 
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In the natural form of this gene regulation method, an antisense RNA molecule is 
synthesised inside the cell by transcription. This high molecular weight nucleic acid 
binds to its target mRNA and prevents the message from being translated into proteins 
in the ribosomes. Observed in both prokaryotess and eukaryotes, 6 antisense regulation 
can also be introduced artificially via transfection with antisense genes. These 
processes have no "drug delivery problem" because the antisense reagent is produced 
inside the cell. 
The chemical version of the antisense technique employs antisense sequences that are 
synthesised outside the cell, such as on a DNA synthesiser. For several reasons, 
including enhanced cellular uptake and lower cost, synthetic antisense molecules are 
much lower in molecular weight (typically 17-20 nucleotides long) than the full-length 
gene transcripts employed in the natural antisense method. Since, statistically, the 
base sequence of a 17-mer oligonucleotide occurs just once in the sequence of the 
human genome, extremely selective intervention ought to be possible with antisense 
oligonucleotides of this length. 
The mechanism of action of the short, synthetic antisense sequences does not 
necessarily parallel the natural antisense mechanism, which involves sequestering the 
target mRNA by binding it to a complementary RNA strand. Instead of merely binding 
to specific mRNA sequences, DNA drugs act in concert with the cellular enzyme 
Ribonuclease H (RNase H) to destroy the target mRNA. 2 RNase H is known to digest 
the RNA strand of DNA-RNA duplexes, and it provides a catalytic pathway for 
antisense DNA drugs to operate. 
Given the apparent specificity and catalytic nature of the chemical antisense approach, 
it may be surprising that only one antisense drug is in active use. Several clinical trials 
are now in progress, 8 but a number of difficulties remain to be overcome. Examples of 
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such difficulties include: (1) drug delivery across cell membranes, 9 (2) drug delivery 
to the correct intracellular regions, 10 (3) in vivo stability of DNA drugs to nucleases 
enzymes and other biochemical degradation agents, and (4) cost of the reagents. 
Many advances have been made in the chemistry of DNA analogues" that retain 
Watson-Crick base-pairing ability, while offering improved delivery and stability 
properties. 12 However, a problem with using such anologues is that the enzyme RNase 
H is highly specific about which nucleic acids it will accept as templates for RNA 
digestion, 13 it is a DNA-dependent RNA hydrolysis catalyst. Thus, RNA does not 
promote RNase H-mediated RNA cleavage, nor do most DNA analogues. Therefore, 
the dilema arises that chemical modifications designed to enhance the stability and 
uptake of DNA drugs may actually block the catalytic pathway. 
1.1 Ribozyme Mimics 
Up until a few years ago it was generally believed that only proteins catalyse chemical 
reactions in vivo. However, it has been discovered recently that ribozymes are catalytic 
nucleic acids that often, as part of a larger mRNA structure, catalyse the self-splicing 
of the primary transcript. 14 
Functional mimics of ribozymes and ribonucleases are defined as "synthetic molecules 
that cleave RNA in a sequence-directed manner, using biomimetic chemical reactions 
such as transesterification and hydrolysis". For simplicity, the term "ribozyme 
mimics" will be used to represent these compounds. The transesterification and 
hydrolysis reactions are grouped together as "nucleophilic cleavage reactions" for 
several reasons (Scheme 1). ' These reactions are closely related by the nucleophilic 
attack on phosphorus (V) that each employs. The mechanistic connection between 
these reactions was unified by Perreault and Anslyn. 15 For transesterification, the 
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nucleophile is an alcohol or alkoxide, while for hydrolysis, the nucleophile is almost 
always water or hydroxide. 16 Furthermore, most inorganic reagents that catalyse RNA 
transesterification go on to hydrolyse the resulting 2', 3'-cyclic monophosphate to a 
mixture of 2'- and 3'-phosphate monoesters, as indicated in Scheme lb. 
(a) 
,:: 
N 
OO N-base 
0. 
,O 
d0 
HO N-base 
a OH 
(b) H2O 
O 
-W-base 
HO O 
O=P\7O(D 
OH 
Scheme 1. Nucleophilic cleavage of RNA: (a) Transesterification with concommitant cleavage of the 
phosphodiester backbone. (b) Hydrolysis of the 2', 3'-cyclic monophosphate to a mixture of 2'- and 3'- 
monophosphates. 
Ribozyme mimics can be constructed by covalent incorporation of active RNA 
cleavage catalysts into DNA oligonucleotides or their analogues. The specificity of 
these reagents is consequently derived from the Watson-Crick hydrogen bonding of 
the DNA strand to its complementary RNA sequence (Scheme 2), and it exhibits the 
full specificity of the genetic code. The chemoselectivity of the mimics arises from the 
relative ease of nucleophilic cleavage of RNA compared with DNA. 17 This, in turn, is 
derived from the facile intramolecular nature of the nucleophilic attack that typically 
drives RNA cleavage (Scheme 1). DNA lacks the 2'-OH functionality and has proved 
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almost completely inert to hydrolysis or transesterification by small molecule 
catalysts, with a few notable exceptions. '8 
Catalyst 
Linker Arm 
DNA Probe 
11111111111 III 1111111111 
Target mRNA 
k., k, 
k3 
k2 
IT] 11 If LL 
Scheme 2. Potential catalytic cycle of a ribozyme mimic. The first step involves recognition and 
binding of the target mRNA (k1). In the second step, the RNA target is cleaved in a site-specific manner 
(k2). Finally, the product fragments are released (k3), and the mimic is ready for another cycle. 
A balance is needed between the on-rate for nucleic acid binding (Scheme 2, k1) and 
the rate of chemical cleavage (Scheme 2, k2). Too high a rate of chemical cleavage 
will result in nonspecific RNA degradation. For catalytic turnover to be achieved with 
ribozyme mimics, the off-rate for release of cleaved RNA fragments by the DNA 
strand (Scheme 2, k3) is also of fundamental importance. 
1.2 Catalysts and their Mechanisms of RNA Cleavage 
One remarkable feature of RNA transesterification and hydrolysis is that these 
reactions are catalysed by a large variety of species that span almost the entire Periodic 
II III 
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Table. Protons, hydroxide, amines and other nitrogen derivatives, Mg(II), Ca(II), 
Fe(III), Ni(II), Cu(II), Zn(II), Pb(II), trivalent lanthanides, U02 2+19 and Th salts 20 are 
just some of the species known to cleave RNA through nucleophilic paths. Of course, 
enzymes and ribozymes must be added to the list. Most of these individual catalyst 
types have been reviewed recently. 21 
Certain features are generally applicable to RNA transesterification. However, for any 
given combination of a particular catalyst and a particular RNA substrate, the order of 
events, the order of the reaction, the simultaneous or stepwise nature of the processes, 
and importance of each individual step can vary dramatically. 
_; -o 
o. Ba 
, 
r. ''' ; 1111 
O N-base 
HO O N-base 
++ Base 
O, 
,O 
ed O OH 
Scheme 3 
Transesterification of RNA normally requires participation of the 2'-OH as a 
nucleophile22 (except for some ribozymes, which employ other nucleophilic 
hydroxyls). During the reaction, the 2'-OH must be deprotonated, and the leaving 5'- 
alkoxy group must be protonated. Both steps can be accomplished by one round of 
base catalysts, for example by imidazole or a metal hydroxide (Scheme 3). 
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It is possible that deprotonation of the nucleophile may occur by prior coordination of 
a metal ion to the 2'-OH, since this would lower the relevant pKa23 The effective 
nucleophile would then be a metal alkoxide (Scheme 4). 
O 
-V N-base 
p OH 
0-, 
-base 
OOH 
OO N-base 
ÖO 
M(H20)n2+ 
ö 
Scheme 4 
It is also possible that protonation of the leaving group is of secondary importance to 
stabilisation of the departing alkoxide by a metal ion (Scheme 5). 
0- 
-base 
Op 
-base 
O, 
,O 
O. 
.OpP 
ivO "-uaýý (n. 1)+ 
(9 
'O O N-base 0OH 
O OH 
Scheme 5 
In general terms, the nucleophile derived from the 2'-OH must attack a tetrahedral 
phosphodiester, generating either a phosphorane intermediate or a shorter-lived 
activated complex. Nucleophilic attack on an anionic phosphodiester is notoriously 
unfavourable from an electrostatic perspective. '7 Therefore, some means of preventing 
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a large negative charge from building up in the activated complex is typically 
necessary. Protons or Lewis acids may provide this charge stabilisation. 
The number of metal ions involved in metal-mediated RNA cleavage is a matter of 
some interest and dispute, whether the reaction is performed by enzymes, ribozymes 
or small metal complexes. To design the most effective ribozyme mimic, it is of vital 
importance to know how many metal ions must be delivered to the substrate. 
1.3 Sequence-Specific Nucleophilic RNA Cleavage 
1.3.1 Key Design Features. 
It is by now generally understood that certain design features are critical to the 
development of effective ribozymes mimics. One of the most heavily emphasised 
requirements is that of "cleavage within the DNA-RNA duplex region' . 24 This design 
element is essential for catalytic turnover because the DNA-RNA binding constant is 
strongly length-dependent. Cleavage within the duplex greatly reduces the binding 
constant between the ribozyme mimic and its RNA target, which allows the product 
fragments to be released. This is illustrated in Scheme 6, along with the alternative 
design which places the cleavage agent at the end of the duplex region. Reagents for 
external cleavage are usually simpler to prepare than reagents for internal cleavage. 
However, external cleavage results in complete product inhibition, because the DNA- 
RNA binding constant is not decreased by the cleavage event, so the "catalyst" is 
entombed in an RNA strand. 
The length of the linker arm between the DNA probe and the pendant RNA cleavage 
catalyst is of major importance. Molecular modelling is a useful method for estimating 
the optimun linker arm length for delivering the catalyst to the RNA target. Early 
designs have used flexible linkers sacrificing precision to achieve activity. 
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DNA Probe 
_III11111Itl1IIIIIIIIIIII Target mRNA 
k-I k1 
k2 
UNSTABLE 
k3 
Trm DNA Probe 
IIIIIIIIIIIIIIIIIIIII(11 
Target mRNA 
k4 kl 
k2 
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--\ 
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kg 
TTMI III I I' Trrrrrr IIII 
Scheme 6. Cleavage of RNA within the duplex region verses cleavage outside the duplex region. 
1.3.2 Preparation and Behavior of Sequence-Specific RNA Cleavage Agents 
1. Ribozyme Mimics Based on Organic Catalysts 
Synthetic ribonucleases have been developed by the covalent attachment of organic 
RNA transesterification catalysts to deoxyoligonucleotides. This work started with the 
ideas reported by Cohen25 and with subsequent papers by the Bashkin group on the 
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synthesis of DNA building blocks containing organic catalysts. 26 Komiyama and 
coworkers were the first to report successful sequence-specific RNA cleavage using 
this method 27 Their mimic consisted of a urethane-linked ethylenediamine at the 5'- 
end of a 19-mer DNA probe complementary to A44-A62 of tRNA' (Figure 2). It was 
prepared by the treatment of a solid-supported DNA 19-mer with 1,1'- 
carbonyldiimidazole, followed by diethylenetriamine. This artificial enzyme site 
specifically cleaved about 10% of the tRNA after 4h at 50°C. Cleavage occurred just 
outside the duplex region adjacent to the ethylenediamine residue. Reactions consisted 
of 0.1 mM probe, 1 µM tRNA and 1 mM EDTA at pH 8.0. The EDTA was added to 
the reaction mixture to sequester any metal ions and rule out the participation of metal 
ions in the cleavage reaction. Site-specific cleavage of a linear 30-mer 
oligoribonucleotide was also achieved using the same construct. 28 The extent of 
cleavage was 10% after 4h at pH 8.0 and 50°C. The concentrations of conjugate and 
RNA were 100 and 1.0 µM, respectively. 
H 
DNA 19-mer HO N NýýNH2 
Figure 2. An ethylenediamine-DNA hybrid. 
Reynolds et al. made an imidazole-based synthetic ribonuclease. 29 Recognising that 
single-stranded RNA is more susceptible to nucleophilic cleavage than duplexed RNA 
(and also the importance of cleavage within the duplex region for release of the 
cleaving agent), they engineered into their probe a nonnucleotide-linker L with 
attached imidazole groups in place of one of the complementary bases (Figure 3). 
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RNA 3'- AUCGAAGGAAUCGAGGACGUAC-5' 
MPO S- TAGCTTCCTTLCGCTCCTG 
- 
3' 
ö AN L= N Ilý N"J1 N H3C HHHH  H 
-110 lýI 
ýýý\///ýý_ 
N 
3' HHH 
Figure 3. Structure of the antisense methylphosphonate oligonucleotide (MPO) cleaving agent and its 
RNA target. 
Using this technique, the authors hoped to introduce added flexibility into the opposite 
RNA strand, thereby allowing it to adopt a conformation more favourable for 
transesterification. Two of their probes yielded site-specific cleavage of a 22-mer 
RNA strand within the duplex region. Less than 10% cleavage was observed after 5 
days at 25°C and pH 7.2, with a final probe concentration of 75 . tM. EDTA (1.0 mM) 
was also added to each reaction to scavenge metals, thus ruling out the participation of 
metal contaminants in the reaction. 
Quite recently, Vlassov et al. 30 obtained remarkable site-specific cleavage for an 
organic-based synthetic ribonuclease. They made deoxyoligonucleotide derivatives 
conjugated with moieties containing two histamine residues that mimic the catalytic 
active site of RNase A. Deoxyoligonucleotides with the modifications at either the 3'- 
or 5'-end, separately or together, site specifically cleaved tRNA. Maximun cleavage 
(60%) of the target was attained after 8h at 37°C (pH 7.0). Two probes were used and 
the longer of them with the modification at the 5'-end gave the most efficient cleavage 
(Figure 4). The cleavage pattern corresponded to regions on the RNA just opposite the 
histamine groups, outside the duplex region. An additional cleavage site was found 
away from the expected targeted region. Apparently this site is close, in a three- 
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dimensional sense, to the targeted cleavage region after folding. To show that the 
cleavage was not due to metals binding to the histamines, all solutions contained 1 
mM EDTA. 
5' 
- 
TCCAGGACACAAGCTAG 
-R 
oN) N 
R=N 
H 
gNH 
H 
INN 
Figure 4. Oligonucleotide conjugate containing a diamidazole construct attached at the 3'-end. 
2. Hybrid Enzymes 
The first reported examples of artificial site-specific cleaving agents for RNA were 
created by the covalent attachment of nuclease enzymes to deoxyoligonucleotides. 
Through Watson-Crick base pairing interactions, the deoxyoligonucleotides delivered 
the relatively nonspecific enzymes to defined sites on the target RNA molecules. 
Zuckermann and Schultz31 attached a mutant Staphylococcal nuclease (Lys-116 to 
Cys-116) to the 3'-end of a deoxyoligonucleotide (14-mer) via a disulfide linkage 
(Figure 5). Treatment of a 59-mer single stranded RNA target with this construct (in 
the presence of Cat+) resulted in cleavage over a 3- to 5-nucleotide region directly 
adjacent to the hybridisation site. Unfortunately, the reagent's specificity decreased 
with increasing reaction times, possibly as a result of self-cleavage of the DNA- 
enzyme construct. Staphylococcal nucleases hydrolyse the phosphodiester bonds of 
both single stranded RNA and DNA, which means that it can also destroy the DNA 
probe to which it is attached. 
81 
Synthesis of backbone modified DNA using transition metal catalysis Introduction 
Cys 116 
H2 0 
Staphylococcal C, Sýs o-P-O DNA 14-mer 
nuclease 0o 
Figure 5 
As a possible solution to this problem, the same group coupled RNase S (a subtilisin 
digested version of RNase A) to a deoxyoligonucleotide (14-mer) to create a 
sequence-specific ribonuclease 32 In contrast to the hybrid staphylococcal nuclease, 
this hybrid was incapable of self-cleavage because RNase S is specific for RNA only. 
As was expected, the oligonucleotide delivered the enzymatic activity to a specific site 
on its 62-mer RNA target. Cleavage occurred at one pyrimidine-purine site adjacent to 
the site of hybridisation. Unfortunately, cleavage efficiency and specificity decreased 
at elevated temperatures (>37°C), and the authors attributed this to the probable 
dissociation of the RNase S adduct into its two protein fragment components. 
Kanaya and colleagues33 later created a hybrid enzyme by covalently linking E. coli 
RNase H to the 5'-terminus of a 9-mer deoxyoligonucleotide (Figure 6). This was 
accomplished using site-directed mutagenesis to substitute a cysteine residue for 
Glutas in a mutant form of the enzyme. The free cysteine residue allowed for coupling 
of the enzyme to a maleimide group, which was attached at the 5'-end of the 9-mer 
deoxyoligonucleotide via a flexible tether. The target for this conjugate was a 
synthetic 9-mer single-stranded RNA, and sequence-specific cleavage was achieved 
between the fifth and sixth residues of the target. An important property of this 
particular hybrid is that catalytic turnover was achieved. This property can better be 
explained by the fact that the cleavage event must occur within the duplex region 
(since RNase H only cleaves RNA in DNA-RNA duplexes), and this must lower the 
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binding affinity enough to allow for the dissociation of the cleavage products from the 
hybrid and free it for another cycle. Subsequent melting temperature studies performed 
on the DNA 9-mer and the RNA cleavage products indicated that a dramatic decrease 
in the stability of the DNA-RNA duplex would occur after cleavage by RNase H. The 
same group later reported the preparation of a series of the same hybrid in which the 
length of the linker arm was varied (18,24 and 27 A). The hybrid with the 27 A linker 
arm cleaved a 22-mer RNA target at almost exclusively one position. 
Cys 135 
H2 0 C, 
.S1 
RNasee/ 1SN NC-P-o 
DNA 9-mer 
4H5 QD 
0 
Figure 6 
3. Ribozyme Mimics Based on Metal Complexes 
While hybrid enzymes exhibit highly specific and efficient cleavage of their RNA 
targets, their large molecular weights and difficulty of preparation probably preclude 
their use in practical applications. Recently, several groups have covalently attached 
metal complexes to oligonucleotides to form ribozymes mimics. In 1994, the first 
example of a wholly synthetic, functional mimic of a ribozyme was reported. 24 This 
mimic consisted of a 17-mer DNA oligonucleotide with a covalently attached 
terpyridine ligand at C-5 of an internal uracil residue (Figure 7). The mimic was 
synthesised (via solid-phase DNA chemistry) using a modified DNA building block. 
The target was a 159-mer RNA sequence derived from the gag-mRNA of HIV, and 
sequence-specific cleavage was observed at physiological pH (7.5) in the presence of 
CuC12. The cleavage was located at two positions within the duplex region opposite 
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the modified base. The efficiency of cleavage was 11% at 37°C and 18-25% at 45°C 
over a period of 72 h, with a probe concentration of 5 µM and a RNA target 
concentration of 10"3 µM. These results were pivotal in that they proved the concept 
that ribozyme mimics can be constructed by covalently linking RNA 
transesterification catalysts to DNA. Thus, the complex catalytic region of a natural 
ribozyme was replaced with a small molecule catalyst. 
5'- 109GACUAUGU'16 
- 
3' (159-mer RNA target) 
3' 
- 
CTGAXACA 
- 
5' (ribozyme mimic) 
X= 
i 
N. 
A-3 
H 
Ný 
NN/ 
Figure 7. The first wholly synthetic, functional mimic of a ribozyme. 
Shortly thereafter, other examples of sequence-specific RNA cleavage agents based on 
metal complexes were reported. Matsumura et al. 34 prepared a 15-mer 
deoxyoligonucleotide which was functionalised at the 5'-end with a lanthanide- 
complexing aminodiacctate residue (Figure 8). 
0 
1 DNA 15-mer O-P 
-O, 
N (60H 
Oý 6ý OH 
0 
Figure 8. A DNA 15-mer functionalised at the 5'-end with an aminodiacetate residue. 
This conjugate was synthesised using a modification in which a DNA 15-mer with an 
amino group at its 5'-end was reacted with the 4-nitrophenyl ester of the metal- 
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complexing moiety. In the presence of various lanthanide ions [i. e., Lu(IIl), Th(III) 
and Eu(III)], the modified oligo cleaved a synthetic 39-mer RNA target outside the 
duplex region, opposite the metal complex. The efficiency of cleavage was 7.3% after 
4h and 17% after 8 h. Reactions were performed at 37°C and pH 8, and the 
concentrations of probe and RNA target were 10 and 0.3 µM, respectively. 
Magda et al. 35 synthesised ribozyme mimics by attaching Eu(III), chelated by a 
monoanionic, pentadentate texaphyrin ligand (EuTx), to 20-mer DNA probes. Their 
strategy involved the synthesis of DNA oligonucleotides containing alkylamine groups 
either a C-5 of an internal thymine residue or at a 5'-terminal phosphate. This was 
followed by treatment of the deoxyoligonucleotides with the europium(III)-texaphyrin 
carboxylic acid to effect amide coupling to the alkylamine groups (Figure 9a). The 
conjugate with the texaphyrin complex attached at the 5'-end of the DNA strand site 
specifically cleaved a chemically synthesised 30-mer RNA target near the expected 
location. Approximately 30% cleavage was observed after 24 h at 37°C and pH 7.5 in 
a reaction containing 2.5 nM probe and 1 nM RNA target. In contrast, no cleavage was 
observed with the internally modified deoxyoligonucleotides. A major contribution of 
this work was the use of the stable performed Eu(III) complex. Whereas other 
approaches required the addition of free metal ion cofactors for the cleavage event to 
take place, this method allowed the cleavage reaction to occur independently of such 
cofactors. This may prove to be extremely important when considering the use of 
ribozyme mimics for in vivo applications in the presence of competing protein ligands 
and other bioavailable metals. 
More recently, Magda reported a variation of this approach in which the synthesis of 
similar cleavage agents was accomplished using a dysprosium (III) texaphyrin 
phosphoramidite as an auxiliary reagent on a commercial DNA synthesiser (Figure 
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9b). 36 The objective was to avoid the need for solution-phase conjugation of the 
preformed metal complex and postsynthetic addition of a metal cation to a DNA- 
bound ligand. The complex was attached at the 5'-end of a 20-mer 
deoxyoligonucleotide during the course of automated DNA synthesis, and sequence- 
specific cleavage of a complementary 36-mer RNA target was achieved. A series of 
structural variants of this conjugate was constructed, and one mimic cleaved 
approximately 80% of the RNA target after 6h at 37°C and pH 7.5. The 
concentrations of conjugate and RNA target were 50 nM and 2.0 nM, respectively. 
(a) 
H 
DNA 20-mer 0ý 
/0 
O. ý, O ° 
-' 
'CN 
DY I 
Omen 
N(iPr2) 
, 
N, J 
(a) 
Figure 9. (a) Eu(III) texaphyrin conjugate used for sequence-specific RNA cleavage and (b) Dy(III) 
texaphyrin phosphoramidite used as a reagent for the automated synthesis of ribozyme mimics. 
Much success has been achieved by Hall et a1.37 with the terpyridine-derived, 
lanthanide macrocyclic complexes linked covalently to deoxyoligonucleotides. 
Previous work by Morrow et al. revealed that related, hexadentate Schiff base 
macrocyclic lanthanide complexes (Figure 10a) were efficient RNA transesterification 
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catalysts. ' Unfortunately, these complexes were susceptible to hydrolytic 
decomposition in aqueous solution, and this prompted the synthesis of the terpyiridine 
derived macrocyclic complexes with hydrazone-type linkages in place of the imine 
linkages for added stability (Figure 10b). 
ýN Ný 
N 
N IV 
I/ Iý 
(a) (b) 
Figure 10. (a) Hexadentate Schiff base macrocyclic lanthanide complex. (b) Hexadentate tertpyridine 
macrocyclic lanthanide complex. 
Europium (III) complexes of this type were linked to a 5'-hexylamino-derivatised 
deoxyoligonucleotide (20-mer) by using postsynthetic strategies, and the resulting 
conjugates (Figure 11) were tested for their ability to effect the specific cleavage of a 
synthetic 29-mer RNA target. Analysis revealed near-quantitative cleavage (88%) of 
the target RNA strand at almost exclusively one site outside of the duplex region after 
incubation at 37°C and pH 7.4 for 16 h. Reactions contained an RNA target 
concentration of 10-50 nM and a probe concentration of 400 nM. 
Lönnberg and co-workers38 developed a sequence-specific RNA cleavage agent by 
tethering a histamine group to the 3'-terminus of a 10-mer deoxyoligonucleotide 
(Figure 12). This was accomplished by attaching an ester function to the 
deoxyoligonucleotide during chain assembly. 
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NN 
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Ný 
DNA 20-mer 
N 
H5 
-H 
Eu Ný ýN DNA 20-mer 
O 
Figure 11 
Treatment of the deoxyoligonucleotide shown in Figure 12 with the appropriate 
primary amine afforded the desired conjugate. Site-specific cleavage of a synthetic 16- 
mer RNA target was observed only in the presence of zinc (II) ion. The extent of 
cleavage was determined to be 2-5% after 19 h at room temperature in a reaction 
containing 2.5 µM deoxyoligonucleotide conjugate, 50 mM Zn2+ and 0.5 µM RNA 
target at pH 7.0. Cleavage was achieved with only the 3'-end modified probe and not 
with probes containing the histamine at the 5'-end or with I'-modified 
deoxyoligonucleotides containing the histamine at an internal duplex position. 
q Iý 5' 
- 
AAGAGTGGAA-O-P-O NN 00 H 
Figure 12. A ribozyme mimic with a histamine at the 5'-end of the DNA probe. 
In 1997, Magda et al. 39 reported an important result in this area. They prepared a probe 
which contained a dysprosium (III) texaphyrin metal complex attached at an internal 
position within the DNA oligomer (Figure 13). Addition of a 10-fold excess of RNA 
88 
Synthesis of backbone modified DNA using transition metal catalysis Introduction 
(500 nM RNA) this conjugate cleaved 67% of the total RNA. This level of cleaved 
RNA, 335 nM after 24 h corresponded to a value that is 6.7 times the concentration of 
the DyTx-DNA conjugate 2 present in the reaction medium. The above data supported 
the contention that the DyTx-DNA conjugate 2 was able to exhibit catalytic turnover. 
A similar conjugate where the DyTx complex was attached to the 5'-end (1) cleaved 
only 5% of the total RNA under the same conditions. This critical difference between 
the activity of the two conjugates confirmed the hypothesis explained previously in 
Scheme 6. 
il i 3'- A AAU AAA ACC UCU GAA GUA GAC ACU CGG CCC ACA AC 
- 
5' 3 
5'- DyTx(CH2)3-PO4-CAT CTG TGA GCC GGG TGT TG 
- 
3' 1 
5' 
- 
TGG AGA CTX CAT CTG TGA 
- 
3' 2 
1 
DyTx(CH2)3PO4 
(X = glyceryl linker) 
DyTx = 
H2 H 
? H2 
OMe 
"2 AcO" 
Figure 13. Structure and sequence of DyTx-DNA conjugates 1 and 2 analysed in this study. Also 
shown is the sequence of complementary 5' 32P-radiolabeled RNA target 3. The larger arrow indicates 
the major site of cleavage produced upon incubation of this RNA target with conjugate 1 or 2 at 37°C. 
Figure 14 shows the molecular structure of natural DNA and the structure of the 
conjugate 2 (Figure 13). In spite of its successful activity, it is important to mention 
that in 2 the structure of DNA is highly modified. It contains five extra atoms and two 
extra negative charges in comparison with the natural structure of DNA. Also, they are 
prepared as diastereomeric mixtures due to the chirality at C(*). 
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(a) (b) 
Figure 14. (a) Molecular structure of natural DNA. (b) Molecular structure of conjugate 2 (Figure 13). 
An important modification in the structure of the nucleic acids affects the Watson- 
Crick base pairing and consequently the binding constant between the probe and its 
RNA target. These highly modified drugs could also present problems of specificity. 
It may be possible to improve the catalytic activity of these probes if 
diastereomerically pure conjugates with a more similar molecular structure to that 
present in natural DNA were synthesised. 
Additionally, there are other interesting molecules that could be attached to nucleic 
acids, other than RNA cleavage catalysts. These include molecular transporters4° 
which can facilitate the cellular uptake of drugs, and fluorescent molecules which are 
important for a number of studies such as organ distribution. 
The objective of the work described in the following chapters of this thesis is to 
synthesise backbone modified nucleic acids using transition metal catalysis, ie. 
palladium catalysed cross-coupling or olefin cross-metathesis reactions, to allow the 
attachment of "interesting" molecules at internal positions of nucleic acids. 
0 
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2. Results and Discussion 
As seen in the introduction, it is important to synthesise backbone modified nucleic 
acids that can facilitate conjugation with other molecules in an internal position of an 
oligonucleotide. With this aim, we propose the synthesis of the following building 
blocks: 
iu PlO-ý N-base 
0\ 
,O 
P2HNý O-P 
-O N-base 
p6 
Figure 15. (I) Non-ionic building block (chiral at P). (II) Ionic building block (non-chiral at P). 
Both molecules contain a vinylphosphonate moiety which makes them stable to 
hydrolysis by nucleases and their backbones have the same number of atoms as in 
natural DNA. The value of the P-C=C bond angle a is 120° (sp 2 hybridised) and the 
torsion angle ß is locked at 180° which are very similar to the angles a and ß in natural 
DNA (Figure 16). 
R'q GO-P=o ýß=180° 
RYY2 
Figure 16.5'-0-bridge bond angle a and torsion angle ß (Newman projection) in natural DNA. 
Both compounds contain hydrocarbon linkers with pendant amines with the aim of 
attaching other molecules to these structures (for example via peptide coupling). 
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In the building block I, the linker and the amine are attached to the oxygen of the 
phosphonate to give a neutral compound which is chiral at phosphorus, whereas in 
building block II the linker and the amine are attached to a carbon atom to give an 
anionic compound which is not chiral at phosphorus. 
Both compounds present interesting synthetic challenges, and our approach to each 
will be described below. 
2.1 Synthesis of the Building Block I 
As seen previously, building block I contains the amine linker derived attached to the 
oxygen of the phosphonate to give a neutral compound which is chiral at phosphorus. 
The following scheme illustrates the retrosynthetic analysis proposed for building 
block I: 
P1O-N-base 
PlO-ý N-base 
P2HN'n OýP 
PZHN"YO_Pý --" H Br 
= 
N-base 
- 
N-base 
P30 p3Ö 
Scheme 7. Retrosynthetic analysis proposed for building block I. 
In principle, this building block can be prepared using methodology developed 
previously in our research group, in which a vinylphosphonate linked dinucleotide is 
synthesised via a palladium catalysed cross-coupling reaction between a vinyl bromide 
and an H-phosphonate 41 These reactions proceed in good to excellent yield, and are 
stereospecific with retention of configuration at phosphorus (Scheme 8). 
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H 
O 
Br 
HNH 
N-< OO 
HO 
(I) N 
Scheme 8. Palladium catalysed cross-coupling reaction between a vinylbromide and an H-phosphonate. 
(i) Pd(OAc)2, dppf, propylene oxide, THF, 14 h, 60%. 
The vinylbromides 7 and 8 were prepared using our previously described 
methodology41(Scheme 9). 
HN OOO 
H (i) 
H", 
H (ii) H 
HO O N-ý º TBSO N-_ -º TBSO O N-j 
ý 
0A0 
HÖ H6 TBDPSÖ 
23 
OO 
(iii) 
HNH 
(iv) 
ý/ 4ý 
NH (v) 
Voý 
ýI O 
TBDPSO TBDPSI5 
-// 
45 
0 
Br 
HNH 
vi N ýý 
Br D 
ýO 
IN 
TBDPSÖ 
6 
O 
Br NH 
H 
ON 
(vii) 
TBDPSO 
7 8 
Scheme 9. Synthesis of the vinylbromides 7 and 8. (i) TBS-C1(1.3 eq), imidazole (1.5 eq), DMF, 0°C to 
RT, 14 h, 98%; (ii) TBDPS-C1(1.3 eq), imidazole (1.5 eq), DMF, 0°C to RT, 14 h, 98%; (iii) aq 11F (12 
eq), CH3CN, RT, 1.5 h, 90%; (iv) Dess-Martin periodinane (1.2 eq), DCM, RT, 1 h, 83%; (v) CBr4 (2 
eq), Ph3P (4 eq), DCM, 0°C to RT, 2 h, 60%; (vi) (CH3O)2P(O)H (4 eq), NEt3 (4 eq), DMF, RT, 14 h, 
47%; (vii) TBAF (2 eq), THF, RT, 1 h, 84%. 
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This synthesis starts with selective protection of the secondary alcohol of thymidine 1 
to give alcohol 4, which after oxidation and a Wittig reaction affords dibromide 6. 
Vinylbromide 7 is obtained by reduction of 6 and can be converted into vinylbromide 
8 by treatment with TBAF. 
Vinylbromide 7 was prepared with the aim of synthesising (3'-O-TBDPS)- 
dinucleotides, whereas vinylbromide 8 was used for the synthesis of 3'-OH 
dinucleotides. 
2.1.1 Synthesis of the H-Phosphonate Coupling Partners 
As shown in Scheme 10, it was necessary to prepare H-phosphonates with a linker and 
an amine attached to the oxygen of the phosphonate moiety. The first approach 
attempted was the synthesis of H-phosphonates containing a two methylene linker and 
a Boc-protected amine using known methodology. 42 
O 
NH 
TBSO-ý 
, 
N-ý 
1(ý"ýJI O 
HO 
2 
(i) T 
9 
+ 
BocHN 
,0 
SiO2 
10 
H 
11 12 12 
minor product major product only product 
Scheme 10. (i) Diisopropylphosphoramidous chloride (1.5 eq), NEt3 (20 eq), DCM, 
-10°C, 30 min; (ii) 
N(Boc)-ethanolamine (2 eq), DCM, 
-10°C, 20 min and then RT, 1 h, 26% over two steps; (iii) 1H- 
tetrazole (2 eq), DCM, RT, 15 min, H20, RT, 1 h, 53%. 
H 
(ii) 
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Unfortunately, due to the high electrophilic character of the phosphorus, the cyclic 
product 12 was formed as the major product in the last step (Scheme 10). The mixture 
of 11 and 12 was chromatographed but only 12 was obtained, suggesting that 11 was 
unstable and maybe decomposed during the purification process on Si02. 
Another drawback of this strategy was the low yield of the first two steps due to the 
moisture sensitive characteristics of the trivalent phosphorus species 9. 
The structure of cyclic product 12 was confirmed by 'H-NMR and MS. The formation 
of this product suggested that it is necessary to diprotect the amine to completely 
eliminate its nucleophilic character and avoid any possibility of cyclisation. 
The presence of 12 also questioned the stability of the proposed building blocks 
(Figure 15) due to the possibility of intramolecular nucleophilic cleavage of the 
dinucleotide after deprotection of the amine (Scheme 11). 
PlO- 
 
_N-base 
Hd 
H21 
P36 
----------- o 
nP ýO ýN 
- 
N-base 
Pad 
Scheme 11. Possible intramolecular cleavage of the dinucleotide. 
It was therefore decided to attempt the synthesis of H-phosphonates with an amine 
protected as a phthalimide and a linker with five methylene groups. The diprotection 
of the amine as a phthalimide completely eliminates the nucleophilic character of the 
nitrogen and a linker of five methylene groups would reduce the tendency for 
cyclisation as this would lead to the unfavourable formation of an eight membered 
ring. 
95 
Synthesis of backbone modified DNA using transition metal catalysis Results and discussion 
Firstly, alcohol 14 was prepared using Mitsunobu conditions (Scheme 12). 43 
HOWOH 
(i) \ NWOH 
13 14 
Scheme 12. (i) DIAD (1.2 eq), Ph3P (1.2 eq), phthalimide (1.2 eq), THF, 0°C to RT, 15 h, 51%. 
The desired H-phosphonate 17 was prepared in a method analogous to Scheme 10 but 
again the yields were very low. It was necessary to develop new methodology for the 
synthesis of this H-phosphonate, and after several attempts, the desired H-phosphonate 
coupling partner was synthesised in 76% overall yield using the strategy illustrated in 
Scheme 13. 
ýý4"uN 
H 
TBSO-ý 
. 
N0 (i) ýý"/y O 
HÖ 
2 
O /NH 
TBSO- N--ýO (ii) 
, 
P-cl 
15 
O 
O 
17 16 
Scheme 13. New methodology developed for the synthesis of the H-phosphonate coupling partners 17. 
(i) PC13 (4.5 eq), pyridine (5 eq), THF, 
-78°C to reflux, 3.3 h; (ii) Alcohol 14 (1 eq), pyridine (5 eq), 
THF, RT to reflux, I h; (iii) H2O, RT, 5 min, 76% over 3 steps, 1: 1 mixture of diastereomers separable 
by column chromatography. 
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This strategy consists of three nucleophilic substitutions onto phosphorus trichloride, 
first by the 3'-OH of (5'-O-TBS)-thymidine, second by alcohol 14 and the third by 
water. After tautomerisation of 16, the desired H-phosphonate 17 was obtained as a 
1: 1 mixture of diastereomers at phosphorus which were readily separated by column 
chromatography. 
At the moment, we do not know the stereochemistry at phosphorus in the H- 
phosphonates 17 and with this aim, crystallisation experiments44 and NOE studies 
have been performed without success. Therefore, we are going to name 17(fast) the 
least polar diastereomer and 17(slow) the most polar diastereomer (Figure 17). ' 
O 
O 
0 
\ 
N-ý-ý 
0 
17(fast) 17(slow) 
Figure 17 
2.1.2 Palladium Catalysed Cross-Coupling Attempts 
With the desired H-phosphonates in hand, the palladium catalysed cross-coupling 
reaction with vinylbromide 7 was attempted using H-phosphonate 17 as a 1: 1 mixture 
of diastereomers [17(fast) and 17(slow)]. Pleasingly, the desired dinucleotide 18 was 
obtained in 60% yield as a 1: 1 mixture of diastereomers showing that both H- 
phosphonates are reactive under the palladium catalysed cross-coupling conditions 
(Scheme 14). 
An arbitrary stereochemistry at phosphorus is shown. 
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Scheme 14. Palladium catalysed cross-coupling reaction using (3'-O-TBDPS)-vinylbromide 7 (1.0 eq) 
and H-phosphonate 17 (1.2 eq) as a 1: 1 mixture of diastereomers. (i) Pd(OAc)2 (0.2 eq), dppf (0.4 eq), 
propylene oxide (5 eq), THF, 70°C, 15 h, 60%, 1: 1 mixture of diastereomers. 
Eventually, these dinucleotides need to be incorporated into an oligomer using a DNA 
synthesiser. For this purpose, it is necessary to use vinylbromide 8 to prepare dimers 
with a free 3'-OH group, which can be further elaborated into a 3'-phosphoramidite. 
Unfortunately, when the palladium cross-coupling reaction was attempted using 
vinylbromide 8, the desired dinucleotide 21 was formed in very low yield. This 
reaction was performed several times and it was observed that better yields were 
obtained when smaller flasks were used. Due to the volatile character of propylene 
oxide (bp 34°C) and the temperature at which the palladium catalysed cross-coupling 
reaction takes place (70°C) the reaction proceeded until no more propylene oxide was 
present in the reaction mixture. Thus, the possibility of performing these reactions in 
sealed, thick walled reaction vials instead of the conventional flask fitted with a 
condenser was investigated. 
A model reaction using vinylbromide 8 and dimethyl phosphite 19 as the H- 
phosphonate was studied using different ligands "L" (dppf, TFP, Ph3P and Ph3As) and 
different HBr scavengers "B" (propylene oxide, epichlorohydrin, NEt3 and K2CO3) in 
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sealed, thick walled reaction vials (Scheme 15). It was found that propylene oxide was 
the best "base" for this transformation and Ph3P the best ligand, giving the desired 
coupling product 20 in 70% yield. 
8 
9 
McO'P'H 0 
MeO 
19 
MeO ,P NH 
Me0 
(I) 00 
HO 
20 
Scheme 15. Model reaction using vinylbromide 8 (1.0 eq) and dimethylphosphite 19 (2.0 eq). (i) 
Pd(OAc)2 (0.1 eq), "L" (0.2 eq), "B" (2 eq except with propylene oxide: 20 eq), THF, 70°C, 15 h. 
Pleasingly, when the diastereomerically pure H-phosphonate 17(fast) was used instead 
of dimethyl phosphite the desired dinucleotide 21 with a free 3'-OH was obtained in 
80% yield (Scheme 16). The reaction with H-phosphonate 17(slow) has not yet been 
attempted but we anticipate that it should also work, and this will be completed in due 
course. 
NTBSO 
O N--\ O 
0 
\%O 
17(fast) 
O 
Br NH 
O N-j O 
HO 
8O 
Nei \l 
O 
21 
Scheme 16. Palladium catalysed cross-coupling reaction using vinylbromide 8 with the free 3'-OHI (1.0 
eq) and H-phosphonate 17(fast) (1.25 eq). (i) Pd(OAc)2 (0.1 eq), Ph3P (0.4 eq), propylene oxide (20 eq), 
THF, 70°C, 15 h, 80%. 
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The above study not only provided us with good conditions to perform the desired 
reaction with the free 3'-OH, but also revealed that the use of sealed, thick walled 
reaction vials in these palladium catalysed cross-coupling reactions generally 
improves the yield and constitutes a very easy method to carry out these 
transformations. 
With the aim of making dinucleotide 21 suitable for solid support synthesis used in 
DNA synthesisers, the coupling of 21 with bis(diisopropylamino) 
cyanoethylphosphite42 was attempted, and pleasingly the desired dinucleotide 22 was 
obtained in 80% yield (Scheme 17). 
O > 
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TBSO-1ýd-ý 
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Scheme 17. Coupling of dinucleotide 21 with bis(diisopropylamino)cyanoethylphosphite. (i) 
Bis(diisopropylamino)cyanoethylphosphite (1.5 eq), 1H-tetrazole (1.0 eq), DCM, RT, I 11,80%, 1: 1 
mixture of diastereomers at the trivalent phosphorous. 
2.1.3 Amine Deprotection and Arginine Attachment 
Fortunately, the palladium catalysed cross-coupling reactions of the diastereomerically 
pure H-phosphonates 17(fast) and 17(slow) with vinylbromide 8 in sealed, thick 
walled reaction vials gave the desired diastereomerically pure dinucleotides 18a and 
18b in 50% and 67% yields, respectively (Scheme 18). 
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Scheme 18. Palladium catalysed cross-coupling reactions using vinylbromide 7 (1.0 eq) and 
diastereomerically pure H-phosphonate 17(fast) (1.01 eq) and 17(slow) (1.08 eq). (i) Pd(OAc)2 (0.1 eq), 
Ph3P (0.4 eq), propylene oxide (20 eq), THF, 70°C, 15 h, 50% and 67% respectively. 
With the dinucleotides 18a and 18b in hand, we needed to prove that it was possible to 
conjugate these with other molecules via the amine moiety. For this purpose, we first 
needed to selectively deprotect the amine of both diastereomers. These deprotections 
were accomplished on the 3'-O-TBDPS protected dinucleotides 18a and 18b with 
hydrazine monohydrate in methanol using literature procedures43 to give the free 
amines 23a and 23b (Scheme 19). 
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Scheme 19. Selective deprotection of the amine. (i) H2N-NH2"H20 (30 eq), MeOH, RT, 2 h. 
Interestingly, it was observed that longer periods of reaction (15 h) caused the 
reduction of the double bond of the vinylphosphonate moiety to give 24, whose 
structure was confirmed by 'H-NMR and MS (Scheme 20). It is known that double 
bonds are reduced under mild conditions with hydrazine in the presence of nitrogen 
due to the formation of the reducing agent diimide. 45 
ý/ 
NH 
TBSON-ý KH fi N 
-10 
p NýNý N=N 
-ý Hý H 
NN 
AN=N 
HXNýý O Pip NH 
24 
Scheme 20. Reduced product 24 after 15 h reaction and mechanism for the formation of diimide. 
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The reduction of the double bond was not a problem because the deprotection of the 
amines could be followed easily by electrospray MS which showed that this reaction 
finished after 2 h. 
After the successful deprotection of the amines, the next step was to attempt the 
conjugation of a molecule to these amines. As mentioned in the introduction, 
molecular transporters are molecules that enable or enhance cellular uptake. Some of 
these molecules are polypeptides (peptoid molecular transporters), and one that 
presents excellent activity is polyarginine. 40 
S-N1 
011 H 
-ýo 
f) 
23a 
o SN 
ÖH 
- -F, (I) 23b 
--, 
O 
NH 
1-ý\O 
Scheme 21. Peptide coupling of 23a and 23b with diprotected arginine. (i) Fmoc-Arg(Pbf)-011(1.1 eq), 
EDC (1.1 evil, BtOH (1.1 eq), NMM (1.5 eq), DCM, 0°C to RT, 15 h, 49% and 67% respectively from 
18a and 18b. 
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Due to the molecular transporter characteristics of polyarginine and the complex 
structure of arginine, this amino acid was chosen as a good candidate to attempt this 
reaction. Pleasingly, treatment of the crude amines 23a and 23b with diprotected 
arginine under peptide coupling conditions, gave the coupled products 25a and 25b in 
49% and 67% overall yield over two steps (amine deprotection and peptide coupling) 
(Scheme 21). 
These results successfully prove that it is possible to attach complex molecules to this 
type of modified dinucleotide. The introduction of these dimers into an 
oligonucleotide sequence using a DNA synthesiser remains to be accomplished. 
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2.2 Approaches to the Synthesis of Building Block II 
After the successful preparation of building block I, the synthesis of building block II, 
in which the linker and the amine are attached to a backbone carbon atom (Figure 18), 
was examined. 
Figure 18. Structure of the building block II. 
2.2.1 Palladium Catalysed Cross-Coupling Approach 
2.2.1.1 Synthesis of Alkynylphosphonates 
Scheme 22 illustrates the proposed retrosynthetic analysis for the synthesis of building 
block II. 
N- base PlO-l ei 
0. O 
P20- Pý 
H Br 
-O N-base Br 
P30 
Scheme 22. Retrosynthetic analysis proposed for building block H. 
Building block II could potentially be synthesised from a vinylphosphonate 
dinucleotide which contains a vinylbromide that may allow the introduction of the 
linker and the amine via a Suzuki46 or Stille47 coupling. The vinylbromide dinucleotide 
could in turn be prepared via a palladium catalysed cross-coupling reaction similar to 
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the reaction seen for the preparation of building block I, the difference being that 
instead of a mono-vinylbromide a 1,1-dibromoalkene is used. 8 
The first reaction attempted was a model reaction between dibromoalkene 26** and 
dimethyl phosphite, and surprisingly the major product isolated was the 
alkynylphosphonate 28 (Scheme 23). 
O 
F-We 
Br 
H' 
OMe Cj"ýBrr 
V) 
26 
O P-OMe 01"ýIrr 
OMe 
27 
minor product 
24% 
O P-OMe 
+ 
OMe 
28 
major product 
41% 
Scheme 23. (i) Pd(OAc)2 (0.2 eq), dppf (0.4 eq), propylene oxide (3 eq), dimethyl phosphite (2 eq), 
THF, 70°C, 15 h, 24% yield of 27 and 41 % yield of 28. 
A literature search revealed an article in which Shen et al. 49 synthesised selectively 
mono- and di-coupled products or acetylenes by Stille coupling using 1,1- 
dibromoalkenes and vinylstannanes (Scheme 24). They found that the polarity of the 
solvent was crucial for the selective formation of the different type of compounds. 
z 
Ph Br 
Me02C 
Br McO2C 
I 
Br 
Ph 
Me02 
Ph 
McO2C Ph 
Scheme 24. (i) PhSnMe3 (1.05 eq), Pd2(dba)3 (0.025 eq), TFP (0.15 eq), PhMe, 100°C, 20 h, 92%. (ii) 
PhSnMe3 (2.2 eq), Pd2(dba)3 (0.025 eq), TFP (0.15 eq), PhMe, 105°C, 48 h, 100%. (iii) PhSnMC3 (1.05 
eq), Pd2(dba)3 (0.025 eq), TFP (0.15 eq), DIPEA (1.5 eq), DMF, 80°C, 10 h, 91%. 
** 1,1-dibromoalkenes were prepared from the corresponding aldehydes using the Corey-Fuchs 
procedure. 
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Both types of transformations are very important for the present work. Using the 
nucleotide substrates 29 and 30, a monocoupling reaction would form 31, a possible 
precursor to synthesise building block II (32) (Scheme 22), and the acetylene 
formation is important for a number of reasons. Firstly, an alkynylphosphonate 
modified dinucleotide 33 has not yet been prepared and constitutes an interesting 
backbone modification in nucleic acid chemistry. Secondly, vinyiphosphonates are not 
good Michael acceptors, whereas Michael additions using alkynylphosphonates have 
been performed. 50 This could provide us with other interesting building block (34) in 
which the linker and the amine are attached to the other sp 2 carbon atom (Scheme 25). 
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Scheme 25. Possible products that could be obtained via the palladium catalysed cross-coupling 
reaction using a 1,1-dibromoalkene and the possible formation of building block II (32) and building 
block 34. 
3 
Due to its potential, the reaction shown in Scheme 23 was examined using different 
conditions, and pleasingly the use of palladium acetate, dppf, and DMF at 80°C 
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selectively formed alkynylphosphonate 28 in good yield. The results of this study are 
shown in Table 1. 
O 
Br 
Br 
Cr' 
P-OMe 
H' OMe 
/ýI ýQ 1 ýýlyst 
0 
11 0"' Br 
Ome BI r M  
P-OMe 
OMe 
26 800C 27 28 
Solvent Catalyst Yield of 27 (%) Yield of 28 (Y. ) 
DMF 
DMF 
THE 
Toluene 
Pd(OAc)2, dppf 
Pd2(dba)3, dppf 
Pd(OAc)2, dppf 
Pd(OAc)2, dppf 
0 
trace 
24 
15 
89 
43 
41 
48 
Table 1. Different conditions used for the selective synthesis of the alkynylphosphonate 28. Pd(OAc)2 
or Pd2(dba)3 (0.2 eq), dppf (0.4 eq), propylene oxide (3.0 eq), dimethyl phosphite (2.0 eq), 80°C, 15 h. 
Table 1 shows that there is a solvent effect on the yield and product ratio and that 
DMF was the best solvent to use for the selective formation of the 
alkynylphosphonate. Using these conditions, the transformation was successfully 
accomplished with a number of substrates and the results are summarised in Table 2.5' 
2.2.1.1.1 Results using dppf as the Ligand 
Using dppf with alkyl-substituted dibromoalkenes (Table 2, entries 1 and 2), the 
alkynylphosphonates 28 and 42 were obtained in good yield (89% and 66%, 
respectively). Aryl dibromides with para electron donor groups 36 and 37 (Table 2, 
entries 3 and 4) and phenyl-substituted dibromide 38 (Table 2, entry 5) also gave the 
corresponding alkynylphosphonates 43,44 and 45 in good yield (73%, 68% and 63%, 
respectively). 
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Br O Pd(OAc)2, L 
+ H, P-OMe 10 ýF-OMe R Br OMe 
, 
v0 DMF, 800C R OMe 
Entry R Dibromo L Yield (%) Product 
dppf 89 1 26 28 
TFP 33 
2 35 dppf 66 42 
TFP 27 
\ 
3 
MeO 
I 36 dppf 73 43 
4 
AcO , 
37 dppf 68 44 
5 38 dppf 63 45 
6 
N 
39 dppf 27 I 46 
i TFP 31 OZN 
dppf 7 7 40 47 
NC TFP 29 
8 11 41 
dppf 18 
48 TFP 60 
Table 2. Synthesis of alkynylphosphonates. Pd(OAc)2 (0.2 eq), ligand (L): dppf (0.4 eq) or TFP (0.8 
eq), propylene oxide (3.0 eq), dimethyl phosphite (2.0 eq), DMF, 80°C, 15 h. 
In all of the above cases the alkynylphosphonate was the only product isolated after 
the reaction. However, when the palladium catalysed cross-coupling reaction was 
attempted with dppf using electron deficient aryl (Table 2, entries 6 and 7) or furyl- 
substituted dibromides (Table 2, entry 8), lower yields of the corresponding 
alkynylphosphonates were obtained (27%, 7% and 18%) and other products were 
formed. In the case of the p-nitrophenyl dibromide 39 (Table 2, entry 6) 
vinylphosphonate 49 was formed in 11% yield. Using a p"cyanophenyl substituted 
dibromide (Table 2, entry 7) only a small amount of acetylene 47 was produced, along 
with a major product which had a very complicated 'H- and 13C-NMR. Fortunately, 
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crystals were grown and its structure was determined by X-ray crystallography (Figure 
19a). When this reaction was attempted using a furan substituent (Table 2, entry 8) 
three products were obtained. The monocoupling product 52 was the major product 
formed in this reaction, and its structure and stereochemistry were confirmed by X-ray 
crystallography (Figure 20). The other two products were the desired acetylene 48 and 
a small amount of the palladium complex 51 whose structure was again elucidated by 
X-ray crystallography (Figure 19b) and was found to be analogous to the structure of 
the palladium complex 50 (Figure 19a). The results of entries 6,7 and 8 (Table 2) 
using dppf as the ligand are summarised in Scheme 26. 
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Ph2P-Pd-Br O ÖMe 
/ 
PPh2 
LeFe. NC 
47 
50 
43%* 
Br (i) 
Br 
41 
Meq ýOMe 
Ph2P-Pd-BrO 
PPh2 
51 
34%` 
O 11 
F-OMe O OMe 
+\l+ 
48 
18% 
7% 
0 P-OMe 
1 
flrOMe 
52 
25% 
Scheme 26. Different products obtained in the palladium catalysed cross-coupling reactions Table 2, 
entries 6,7 and 8 using dppf. (i) Pd(OAc)2 (0.2 eq), dppf (0.4 eq), propylene oxide (3.0 eq), dimethyl 
phosphite (2.0 eq), DMF, 80°C, 15 h. * Yield based in the amount of Pd(OAc)2. 
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Figure 19. X-ray crystal structures of the palladium complexes 50 (a) and 51 (b). 
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Figure 20. X-ray crystal structure of the monocoupling product 52. 
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The palladium complexes shown in Figure 19 have been formed using the p- 
cyanophenyl and the furan substituted dibromides 40 and 41 (Table 2, entries 7 and 8), 
however using p-nitrophenyl dibromide 39 (Table 2, entry 6) vinylphosphonate 49 was 
obtained, which could come from the protonation of a similar palladium species. This 
could mean, that the formation of a palladium complex could have taken place in the 
three cases where the palladium catalysed cross-coupling reaction using dppf afforded 
low yields of the corresponding alkynylphosphonates. 
The most interesting feature observed in the palladium complexes 50 and 51 (Figure 
19) is that the palladium atom is attached to the ß-carbon instead to the a-carbon. Our 
explanation for the formation of these two complexes is that in both cases the desired 
alkynylphosphonates were formed in the reaction, however they reacted further. They 
could react via an addition of HBr followed by a palladium oxidative insertion into the 
C-Br bond (Scheme 27). 
9 
H'P-OMe 
Br OMe RýI 
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MeQ OMe 
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Scheme 27. Possible explanation for the formation of the palladium complexes 50 and 51. (i) Pd(OAc)2 
(0.2 eq), dppf (0.4 eq), propylene oxide (3.0 eq), dimethyl phosphite (2.0 eq), DMF, 80°C, 15 h. 
Interestingly, the palladium complexes 50 and 51 are stable enough to survive column 
chromatography and they did not react further with another molecule of dimethyl 
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phosphite, in spite of the addition of two equivalents of this reagent. This fact could be 
explained by an impossible access to the Pd metal due to steric hindrance. One face of 
the square-planar palladium structure is blocked by the phosphonate group and the 
other by the aromatic groups of dppf (See X-rays crystal structures in Figure 19). 
2.2.1.1.2 Results using TFP as the Ligand 
In the article mentioned previously by Shen et a1., 49 TFP was generally used as the 
ligand in the Stille coupling reactions with 1,1-dibromo compounds. Thus, it was 
decided to examine the palladium catalysed cross-coupling reaction using this ligand. 
Interestingly, using TFP better yields were obtained and cleaner reactions took place 
using electron deficient aryl (Table 2, entries 6 and 7) or furyl-substituted dibromides 
(Table 2, entry 8). Using the aryl dibromides 39 and 40 (Table 2, entries 6 and 7) 
compounds 46 and 47 were obtained in 31% and 29% yield respectively, and in the 
case of the furyl-substituted dibromide 41 (Table 2, entry 8) alkynylphosphonate 48 
was formed in 60% yield. 
After these results, the palladium catalysed cross-coupling reaction using TFP was 
examined with 1,1-dibromoalkenes which gave a good yield in the 
alkynylphosphonate formation with dppf. Dibromo compounds 26 and 35 were 
exposed to the reaction conditions using TFP affording the corresponding 
alkynylphosphonates 28 and 42 in lower yields (33% and 27%, respectively). 
The use of TFP as the ligand has improved the yield and the ratio of the desired 
alkynylphosphonates in the cases where using dppf the reactions did not work well. 
However, with substrates that afforded good yields of the alkynylphosphonate with 
dppf, the use of TFP gave lower yields of the products suggesting that there is a 
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correlation between the substrate and the ligand and that there is not a general ligand 
for this transformation. 
2.2.1.2 Mechanistic Studies 
At this point, the mechanism of acetylene formation was investigated. It is relatively 
easy to propose a mechanism in which the alkynyl phosphonate is formed from the 
monocoupled product via an elimination of HBr, with or without promotion by 
palladium (Scheme 28a). It also could be possible that the elimination of HBr is the 
first step in the reaction and the resulting alkynyl bromide undergoes coupling with the 
H-phosphonate to give the acetylene (Scheme 28b). 
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Scheme 28. Possible mechanisms for the formation of the alkynylphosphonates. 
The following reactions were performed with the aim of elucidating the correct 
mechanism. Monocoupled product 27 was exposed to the palladium coupling 
conditions to try to prove mechanism (a) and only starting material was obtained 
suggesting that the monocoupled products are not the precursors of the 
alkynylphosphonates (Scheme 29). 
Pý 
BrOMeMe 
(I) % game 
27 28 
Scheme 29. Attempt of the synthesis of alkynylphosphonate 26 from the monocoupled product 25. (i) 
Pd(OAc)2 (0.2 eq), dppf (0.4 eq), propylene oxide (3.0 eq), DMF, 80°C, 15 h. 
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With the aim of proving mechanism (b) the reactions shown in Scheme 30 were 
attempted. The elimination of HBr was attempted in the absence of the catalytic 
system to see if propylene oxide alone was responsible for the elimination of HBr. The 
reaction was also attempted in the presence of the catalyst [Pd(OAc)2 / dppfj to see if 
the elimination of HBr is a palladium catalysed process. 
MeO \ 
Br 
ýý Br 
Me0 
I 
Br 53 
36 SM + MeO /- OMe 
21 
54 
Scheme 30. Attempts to eliminate HBr from 1,1-dibromoalkene 36. (i) Propylene oxide (3.0 eq), DMF, 
80°C, 15 h. (ii) Pd(OAc)2 (0.2 eq), dppf (0.4 eq), propylene oxide (3.0 eq), DMF, 80°C, 15 h. 
When the reaction was performed without the catalyst, only starting material was 
recovered suggesting that the elimination of HBr is not possible when only propylene 
oxide is present in the reaction, however the formation of the compound 54 does not 
eliminate the possibility of a catalytic elimination. 
WC13P r-I 
C16P 
r24P 
Cl1 
CBC ? Br2 
yr 
Ph2P-Pd-Br 
LLPPhy Feý 
Figure 21. X-ray crystal structure of the palladium complex 55. 
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In all of the reactions to give alkynylphosphonates the palladium complex 55 was 
detected, the structure of which was confirmed by X-ray crystallography (Figure 21). 
This complex could be the end of the catalytic system in all of these transformations, 
but unfortunately it does not give us any information about the mechanism. 
The mechanism of the alkynylphosponate formation is unclear and we propose the two 
mechanisms (a and b) shown in the Scheme 31. Firstly, the Pd(O) is inserted into the 
trans C-Br bond of the 1,1-dibromoalkene and the resulting Pd(II) species 56 
undergoes elimination of HBr via the mechanism a or the mechanism b to give the 
palladium-alkyne complex 58 which is coupled with the H-phosphonate to form the 
alkynylphosphonate. 
In the mechanism a HBr is eliminated in two steps, a bromide is first eliminated to 
give the palladium (N) carbenoid species 57 which undergoes the rearrangement 
shown in the scheme to give the palladium-alkyne complex 58. In the mechanism b, 
complex 58 is directly formed from the Pd(II) species 56. Based in literature 
precedents, 52 a-halopalladium complexes such as 56, have unusual values for the a 
and ß angles (Scheme 31). The elimination of HBr in these structures could be 
facilitated by the fact that the value for the a angle is usually higher than 120° and the 
value for the ß angle is usually lower than 120°. 
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Scheme 31. Mechanisms proposed for the formation of the alkynylphosphonates. 
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2.2.1.3 Synthesis of an Alkynylphosphonate Dinucleotide 
With the successful conditions for the synthesis of alkynylphosphonates in hand, the 
synthesis of a dinucleotide containing this modification was examined. 
First, a model reaction using 1,1-dibromonucleotide 6 with dimethylphosphite was 
attempted to see if the conditions were tolerant to the functionality present in 
nucleotides (Scheme 32). 
O meQ MeO O0 
MO 
-pp ýp Me0 \P 
Br NH HNH 
-N 
`\ 
N- 
Br O (i) O 
TBDPSÖ TBDPSÖ 
6 59 
Scheme 32. Model reaction using 1,1-dibromonucleotide 6 and dimethylphosphite. (i) Pd(OAc)2 (0.2 
eq), dppf (0.4 eq), propylene oxide (3.0 eq), DMF, 80°C, 15 h, 63%. 
Pleasingly, when dibromo 6 was exposed to the palladium catalysed cross-coupling 
reaction conditions, the desired alkynylphosphonate 59 was formed in good yield 
(63%). 
Having shown that the thymidine-derived dibromide 6 successfully coupled with 
dimethyl phosphite, the next step was to attempt this reaction with the more 
functionalised H-phosphonate 62. For this purpose, it was necessary first to synthesise 
H-phosphonate 62, and this compound was prepared using the methodology developed 
for the synthesis of H-phosphonate 17 (Scheme 13). Instead of alcohol 14, methanol 
was used to give the desired methyl H-phosphonate 62 as a 1: 1 mixture of 
diastereomers in 60% overall yield. These reactions are illustrated in the following 
Scheme. 
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Scheme 33. (i) PC13 (4.5 eq), pyridine (5 eq), THF, 
-78°C to reflux, 3.3 h; (ii) MeOH (1 eq), pyridine (5 
eq), THF, RT to reflux, 1 h; (iii) H20, RT, 5 min, 60% over 3 steps, 1: 1 mixture of diastereomers at P. 
With methyl H-phosphonate 62 in hand, the synthesis of a modified nucleotide dimer 
was attempted, and pleasingly the desired alkyne-containing thymidine dimer 63 was 
formed in 51% yield (+12% of recovered 6) as a 1: 1 mixture of diastereomers which 
were readily separated by column chromatography (Scheme 34). 51 Considering the 
complexity of this product, we believe that this result is particularly impressive and it 
clearly demonstrates the potential of this methodology to allow access to highly 
functionalised targets. 
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Scheme 34. (i) Pd(OAc)2 (0.2 eq), dppf (0.4 eq), propylene oxide (3.0 eq), 62 (1.4 eq), DMF, 80°C, 15 
h, 51% (+12% of recovered 6), 1: 1 mixture of diastereomers separable by column chromatography. 
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As alkynylphosphonates are known Michael acceptors, 50 model reactions using 59 to 
investigate the possibility of introducing nucleophiles into this system were attempted. 
Heating alkynylphosphonate 59 in the presence of amyl amine, unfortunately afforded 
decomposition and treatment of 59 with the organocopper compound derived from 
°BuLi and CuI gave the terminal alkyne 64 (Scheme 35). 
Mel3, OO0 
Me0-P 
NH ý NH N-4 () ý` N-O 0O 
TBDPSÖ TBDPSÖ 
59 64 
Scheme 35. Model reaction of Michael addition using alkynylphosphonate 59. (i) Cul (3.4 eq), °BuLi 
(6.0 eq), THF, 
-78°C, 15 min, alkynylphosphonate 59 (1.0 eq), THF, 
-78°C to RT, 1.5 h, 38%. 
The formation of terminal alkyne 64 could be explained by the fact that the 
organocopper species was not formed in the reaction and 64 was the result of 
nucleophile attack of' BuLi onto the phosphorus atom. 
Following the problems encountered in the Michael addition experiments, a new 
strategy based in an olefin cross-metathesis reaction, to synthesise a building block 
with a linker and anamine attached to an sp2 carbon atom, was considered and it will 
be discussed below. 
2.2.2 Olefin Cross-Metathesis Approach. A New Method for the 
Synthesis of Vinylphosphonate-linked Nucleic Acids 
As seen previously, the use of 1,1-dibromoalkene 6 in the palladium catalysed cross- 
coupling reaction with H-phosphonate 62 afforded alkynylphosphonate 63 instead of 
the desired monocoupled product necessary for the synthesis of building block II. 
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At this point, we wondered if it would be possible to access the vinylphosphonate 
internucleotide linkage using an olefin cross-metathesis reaction. This reaction was 
investigated with the aims of having a novel approach to these backbone modified 
nucleic acids (Scheme 36a) and to re-examine the synthesis of building block II 
(Scheme 36b). 
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Scheme 36. (a) Retrosynthetic analyisis proposed for the synthesis of vinylphosphonate-linked nucleic 
acids via an olefin cross-metathesis reaction. (b) Retrosynthetic analysis proposed for the synthesis of 
building block II. 
Olefin cross-metathesis reactions usually proceed with good yields and good E/Z 
ratios. 53 Grubbs et al. have recently published a method for the synthesis of 
vinylphosphonates via an olefin cross-metathesis reaction 5.4 A vinylphosphonate- 
linked dinucleotide might be synthesised by a cross-metathesis reaction between a 
vinylphosphonate and a terminal alkene. For the synthesis of building block II it is 
necessary to use 1,1-disubstituted olefins, and because olefin metathesis processes are 
more favourable when less substituted olefins are used due to steric effects, the 
120 
Synthesis of backbone modified DNA using transition metal catalysis Results and discussion 
synthesis of a vinylphosphonate dinucleotide using terminal olefin containing 
nucleotides (Scheme 36a) was investigated first. 
2.2.2.1 Synthesis of Vinylphosphonate-linked Nucleic Acids by Olefin Cross- 
Metathesis 
To attempt this reaction it was necessary to prepare both coupling partners. The 
synthesis of terminal alkene 65 was accomplished according to literature procedures" 
based on a Wittig reaction from the corresponding known aldehyde 5 (Scheme 37). 
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Scheme 37. Synthesis of terminal alkene 65. (i) Methyltriphenylphosphonium bromide (4 eq), °BuLi (4 
eq), THF, 0°C to RT, 18 h, 24%. 
The low yield obtained in this reaction was attributed to the presence of two acidic 
protons in compound 5, the proton of the thymine and the proton a to the aldehyde 
function, which can be abstracted by the non-stabilised ylide formed from "BuLi and 
methyltriphenylphosphonium bromide. Other bases, such as KHMDS and tBuOK were 
used in an attempt to improve the yield, but without success. Other reagents used for 
the methylenation of aldehydes and ketones when acidic protons are present, such as 
Tebbe56 and Nysted, 57 were also attempted. A better yield (37%) was obtained in the 
case of the Tebbe reagent experiment and when the Nysted reagent was used, the 
reaction did not go to completion however, in both cases problems in purification of 
the resulting alkene 65 were found. 
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The synthesis of terminal vinylphosphonates was examined next. These coupling 
partners may be prepared using a similar palladium cross-coupling reaction as seen 
previously (Section 2.1) for the formation of the P-C bond between an H-phosphonate 
and vinylbromide (Scheme 38). 
Pb0 N-base PlO-10N-base 
0 z 
p20 p 0-P p H Bra 
Scheme 38. Retrosynthetic analysis proposed for the vinylphosphonate coupling partners. 
H-phosphonate 62 was prepared as a 1: 1 mixture of diastereomers at phosphorus as 
seen in the previous section and vinylbromide is a comercial available compound as a 
1.0 M solution in THE 
This reaction was initially attempted using a conventional round bottomed flask fitted 
with a condenser, but only starting material was recovered due to the high volatility of 
vinylbromide (bp 16°C). Pleasingly, when this reaction was performed in a sealed, 
thick walled reaction vial and using an excess of vinylbromide the desired 
vinylphosphonate 66 was obtained in 64% yield as a 1: 1 mixture of diastereomers at 
phosphorus (Scheme 39). 
62 66 
Scheme 39. (i) Pd(OAc)2 (0.1 eq), Ph3P (0.2 eq), vinylbromide (4.1 ecfj, propylene oxide (17 eq), THHF, 
70°C, 15 h, 64%, 1: 1 mixture of diastereomers at phosphorus. 
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With the two desired coupling partners in hand, the olefin cross-metathesis reaction 
was examined. Among several catalysts available for olefin cross-metathesis reactions, 
the ruthenium based Grubbs catalysts 67 and 6858 (Figure 22) were chosen for this 
study due to their excellent functional group tolerance, their reasonable moisture and 
air stability and because they are comercial available compounds. 
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u , d Cl l 
PCy3 h 
CI 
R 
PC Ph 
67 68 
Figure 22. Grubbs catalysts chosen to attempt the olefin cross-metathesis reaction. 
Initially, the olefin cross-metathesis reaction of 65 and 66 was attempted with the first 
generation Grubbs catalyst 67. In this case, the desired product 69 was not detected by 
'H-NMR of the crude reaction mixture, which consisted only of unreacted starting 
materials. This lack of reactivity could be due to the formation of relatively stable 
chelate structures (Figure 23). 59 
H 
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NO 
OX 
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Figure 23. Possible stable chelate structures formed using catalyst 67. 
Catalyst 68 contains a 1,3-dimesityl-4,5-dihydroimidazol-2-ylidine group which 
makes it a more electron rich catalyst compared with 67. It has been proposed that the 
more electron rich ruthenium centre is less prone to chelate formation. Another 
123 
Synthesis of backbone modified DNA using transition metal catalysis Results and discussion 
advantage of having a more electron rich ruthenium centre is that formation of the 
"productive" metallo-cyclobutane shown in Figure 24 should be relatively more facile, 
based upon electronic grounds, resulting in better catalyst turnover and increased 
yields of the desired cross-metathesis product. 
Figure 24. "Productive" metallo-cyclobutane. 
Pleasingly, when the olefin cross-metathesis was attempted using the second 
generation Grubbs catalyst 68, the desired dinucleotide 69 was obtained as a 1: 1 
mixture of diastereomers at phosphorus in 58% yield (70% based on recovered 65) 
(Scheme 40). 60 This product was identical in all respects to material that was prepared 
previously in our research group using a palladium (0) catalysed P-C=C cross- 
coupling reaction. 41 Analysis of the 1H-NMR clearly showed that the (E)- 
vinylphosphonate had been produced as the major compound and it was not possible 
to detect the corresponding (Z)-isomer. A number of other minor products were 
formed in this reaction which might be the products of benzylidene transfer from the 
catalyst 68 to 65 and 66, the cross-metathesis of 65 with itself and the cross-metathesis 
of 66 with itself. In order to confirm these suspicions, a series of control experiments 
were performed to examine the behaviour of each of the cross-methathesis partners 65 
and 66 under the reaction conditions. 
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Scheme 40. Olefin cross-metathesis reaction between vinylphosphonate 66 (1.25 eq) and alkene 65 (1.0 
eq). (i) Catalyst 68 (0.2 eq), DCM, 35°C, 16 h, 58% (70% based on recovered 65), 1: 1 mixture of 
diastereomers at phosphorus. 
Firstly, terminal alkene 65 was exposed to the metathesis conditions and two products 
were formed (Scheme 41). The major product was the homo-dimer 70 (5: 1 E: Z), 
produced by cross metathesis of 65 with itself in 72% yield and the minor product was 
the alkene 71 produced by transfer of the benzylidene group from the catalyst 68. As 
20 mol% of catalyst was used, this latter product represents a quantitative transfer of 
the benzylidene moiety during catalyst activation. 
0 QTBDPS 0 
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SNH 
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p N-ý + Op HN OO 
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65 70 71 
Scheme 41. Terminal alkene 65 under the metathesis conditions. (i) Catalyst 68 (0.2 cq), DCM, 35°C, 
14 h, 72% yield of 70 and 20% yield of 71. 
Vinylphosphonate 66 was next exposed to the cross-metathesis conditions and in this 
case no cross-metathesis of 66 with itself was observed, and instead the 
vinylphosphonate 72 was formed as a 1: 1 mixture of diastereomers at phosphorus in 
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20% yield (Scheme 42). The mass balance of the reaction was unreacted 66 and as 
seen previously, the formation of 72 in 20% yield represents quantitative transfer of 
the benzylidene group during catalyst activation. 
With this study in hand, it was possible to identify the minor products formed in the 
cross-metathesis reaction shown in Scheme 40, and these were 70 (10%), 71 (15-20%) 
and 72 (<5%). 
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Scheme 42. Vinylphosphonate 66 under the metathesis conditions. (i) Catalyst 68 (0.2 eq), DCM, 35°C, 
14 h, 20% yield of 72. 
At this point, the possibility of increasing the yield in the cross-metathesis of 65 and 
66 was examined using lower amounts of the benzylidene catalyst 68 with the aim of 
reducing the amount of the phenyl substituted alkenes 71 and 72, however when this 
reaction was performed using 10 mol%, 5 mol% and 2 mol% lower yields were 
obtained. It was possible to see from the crude 1H-NMR spectra that in this reaction 
the yield is directly dependent of the amount of catalyst used, thus lower amounts of 
catalyst afforded lower yields. This fact was attributed to the formation of relatively 
stable chelated structures similar to those presented in Figure 23 which cause catalyst 
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inhibition. A second way to improve the yield of 69 could be to use a larger excess (2- 
3 eJ of either of the metathesis partners 65 or 66. This approach has found application 
in a number of studies reported in the literature, but is only practical when one of the 
alkenes is readily available in quantity. In our case, both alkenes are produced using 
multistep routes and in this situation it is desirable to use them in near equimolar 
amounts. When the reaction was attempted using a slight excess of the terminal alkene 
65 (1.5 eq) and vinylphosphonate 66 (1.0 eq), the desired dinucleotide 69 was obtained 
in a similar yield (53%) compared with the reaction in which an excess of 
vinylphosphonate 66 (1.25 eq) was used (58%) (Scheme 40). 
The use of a cyanoethyl-phosphate protecting group in the olefin cross-metathesis 
reaction was also examined due to its compatibility with the solid-phase 
oligonucleotide synthesis. Firstly, H-phosphonate 73 was synthesised by the same 
methodology used for the synthesis of H-phosphonates 17 and 62 (Schemes 13 and 
33). Secondly, vinylphosphonate 74 containing this group was prepared in an 
analogous manner to that described for the methyl-protected analogue 66 (Scheme 43). 
Nd NC 
73 74 
Scheme 43. Synthesis of the vinylphosphonate coupling partner 74. (i) Pd(OAc)2 (0.1 eq), Ph3P (0.4 
eq), vinylbromide (4.1 eq), propylene oxide (15 eq), THF, 70°C, 15 h, 25%, 1: 1 mixture of 
diastereomers at phosphorus. 
Vinylphosphonate 74, under identical conditions used previously for the successful 
cross-metathesis of 65 and 66, gave the desired cross-metathesis product 75 in 19% 
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yield, with the mass balance consisting largely of unreacted starting materials and 71 
(Scheme 44) 60 
It was suspected that the 19% yield represented just under one catalytic turnover and 
in order to confirm this, the same reaction was performed using 40 mol% of catalyst 
68. Under these conditions the desired dimer 75 was obtained in 32% yield, with the 
mass balance once again being unreacted starting materials and 71. From these results, 
it was assumed that the introduction of the cyanoethyl group adversely affected 
catalyst turnover. This fact was probably due to the Lewis-base characteristics of the 
nitrile group which could be involved in the formation of chelated structures 
deactivating the catalyst. 
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Scheme 44. Olefin cross-metathesis reaction between vinylphosphonate 74 (1.25 eq) and alkene 65 (1.0 
eq). (i) Catalyst 68 (0.2 eq), DCM, 35°C, 16 h, 19%, 1: 1 mixture of diastereomcrs at phosphorus. When 
0.4 eq of catalyst 68 were used 32% yield of 75. 
2.2.2.2 Attempts to Synthesise Building Block II by Olefin Cross-I%letatliesis 
After showing that an olefin cross-metathesis reaction can be used to access 
vinylphosphonate-linked nucleotide dimers, the synthesis of building block 11 was re- 
examined. This building block can be disconnected across the C=C of the 
vinylphosphonate moiety via a retro cross-metathesis reaction (Scheme 45). 
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Scheme 45. Retrosynthetic analysis proposed for building block II via an olefin cross-metathesis 
reaction. 
In order to attempt this reaction, it was necessary to synthesise a vinylphosphonate 
containing a linker and a protected amine. These new vinylphosphonates could 
potentially be synthesised via a palladium catalysed cross-coupling reaction between a 
vinylhalide and an H-phosphonate. Internal vinylhalides can be prepared from the 
corresponding alkynes with iodo- or bromo-BBN6' (Scheme 46). 
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Scheme 46. Retrosynthetic analysis proposed for the synthesis of a vinylphosphonate containing a 
linker and a protected amine. 
Vinyliodide 78 was synthesised by a Mitsunobu reaction from 5-hcxyn-l-ol 76,43 
followed by an iodination reaction of alkyne 77 using iodo-BBN 60 With vinyliodide 
78 in hand, the palladium catalysed cross-coupling reaction using 11-phosphonatc 62 
(1: 1 mixture of diastereomers at phosphorus) was attempted, and pleasingly, the 
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desired vinylphosphonate 79 was obtained in 43% yield as a 1: 1 mixture of 
diastereomers at phosphorus (Scheme 47). 
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Scheme 47. Synthesis of vinylphosphonate 79. (i) DIAD (2.0 eq), Ph3P (2.0 eq), phthalimide (2.0 eq), 
THF, 0°C to RT, 18 h, 60%. (ii) Iodo-BBN (1.3 eq), DCM, 
-10°C, Ih, AcOll (Xs. ), 
-10°C, 1 h, 
NaOHIH2O2 (Xs. ), 
-10°C to RT, 30 min, 33%. (iii) Pd(OAc)Z (0.1 eq), dppf (0.2 eq), propylene oxide 
(3.0 eq), H-phosphonate 62 (1.5 eq), TIT, 70°C, 15 h, 43%, 1: 1 mixture of diastercomers at 
phosphorus. 
With both coupling partners in hand, the reaction shown in Scheme 48 using identical 
conditions as those used in the successful cross-metathesis reaction (Scheme 40) was 
attempted, but unfortunately only starting materials were recovered, suggesting that 
the presence of the linker and the protected amine in vinylphosphonatc 79 makes this 
process much more difficult to be achieved probably due to steric effects, although 
chelate formation cannot be ruled out. 
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79 80 
H 
Scheme 48. Attempt to synthesise building block II 80 by olefin cross-metathesis. (i) Catalyst 68 (0.20 
eq), vinylphosphonate 79 (1.25 eq), alkene 65 (1.00 eq). DCM, 35°C, 16 h. 
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3. Future Work 
" The stereochemistry at phosphorus in H-phosphonates 17(fast) and 17(slow), and in 
all the dinucleotides synthesised from them, remains to be determined. One possibility 
to resolve this problem could be to synthesise phosphorothioate 82 from 
phosphoroamidite 81 which has a known stereochemistry62 and compare it with the 
phosphorothioates derived from H-phosphonates 17(fast) and 17(slow) (Scheme 49). 
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" It is important to determine if the functionality present in dimcrs 21 and 63 is 
tolerated in solid supported DNA synthesis, and if they can be incorporated into an 
oligonucleotide sequence. For this purpose, the synthesis of the corresponding 5'-0. 
DMT protected dimers need to be accomplished and, possible routes are presented in 
Scheme 50. 
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Scheme 50. A) (i) HF; (ii) DMTCI, base; (iii) Bis(disopropylamino)cyanoethylphosphite; (iv) DNA 
synthesiser. B) (i) Pd(OAc)2, ligand, propylene oxide; (ii) Bis(disopropylamino)cyanoethylphosphitc; 
(iii) DNA synthesiser. 
" 
The palladium catalysed cross-coupling reaction with 1,1-dibromoalkenes needs to 
be studied to try to find the conditions for the selective formation of monocoupled 
products. This may be achieved by using different solvents, bases, ligands, or 
palladium sources, and would be of importance not only to re-examine the synthesis of 
building block II, but also from a methodology point of view. 
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" The successful synthesis of vinylphosphonate-linked dinucleotides by olefin cross- 
metathesis creates many interesting possibilities. One example is to attempt the 
polymerisation of a building block containing two terminal olefins, one at the 3'- and 
another at the 5'-position, by olefin cross-metathesis to synthesise vinylphosphonate- 
linked oligonucleotides (Scheme 51A). It would be even more interesting to expose 
the four building blocks containing the four different bases: A, G, C, and T to the 
metathesis conditions in the presence of an oligonucleotide that could act as a template 
to investigate the preparation of sequence specific oligonucleotides (Scheme 51B). 
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Scheme 51. A) Polymerisation of a nucleotide building block by olefin cross-mctathesis. B) 
Polymerisation of a nucleotide building block by olefin cross-metathesis in the presence of a template. 
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4. Experimental 
General Details. 
- 
As in the experimental of the synthesis of azatriquinacene (Part I). 
N-(5-Hydroxypentyl)phthalimide 14. 
DIAD (6.7 mL, 0.034 mol) was dropwise added to a stirred 
solution of Ph3P (8.90 g, 0.034 mol) in THE (110 mL) at 0°C 
under a nitrogen atmosphere. The mixture was stirred for 20 min and a solution of 
1,5-pentanediol (3 mL, 0.029 mol) in THE (40 mL) was added followed by 
phthalimide (5.06 g, 0.034 mol) and stirring was continued for 15 h. The solvent was 
removed in vacuo and the residue purified by column chromatography 
(AcOEt: Pentane 1: 1) to give 14 (3.42 g, 51%) as a white solid; mp 44-46°C, (Found: 
C, 66.5; H 6.4; N, 5.9. C13H15N03 requires C, 66.9; H, 6.5; N, 6.0 %); (Found: 
(HRMS FAB) M++H 234.1136, C13H16N03 requires 234.1131); v, 
ax/cm"' 3625,2942, 
2864,1772,1711,1616,1468,1398,1366,1051,961,876; 611(400 MHz) 7.76 (211, 
dd, J 5.4,3.1), 7.65 (2H, dd, J 5.5,3.0), 3.62 (2H, t, J 6.5), 3.57 (2H, t, J 6.5), 2.47 
(1H, br s), 1.65 (2H, app quint, J 7.4), 1.56 (2H, app quint, J 6.7), 1.36 (2H, m); 
8ß(100 MHz) 168.3 (C), 133.8 (CH), 131.8 (C), 123.0 (CH), 62.1 (CH2), 37.7 (C12), 
32.0 (CH2), 28.2 (CH2), 22.9 (CH2); m/z (FAB) 234 (M++H, 29) 133 (29), 160 (19), 
155 (20), 154 (100), 138 (29), 137 (60), 136 (72), 107 (22), 91 (15), 90 (11), 89 (18), 
77 (22), 71 (10), 69 (18), 57 (29), 55 (24). 
Pentylphthalimide H-phosphonate 17. 
A solution of 5'-O-(tert-butyidimcthylsilyl)-a-thymidinc 2 
(0.50 g, 1.40 mmol) in THE (15 mL) was addcd dropwisc to 
a stirring solution of PC13 (0.56 mL, 6.42 mmol) and 
pyridine (0.56 mL, 6.92 mmol) in THE (14 mL) at 
-78°C under an argon atmosphcrc 
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over a period of 22 min. The mixture was stirred at this temperature for 10 min, at RT 
for 1h and then heated at reflux for 2 h. The mixture was cooled to RT and the 
volatiles removed in vacuo. The residue was coevaporated with DCM (2 x 20 mL) to 
remove the excess of PC13 and then dissolved in THE (20 mL) under an argon 
atmosphere. Pyridine (0.56 mL, 6.92 mmol) was added followed by a solution of 14 
(0.324 g, 1.391 mmol) in THE (10 mL). The mixture was heated at reflux for 1h and 
then cooled to RT. Water (10 mL) was added and the mixture was stirred for 5 min. 
DCM (200 mL) was then added and the mixture washed with a saturated aqueous 
solution of sodium bicarbonate. The layers were separated and the aqueous layer 
extracted with DCM (2 x 100 mL). The combined organic phase was dried, the 
solvent removed in vacuo and the residue purified by column chromatography 
(AcOEt: Pentane 4: 1) to give 17 (0.678 g, 76%) as a 1: 1 mixture of the separable 
diastereomers 17(fast) and 17(slow). 
Data for the least polar isomer 17(fast): (Found: (HRMS ES) M++Na 658.2322, 
C29H42N3O9PSiNa requires 658.2326); [a]D +6.0 (c 1.3 in CHC13); Vm. ax/cm'l 3632, 
3393,3188,2931,2860,1772,1714,1462,1397,1363,1322,1292,1277,1128,1068, 
978,906,838,648; 3n(400 MHz) 9.33 (1H, br s), 7.82 (2H, dd, J 5.5,3.0), 7.69 (211, 
dd, J 5.5,3.0), 7.45 (1H, m), 6.86 (1H, d, J 708.6), 6.36 (1H, dd, J 8.9,5.3), 5.09 (111, 
app dd, J 7.6,6.1), 4.23 (1 H, m), 4.09 (2H, m), 3.87 (2H, m), 3.68 (211, t, J 7.1), 2.51 
(1H, ddd, J 13.9,5.5,1.4), 2.15 (1H, ddd, J 14.3,8.9,5.8), 1.90 (311, d, J 1.1), 1.74 
(4H, m), 1.44 (2H, m), 0.90 (9H, s), 0.11 (3H, s), 0.11 (3H, s); SC(100 M11z) 168.4 
(C), 163.9 (C), 150.4 (C), 135.0 (CH), 134.0 (CH), 132.1 (C), 123.2 (CH), 111.2 (CI 1), 
85.8 (d, 3Jcp 5.3) (CH), 84.5 (CH), 76.9 (d, 2Jcp 6.3) (CH), 66.0 (d, 2Jcp 5.7) (0 12), 
63.1 (CH2), 39.6 (d, 3Jcp 3.2) (CH2), 37.6 (CH2), 29.8 (d, 3Jcp 6.3) (CH2), 28.0 (CFI )9 
136 
Synthesis of backbone modified DNA using transition metal catalysis Experimental 
25.9 (CH3), 22.8 (CH2), 18.3 (C), 12.5 (CH3), 
-5.4 (CH3), -5.5 (CH3); 6p(161.98 MHz) 
8.2. 
Data for the most polar isomer 17(slow): (Found: (HRMS ES) M++Na 658.2307, 
C29H42N3O9PSiNa requires 658.2326); [a]D +8.0 (c 0.9 in CHC13); v,,. X/cm's 3632, 
3392,2931,2860,1772,1712,1693,1463,1397,1363,1322,1276,1129,1067,977, 
908,837; 8H(400 MHz) 9.22 (1H, br s), 7.83 (2H, dd, J 5.4,3.0), 7.70 (2H, dd, J 5.4, 
3.0), 7.46 (1H, m), 6.89 (1H, d, J 705.4), 6.37 (1H, dd, J 8.9,5.3), 5.08 (1H, app t, J 
6.4), 4.25 (1H, m), 4.09 (2H, m), 3.88 (2H, m), 3.69 (2H, t, J7.1), 2.50 (1H, app dd, J 
13.6,4.9), 2.13 (1H, ddd, J 14.3,8.5,5.8), 1.91 (3H, s), 1.74 (4H, m), 1.44 (2H, m), 
0.91 (9H, s), 0.11 (3H, s), 0.11 (3H, s); ßc(100 MHz) 168.4 (C), 163.8 (C), 150.4 (C), 
135.0 (CH), 134.0 (CH), 132.1 (C), 123.3 (CH), 111.2 (CH), 86.1 (d, 3Jcp 3.5) (CH), 
84.7 (CH), 76.8 (d, 2Jcp 4.9) (CH), 65.9 (d, 2Jcp 5.8) (CH2), 63.1 (CH2), 39.5 (d, 3Jcp 
4.6) (CH2), 37.6 (CH2), 29.8 (d, 3Jcp 6.4) (CH2), 28.0 (CH2), 25.9 (CH3), 22.8 (CH2)) 
18.3 (C), 12.5 (CH3), 
-5.4 (CH3), -5.4 (CH3); 5p(161.98 MHz) 8.4. 
5'-O-(tert-Butyldimethylsilyl)pentylphthalimidephosphon ate T*T dimer 21. 
A 2.5 mL screw cap reaction vial was charged with 
Pd(OAc)2 (0.007 g, 0.031 mmol, 0.1 eq), Ph3P (0.033 g, 
0.126 mmol, 0.4 eq), H-phosphonate 17(fast) (0.250 g, 
0.394 mmol, 1.25 eq), vinylbromide 8 (0.100 g, 0.315 
mmol), propylene oxide (0.44 mL, 6.3 mmol, 20 eq) and THE (1.8 mL). The stirring 
mixture was heated at 70°C (oil bath temperature) for 15 h. After cooling to RT, the 
volatiles were removed in vacuo and the residue was purified by column 
chromatography (AcOEt: MeOH 20: 1) to give 21 (0.221 g, 80%) as a pale yellow 
solid; mp 93-95°C, (Found: (HRMS ES) M++Na 894.3141, C4QII54N5C131'SiNa 
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requires 894.3123); [a]D +4.6 (c 0.8 in CHC13); v,,, aX/cm-1 3391,2931,1772,1711, 
1464,1398,1363,1276,1128,1074,1002,976,908; SH(400 MHz) 9.49 (1H, br s), 
7.83 (2H, dd, J 5.4,3.0), 7.71 (2H, dd, J 5.4,3.0), 7.48 (1H, m), 7.13 (1H, m), 6.98 
(1H, ddd, J22.7,17.1,4.2), 6.36(1H, dd, J9.0,5.1), 6.29(1H, t, J6.5), 6.06(1H, ddd, 
J20.6,18.4,1.2), 5.02 (IH, app t, J6.4), 4.47 (2H, m), 4.28 (IH, br s), 4.06 (2H, dt, J 
6.8,6.5), 3.87 (2H, m), 3.69 (2H, t, J 7.1), 2.51 (1H, dd, J 13.4,5.0), 2.43 (1H, m), 
2.32 (1H, m), 2.14 (1H, m), 1.92 (3H, s), 1.91 (3H, s), 1.73 (4H, m), 1.44 (2H, m), 
0.91 (9H, s), 0.12 (6H, s); Sc(100 MHz) 168.6 (C), 163.9 (C), 150.7 (C), 150.5 (C), 
149.5 (CH), 135.9 (CH), 135.1 (C), 134.1 (CH), 132.1 (CH), 123.3 (CH), 117.6 (d, 
'Jcp 188.8) (CH), 111.6 (C), 111.4 (C), 86.0 (d, 3Jcp 4.4) (CH), 85.8 (CH), 85.8 (d, 
3Jcp 21.4), 84.7 (CH), 77.3 (d, 2Jcp 5.1) (CH), 74.2 (CH), 66.4 (CH2), 63.4 (CH2), 39.5 
(CH2), 39.2 (CH2), 37.7 (CH2), 29.9 (d, 3Jcp 4.8) (CH2), 28.1 (CH2), 26.0 (CH3), 22.9 
(CH2), 18.4 (C), 12.7 (CH3), 12.6 (CH3), 
-5.3 (CH3), -5.4 (CH3); 6p(161.98 MHz) 18.8. 
5'-O-(tent-Butyldimethylsilyl)-3'-O-(cyanoethyldiisopropylaminophosphin e) 
pentylphthalimidephosphonate T*T dimer 22. 
0 
ýI ý 
0 
Cyanoethylbisdiisopropylamino phosphine (0.10 mL, 
0.31 mmol, 1.52 eq) was dropwise added to a mixture 
of dimer 21 (0.178 g, 0.204 mmol), 111-tctrazole (0.014 
g, 0.200 mmol, 1.02 eq) in DCM (2 mL) at RT undcr an 
argon atmosphere and then, stirred for I h. The mixture 
was diluted with DCM (20 mL) and washed with a saturated aqueous solution of 
sodium bicarbonate (20 mL). The layers were separated and the aqueous layer 
extracted with DCM (2 x 30 mL). The combined organic phase was dried, the solvent 
removed in vacuo and the residue purified by column chromatography (AcOEt) to 
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give 22 (0.176 g, 80%) as a 1: 1 mixture of diastereoisomers. (Data given for the 
mixture of diastereoisomers): (Found: (HRMS ES) M++Na 1094.4279, 
C49H71N7O14P2SiNa requires 1094.4201); [aID +11.7 (c 2.2 in CHC13); vex/cm" 3697, 
3600,3391,2954,2931,2862,2359,2339,2256,1772,1711,1692,1602,1463,1397, 
1366,1266,1128,1075,977,908,838; 5H(400 MHz) 8.88 (2H, m), 7.83 (2H, dd, i 
5.5,3.0), 7.71 (2H, dd, J 5.4,3.1), 7.48 (1 H, m), 7.09 (1 H, m), 6.98 (1 H, ddd, J 22.8, 
17.1,4.3), 6.90 (1H, ddd, J22.7,17.0,4.3), 6.36 (1H, dd, J8.4,5.1), 6.30 (1H, app q, 
J 7.2), 6.06 (1H, ddd, J 20.1,17.1,1.7), 6.03 (1H, ddd, J 19.8,17.0,1.5), 5.04 (1H, 
app t, J6.3), 4.56 (0.5H, m), 4.50 (1.5H, m), 4.23 (IH, m), 4.04 (2H, m), 3.87 (3H, m), 
3.79-3.56 (5H, m), 2.80-2.66 (1H, m), 2.65 (1h, t, J 6.1), 2.55-2.41 (2H, m), 2.34 (1H, 
m), 2.13 (1H, m), 1.92 (6H, m), 1.73 (4H, m), 1.44 (2H, m), 1.19 (12H, m), 0.92 
(4.5H, s), 0.92 (4.5H, s), 0.12 (6H, m); 8ß(100 MHz) 168.5 (C), 163.8 (C), 163.7 (C), 
150.4 (C), 150.4 (C), 150.3 (C), 148.8 (d, 2Jcp 6.0)/148.5 (d, 2Jcp 5.3) (CII), 
135.7/135.5 (CH), 135.1 (CH), 134.0 (CH), 132.1 (CH), 123.3 (CH), 118.4 (d, 1Jcp 
189.5)/117.9 (d, 'Jcp 189.8) (CH), 118.0/117.7 (C), 111.8 (C), 111.2 (C), 86.0 (d, 3Jcp 
4.3) (CH), 85.4 (d, 3Jcp 15.1) (CH), 84.6 (CH), 76.9 (d, 2Jcp 6.1)/76.8 (d, 2Jcp 6.1) 
(CH), 76.0 (d, 2Jcp 15.3)/75.5 (d, 2Jcp 16.8) (CH), 66.2 (d, 2JJP 5.5) (CHZ), 63.3 (Cl12), 
58.2 (d, 2Jcp 13.5)/58.0 (d, 2Jcp 13.3) (CH2), 43.4 (d, 2Jcp 2.6)/43.3 (d, 2Jcp 3.1) (CI! ), 
39.6 (CH2), 38.4/38.4 (CH2), 37.7 (CH2), 29.9 (d, 3Jcp 5.9) (CH2), 28.1 (CH2), 26.0 
(CH3), 24.6 (d, 3Jcp 6.2)/24.6 (d, 3Jcp 7.0) (CH3), 22.9 (C12), 20.5 (d, 3Jcp 3.0)/20.5 (d, 
3Jcp 3.1) (CH2), 18.4 (C), 12.6 (CH3), 12.5 (CH3), 
-5.3 (CH3), -5.4 (Cl13); &p(161.98 
MHz) 150.6,150.5,19.1,18.8. 
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5'-O-(tert-Butyldimethylsilyl)-3'-O-(tert-butyldiphenylsilyl)pentylphthalimide 
phosphonate T*T dimer 18a. 
A 2.5 mL screw cap reaction vial was charged with 
Pd(OAc)2 (0.004 g, 0.018 mmol, 0.13 eq), dppf (0.016 
g, 0.029 mmol, 0.21 eq), H-phosphonate 17(fast) (0.090 
g, 0.142 mmol, 1.01 eq), vinylbromide 7 (0.078 g, 
0.141 mmol), propylene oxide (0.20 mL, 2.86 mmol, 20.3 eq) and THE (1.6 mL). The 
stirring mixture was heated at 70°C (oil bath temperature) for 15 h. After cooling to 
RT, the volatiles were removed in vacuo and the residue was purified by column 
chromatography (AcOEt: Petrol: MeOH 1: 1: 0.1) to give 18a (0.078 g, 50%) as a pale 
yellow waxy solid; (Found: (HRMS ES) M++Na 1132.4279, C56H72N5O13PSi2Na 
requires 1132.4301); [a]D 
-9.8 (c 0.9 in CHC13); v,,, ax/cm"1 3666,3392,2931,2859, 
1772,1713,1693,1589,1462,1396,1366,1322,1294,1276,1113,1066,999,976, 
886,838; SH(400 MHz) 9.24 (1H, br s), 9.16 (1H, br s), 7.81 (2H, dd, J 5.4,3.1), 7.69 
(2H, dd, J 5.4,3.1), 7.63 (4H, m), 7.50-7.36 (7H, m), 6.96 (1H, m), 6.52 (1H, ddd, J 
22.3,17.1,4.9), 6.40 (1H, dd, J 7.9,5.9), 6.36 (1H, dd, J 9.1,5.3), 5.70 (1H, ddd, J 
19.7,17.1,1.6), 4.99 (1H, app t, J 6.6), 4.47 (1H, m), 4.28 (1H, m), 4.14 (1H, d, i 1.0), 
3.94 (2H, m), 3.85 (1H, dd, J 11.7,2.0), 3.79 (1H, dd, J 11.5,2.1), 3.66 (2H, t, J 7.2), 
2.49 (1H, dd, J 13.5,4.9), 2.28 (1H, ddd, J 13.7,6.0,2.9), 2.10 (1H, ddd, J 14.3,9.1, 
5.7), 1.97 (1H, m), 1.92 (3H, d, J0.9), 1.86 (3H, d, J0.8), 1.68 (4H, m), 1.39 (2H, m), 
1.09 (9H, s), 0.91 (9H, s), 0.11 (3H, s), 0.10 (3H, s); 8c(100 MHz) 168.4 (C), 163.8 
(C), 163.6 (C), 150.4 (C), 150.4 (C), 148.7 (d, 2Jcp 5.4) (CH), 135.8 (CH), 135.7 (CH), 
135.3 (CH), 135.0 (CH), 134.0 (CH), 132.7 (CH), 132.1 (C), 130.4 (CH), 130.3 (CH), 
128.1 (CH), 128.1 (CH), 123.2 (CH), 118.2 (d, 'Jcp 189.7) (CH), 111.6 (C), 111.2 (C), 
86.2 (d, 3Jcp 22.5) (CH), 86.0 (d, 3Jcp 4.6) (CH), 85.7 (CH), 84.6 (CH), 77.1 (d, 2Jcp 
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5.0) (CH), 76.1 (CH), 66.1 (d, 2Jcp 5.6) (CH2), 63.3 (CH2), 39.7 (d, 3Jcp 3.2) (CH2), 
39.1 (CH2), 37.6 (CH2), 29.9 (d, 3JJp 6.3) (CH2), 28.1 (CH2), 26.9 (CH3), 26.0 (CH3), 
22.8 (CH2), 19.1 (C), 18.3 (C), 12.6 (CH3), 12.6 (CH3), 
-5.3 (CH3), -5.4 (CH3); 
6p(161.98 MHz) 18.8. 
5'-O-(tert-Butyldimethylsilyl)-3'-O-(tert-butyldiphenylsilyl)pentylphthalimide 
phosphonate T*T dimer 18b. 
°A2.5 mL screw cap reaction vial was charged with 
TBSO 
-iNH Pd OAc 2 0.006 , 0.027 mmol, 0.10 e q), f (0.029 °()(S ýÜ, pp 
ö 
,° 
,Hg, 0.052 mmol, 0.20 eq), H-phosphonate 17(slow) 
V0 N-ý 
° 0.182 0.287 mmol, 1.08 e q), lbromide ( g, Y7 (0.147 TBDPSd 
g, 0.266 mmol), propylene oxide (0.36 mL, 5.14 mmol, 19.3 eq) and THE (2.0 mL). 
The stirring mixture was heated at 70°C (oil bath temperature) for 13 h. After cooling 
to RT, the volatiles were removed in vacuo and the residue was purified by column 
chromatography (AcOEt: Petrol: MeOH 1: 1: 0.1) to give 18b (0.195 g, 67%) as a white 
waxy solid; (Found: (HRMS ES) M++Na 1132.4296, CS6H72NSO13PSi2Na requires 
1132.4301); [a]D +8.9 (c 1.0 in CHC13); v,,, ax/cm 1 3385,2932,2851,1711,1692, 
Z NH 
- No ( )2 ( g, dpp
--o pHg, 
ýN 
- 
vin y  Ö 
1463,1397,1363,1265,1076,1000,908; 611(400 MHz) 9.28 (1H, br s), 9.11 (111, br 
s), 7.83 (2H, dd, J 5.4,3.1), 7.70 (2H, dd, J 5.4,3.1), 7.63 (4H, m), 7.47-7.36 (711, m), 
7.01 (1H, m), 6.55 (1H, ddd, J22.0,17.1,4.7), 6.32 (1H, dd, J 5.0,3.4), 6.30 (1H, dd, 
J6.2,2.9), 5.73 (IH, ddd, J 19.2,17.1,1.7), 4.97 (IH, app t, J6.3), 4.48 (IH, m), 4.32 
(1H, m), 4.20 (1H, d, J 1.0), 3.93 (2H, dd, J 12.6,6.0), 3.89 (1H, dd, J 11.4,1.8), 3.84 
(IH, dd, J 11.4,2.0), 3.67 (2H, t, J 7.2), 2.43 (IH, dd, J 13.7,5.2), 2.24 (IH, ddd, J 
13.6,6.1,3.0), 2.09 (1H, m), 2.01 (IH, m), 1.91 (3H, d, J0.8), 1.87 (3H, d, J0.9), 1.69 
(4H, m), 1.39 (2H, m), 1.08 (9H, s), 0.91 (9H, s), 0.11 (3H, s), 0.10 (311, s); Sß(100 
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MHz) 168.4 (C), 163.7 (C), 150.4 (C), 150.3 (C), 148.9 (d, 2Jcp 5.9) (CH), 136.1 (CH), 
135.8 (CH), 135.7 (CH), 135.0 (CH), 134.0 (CH), 132.8 (C), 132.1 (C), 130.3 (CH), 
130.3 (CH), 128.1 (CH), 128.0 (CH), 123.3 (CH), 118.2 (d, 'Jcp 188.6) (CH), 111.5 
(C), 111.3 (C), 86.5 (CH), 86.3 (d, 3Jcp 18.1) (CH), 86.2 (CH), 84.7 (CH), 77.1 (d, 2JJp 
5.0) (CH), 76.1 (CH), 65.8 (d, 2Jcp 5.5) (CH2), 63.4 (CH2), 39.4 (d, 3Jcp 2.9) (CH2)9 
38.9 (CH2), 37.6 (CH2), 29.9 (d, 3Jcp 6.3) (CH2), 28.1 (CH2), 26.9 (CH3), 26.0 (CH3)1 
22.8 (CH2), 19.1 (C), 18.4 (C), 12.6 (CH3), 
-5.3 (CH3), -5.4 (CH3); 3p(161.98 MHz) 
18.9. 
5'-O-(tert-Butyldimethylsilyl)-3'-O-(tert-butyldiphenylsilyl)-pentylamin o-N- 
(Fmoc-Arg(Pbt))phosphonate T*T dimer 25a. 
Hydrazine monohydrate (0.11 mL, 2.27 mmol, 32.0 
eq) was added dropwise to a stirring solution of the 
dimer 18a (0.079 g, 0.071 mmol) in MeOH (3.8 
mL) at RT under an argon atmosphere and the 
mixture was stirred for 2 h. DCM (30 mL) was added and this organic layer was 
washed with water (20 mL) and brine (20 mL), then was dried and the volatiles 
removed in vacuo to give the crude free amine 23a (0.065 g) as a colourless waxy 
solid; (Found: (HRMS ES) M++H 980.4415, C48H71N5O11PSi2 requires 980.4426); 
[a]D +5.3 (c 1.3 in CHC13); v.,, /cm 1 3392,2931,2859,1692,1463,1363,1277, 
1067,999,975,908,837; SH(400 MHz) 7.65 (4H, m), 7.40 (7H, m), 6.93 (1H, m), 
6.55 (1H, m), 6.40-6.20 (2H, m), 5.72 (1H, m), 4.99 (1H, m), 4.49 (111, m), 4.45-4.32 
(1H, m), 4.18 (1H, m), 4.11-3.74 (6H, m), 2.53 (IH, m), 2.25 (1H, m), 2.19-1.98 (211, 
m), 1.90 (3H, s), 1.86 (3H, s), 1.65 (4H, m), 1.39 (2H, m), 1.09 (9H, s), 0.91 (911, s), 
0.10 (3H, s), 0.10 (3H, s). 
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EDC (0.017 g, 0.089 mmol, 1.44 eq), BtOH (0.015 g, 0.111 mmol, 1.79 eq) and NMM 
(0.011 mL, 0.100 mmol, 1.61 eq) were added to a solution of Fmoc-Arg(Pbf)-OH 
(0.043 g, 0.066 mmol, 1.06 eq) in DCM (2.8 mL) at 0°C under an argon atmosphere. 
The mixture was stirred for 20 min and a solution of the crude free amine 23a (0.061 
g, 0.062 mmol) in DCM (1.5 mL) was added dropwise. The mixture was stirred for 15 
h allowing it to warm to RT. Water (5 mL) was then added and the mixture stirred for 
5 min. The mixture was diluted with DCM (30 mL) and washed with water (10 mL). 
The layers were separated and the aqueous layer extracted with DCM (2 x 20 mL). 
The combined organic phase was dried, the solvent removed in vacuo and the residue 
purified by column chromatography (AcOEt: MeOH 20: 1) to give 25a (0.052 g, 49%) 
as a white solid, mp 129-131°C; (Found: (MS FAB) M++Na 1633, M++H 1611 
C82H109N9O17PSSi2Na requires 1633, C82H110N9O17PSSi2 requires 1611); viaX/cml 
3350,2931,2859,1892,1558,1462,1363,1292,1105,998,974,907,838,641; 
54400 MHz) 9.71 (2H, m), 7.73 (2H, d, J 7.5), 7.67-7.56 (6H, m), 7.51-7.31 (9H, m), 
7.25 (2H, m), 6.96 (1H, m), 6.55 (1H, ddd, J 22.2,17.0,4.5), 6.34 (2H, m), 6.23 (2H, 
m), 5.76 (1H, m), 4.99 (1H, m), 4.47 (1H, m), 4.35 (4H, m), 4.17 (IH, t, J 7.0), 4.12 
(1H, br s), 3.99-3.71 (4H, m), 3.33 (2H, m), 3.16 (2H, m), 2.91 (2H, s), 2.58 (3H, s), 
2.54 (1H, m), 2.51 (3H, s), 2.22 (2H, m), 2.12 (1H, m), 2.06 (3H, s), 1.91 (3H, d, J 
0.9), 1.86 (3H, br s), 1.84 (2H, m), 1.66 (2H, m), 1.53 (4H, m), 1.43 (6H, s), 1.39 (211, 
m), 1.09 (9H, s), 0.91 (9H, s), 0.10 (6H, m); 8ß(100 MHz) 172.4 (C), 164.0 (C), 163.4 
(C), 158.8 (C), 156.7/156.6 (C), 150.8 (C), 150.3 (C), 149.1 (d, 2Jcp 5.9) (CH), 143.9 
(C), 143.8 (C), 141.3 (C), 138.4 (CH), 137.0 (CH), 135.8 (CH), 135.7 (CH), 135.0 
(CH), 133.1 (C), 133.0 (C), 132.7 (C), 132.7 (C), 132.4 (C), 130.4 (CH), 130.3 (CH), 
130.3 (CH), 128.1 (CH), 128.1 (CH), 128.0 (CH), 127.7 (CH), 127.1 (CH), 125.3 
(CH), 124.7 (C), 120.0 (CH), 117.8 (d, 'Jcp 188.6) (CH), 117.5 (C), 111.5 (C), 111.2 
143 
Synthesis of backbone modified DNA using transition metal catalysis Experimental 
(C), 86.5 (d, 3JJp 22.2) (CH), 86.4 (C), 86.2 (d, 3Jcp 3.1) (CH), 86.1/86.0 (CH), 
84.8/84.8 (CH), 77.1 (d, 2Jcp 7.5) (CH), 76.3 (CH), 67.2 (CH2), 66.5 (d, 2Jcp 3.2) 
(CH2), 63.4 (CH2), 54.1 (CH), 47.2 (CH), 43.3 (CH2), 40.1 (CH2), 39.9 (CH2), 39.4 
(CH2), 39.1 (CH2), 38.5 (CH2), 29.8 (CH2), 28.6 (CH3), 26.9 (CH3), 26.0 (CH3), 23.0 
(CH2)) 19.4 (CH3), 19.1 (CH3), 18.4 (CH3), 18.0 (CH3), 12.6 (CH3), 12.6 (CH3), 
-5.3 
(CH3), 
-5.4 (CH3); 8p(161.98 MHz) 19.0. 
5'-O-(tert-B u tyldi methyls ilyl)-3'-O-(tert-b utyld iph enyls ilyl)-p en ty lamin o-N- 
(Fmoc-Arg(Pbf))ph osphon ate T*T dimer 25b. 
Fmoc-Arg(Pbf) H 
Hydrazine monohydrate (0.19 mL, 3.92 mmol, 31.9 
eq) was added dropwise to a stirring solution of the 
dimer 18b (0.136 g, 0.123 mmol) in MeOH (6.5 mL) 
at RT under an argon atmosphere and the mixture 
was stirred for 2 h. DCM (50 mL) was added and this organic layer was washed with 
water (50 mL) and brine (50 mL), then was dried and the volatiles removed in vacuo 
to give the crude free amine 23b (0.130 g) as a colourless waxy solid; (Found: (HRMS 
ES) M++H 980.4459, C48H71N5O11PSi2 requires 980.4426); [aID +2.5 (c 1.3 in 
CHC13); v,,, aX/cm-1 3391,2932,2859,1692,1463,1363,1276,1112,1076,999,975, 
908,838; 6H(400 MHz) 7.62 (4H, m), 7.42 (7H, m), 6.98 (1H, m), 6.54 (111, m), 6.41- 
6.22 (2H, m), 5.73 (IH, m), 4.96 (1H, m), 4.46 (1H, m), 4.32 (1H, m), 4.20 (311, m), 
4.01-3.80 (4H, m), 2.40 (1H, m), 2.22 (1H, m), 2.20-1.97 (211, m), 1.89 (3H, s), 1.85 
(3H, s), 1.64 (4H, m), 1.57-1.32 (2H, m), 1.08 (9H, s), 0.90 (911, s), 0.11 (311, s), 0.10 
(3H, s). 
EDC (0.031 g, 0.162 mmol, 1.41 eq), BtOH (0.018 g, 0.133 mmol, 1.16 cq) and NMM 
(0.020 mL, 0.182 mmol, 1.58 eq) were added to a solution of Fmoc-Arg(Pbf)-011 
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(0.076 g, 0.118 mmol, 1.03 eq) in DCM (5.4 mL) at 0°C under an argon atmosphere. 
The mixture was stirred for 20 min and a solution of the crude free amine 23b (0.113 
g, 0.115 mmol) in DCM (2.7 mL) was added dropwise. The mixture was stirred for 15 
h allowing it to warm to RT. Water (10 mL) was then added and the mixture stirred 
for 5 min. The mixture was diluted with DCM (50 mL) and washed with water (20 
mL). The layers were separated and the aqueous layer extracted with DCM (2 x 30 
mL). The combined organic phase was dried, the solvent removed in vacuo and the 
residue purified by column chromatography (AcOEt: MeOH 20: 1) to give 25b (0.115 
g, 67%) as a white solid, mp 133-135°C; (Found: (MS FAB) M++Na 1633, M++H 
1611 C82H109N9O17PSSi2Na requires 1633, C82H110N9O17PSSi2 requires 1611); 
v, T, a. /cm't 3696,3605,3349,2932,2859,1892,1602,1562,1462,1362,1291,1105, 
998,975,908,837; SH(400 MHz) 9.65 (1H, br s), 9.20 (1H, br s), 7.74 (2H, d, J 7.5), 
7.66-7.55 (6H, m), 7.49-7.33 (9H, m), 7.26 (2H, m), 6.99 (1H, m), 6.51 (1H, m), 6.36 
(1H, m), 6.29 (1H, dd, J 8.8,5.3), 6.10 (2H, m), 5.70 (1H, ddd, J20.2,16.7,1.4), 4.92 
(1 H, m), 4.46 (1 H, m), 4.35 (4H, m), 4.22 (1 H, br s), 4.17 (1 H, t, J 7.0), 3.91 (2H, m), 
3.84 (2H, m), 3.40 (2H, m), 3.14 (2H, m), 2.92 (2H, s), 2.60 (3H, s), 2.52 (3H, s), 2.39 
(2H, m), 2.24 (1H, m), 2.07 (3H, s), 2.06 (1H, m), 1.91 (3H, d, J0.8), 1.87 (3H, br s), 
1.86 (2H, m), 1.64 (2H, m), 1.53 (4H, m), 1.43 (6H, s), 1.38 (2H, m), 1.08 (9H, s), 
0.91 (9H, s), 0.11 (3H, s), 0.10 (3H, s); Sß(100 MHz) 172.3 (C), 164.1 (C), 163.6 (C), 
158.8 (C), 156.6 (C), 150.6 (C), 150.2 (C), 149.1 (d, 2Jcp 5.8) (CH), 144.0 (C), 143.8 
(C), 141.3 (C), 138.4 (CH), 137.8 (CH), 135.8 (CH), 135.8 (CH), 135.1 (CH), 133.1 
(C), 132.9 (C), 132.8 (C), 132.4 (C), 130.4 (CH), 130.3 (CH), 128.1 (CH), 128.1 (CH), 
127.8 (CH), 127.1 (CH), 125.3 (CH), 124.7 (C), 120.0 (CH), 117.6 (d, 'J p 187.8) 
(CH), 117.5 (C), 111.6 (C), 111.1 (C), 86.8 (CH), 86.7 (d, 3Jcp 20.9) (CH), 86.4 (C), 
86.2 (CH), 86.2 (CH), 84.9 (CH), 77.4 (CH), 76.4 (CH), 67.1 (CH2), 66.4 (d, 2Jcp 4.6) 
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(CH2), 63.5 (CH2), 53.9 (CH), 47.2 (CH), 43.3 (CH2), 39.9 (d, 3Jcp 4.4) (CH2), 39.3 
(CH2), 39.2 (CH2), 38.4 (CH2), 29.8 (CH2), 28.7 (CH3), 26.9 (CH3), 26.0 (CH3), 22.8 
(CH2)9 19.4 (CH3), 19.1 (CH3), 18.4 (CH3), 18.1 (CH3), 12.6 (CH3), 12.6 (CH3)9 
-5.3 
(CH3), 
-5.4 (CH3); ßp(161.98 MHz) 18.8; m/z (FAB) 1633 (M+Na, 6), 1611 (M++H, 
10), 441 (12), 419 (17), 189 (16), 179 (12), 176 (25), 155 (14), 154 (52), 149 (37), 138 
(17), 137 (33), 136 (48), 135 (11), 127 (14), 109 (14), 107 (24), 105 (15), 97 (23), 95 
(28), 93 (12), 91 (25), 89 (21), 85 (35), 83 (35), 81 (33), 79 (17), 77 (26), 73 (29), 71 
(64), 70 (10), 69 (64), 67 (33), 57 (100), 55 (85). 
General procedure A for the preparation of alkynylphosphonates: 
A mixture of Pd(OAc)2 (0.2 eq) and dppf (0.4 eq) or TFP (0.8 eq) in DMF was 
flushed with dry nitrogen and stirred at RT for 20 min. A solution of the 1,1- 
dibromoalkene (1.0 eq) in DMF, propylene oxide (3.0 eq) and dimethyl phosphite (2.0 
eq) were added and the mixture was heated at 80°C (bath temperature) for 14 h and 
then cooled to RT. Removal of the solvent in vacuo left a residue which was purified 
by column chromatography. 
[(2R, 3S, 5R)-3-(tert-Butyl-diphenyl-silanyloxy)-5-(5-methyl-2,4-dioxo-3,4- 
dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2ylethynyl]-phosphonic acid 
dimethyl ester 59. 
I° 
According to the general procedure A using Pd(OAc)2 (7 mg, 
o H 
3O-P NH 
0.033 mmol) and dppf (36 mg, 0.066 mmol) in DMF (1 mL), \\ 
N- 
0 dibromo 6 (104 mg, 0.165 mmol) in DMF (1.5 mL), propylenc 
TBDPS6 
oxide (35 µL, 0.50 mmol) and dimethyl phosphite (30 itL, 0.33 
mmol) and after purification by column chromatography (AcOEt: Pentane 3: 1) was 
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obtained 59 (60 mg, 63%) as a white solid, mp 98-100°C; (Found (HRMS FAB) 
M++H, 583.2047, C29H3607N2PSi requires 583.2029); vmax/cm'1 3391,2955,2933, 
2205,1694,1463,1394,1365,1309,1294,1278,1105,1053,980,955,908,843; 
ö 1(400 MHz) 7.64 (4H, m), 7.44 (6H, m), 6.62 (1H, dd, J8.4,5.6), 4.64 (1H, d, J 3.2), 
4.57 (1H, d, J 4.2), 3.74 (3H, d, J 12.2), 3.73 (3H, d, J 12.2), 2.46 (1H, m), 2.05 (1H) 
m), 1.92 (3H, s), 1.09 (9H, s); 5ß(100 MHz, C6D6) 164.0 (C), 150.9 (C), 136.0 (CH), 
135.9 (CH), 134.8 (CH), 132.8 (C), 130.6 (CH), 128.4 (CH), 128.4 (CH), 111.8 (C), 
96.3 (d, 2Jcp 48.2) (C), 86.9 (CH), 78.5 (CH), 78.4 (d, 1Jcp 290.8) (C), 76.4 (d, 3JJp 
3.4) (CH), 52.9 (d, 2Jcp 5.2) (CH3), 39.8 (CH2), 26.8 (3 x CH3), 19.1 (C), 12.7 (CH3); 
ßp(161.98 MHz) 
-3.8; m/z (FAB) 583 (M++H, 33), 525 (21), 307 (20), 201 (45), 176 
(32), 165 (27), 155 (28), 154 (94), 147 (22), 138 (32), 137 (68), 136 (100), 135 (30), 
121 (23), 107 (39), 105 (27), 95 (23), 91 (47), 90 (34), 89 (36), 81 (33), 79 (25), 78 
(20), 77 (47), 73 (66), 69 (39), 67 (25), 57 (46), 55 (48). 
Cyclohexylethynyl-phosphonic acid dimethyl ester 28 and ((Z)-1-Bromo-2- 
cyclohexyl-vinyl)-phosphonic acid dimethyl ester 27. 
0 
According to the general procedure A using 
P-OMe 0 OMe P-OMe Pd(OAc)2 (21 mg, 0.094 mmol) and dppf (102 
OMe Br 
28 27 
mg, 0.184 mmol) in DMF (1 mL), dibromo 26 
(123 mg, 0.459 mmol) in DMF (1.5 mL), propylene oxide (96 µL 1.37 mmol) and 
dimethyl phosphite (84 µl, 0.92 mmol) and after purification by column 
chromatography (AcOEt: Petroleum ether 1: 1) was obtained 28 (88 mg, 89%) as an 
orange oil. When Pd(OAc)2 (16 mg, 0.071 mmol) and dppf (90 mg, 0.162 mmol) in 
THE (1 mL), dibromo 26 (85 mg, 0.32 mmol) in THE (1 mL), propylene oxide (70 µL, 
1.00 mmol) and dimethyl phosphite (60 µL, 
. 
0.65 mmol) were used and after 
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purification by column chromatography (AcOEt: Petroleum ether 1: 1) was obtained 28 
(28 mg, 41%) and 27 (23 mg, 24%) as a separable mixture. 
Data for 28: (Found: C, 55.8; H 7.8. C1oH1703P requires C, 55.6; H, 7.9); (Found 
(HRMS FAB) M++H, 217.1012, CQoH1803P requires 217.0994); v 
,, 
/cm-12937,2857, 
2201,1450,1272,1048,842; 54400 MHz) 3.78 (6H, d, J 12.3), 2.54 (1H, m), 1.83 
(2H, m), 1.71 (2H, m), 1.52 (3H, m), 1.32 (3H, m); 8C(100 MHz, C6D6) 106.2 (d, 2JJp 
51.0) (C), 70.9 (d, 1Jcp 300.5) (C), 52.5 (d, 2Jcp 5.3) (CH3), 31.4 (CH2), 29.3 (d, 3JCp 
3.7) (CH), 25.6 (CH2), 24.5 (CH2); 8p(161.98 MHz) 
-1.3 ; m/z (FAB) 218 (M++H, 
11), 217 (100), 154 (8), 136 (10). 
Data for 27: (Found (HRMS FAB) M++H, 297.0264, C1oH19O3PBr requires 
297.0255); vma. /cm-1 2932,2854,1614,1450,1278,1042,952,881,838; 811(400 
MHz) 6.99 (IH, dd, J 14.4,9.0), 3.77 (6H, d, J 11.2), 2.61 (1H, m), 1.74 (5H, m), 
1.35-1.20 (5H, m); ßc(67.5 MHz) 155.9 (d, 2Jci 13.3) (CH), 108.5 (d, 1Jcp 208.6) (C), 
53.3 (d, 2Jcp 4.9) (CH3), 41.2 (d, 3Jcp 12.1) (CH), 30.7 (CH2), 25.6 (CH2), 25.2 (CH2); 
5p(161.98 MHz) 4.0; m/z (FAB) 297 (M++H, 100), 154 (52), 138 (21), 137 (49), 136 
(40). 
Acetic acid 4-(dimethoxy-phosphorylethynyl)-phenyl ester 44. 
According to the general procedure A using Pd(OAc)2 (13 mg, 0 
POCH3 
0.05 8 mmol) and dppf (61 mg, 0.110 mmol) in DMF (1 mL), 
Ac0 ý dibromo 37 (87 mg, 0.27 mmol) in DMF (1.5 mL), propylenc 
oxide (57 µL, 0.81 mmol) and dimethyl phosphite (50 µL, 0.55 mmol) and after 
purification by column chromatography (AcOEt: Petroleum ether 3: 1) was obtained 44 
(50 mg, 68%) as a colourless oily solid; (Found (HRMS ES) M++H, 269.0563, 
C12H1405P requires 269.0579); vmaX/cm'1 2955,2854,2190,1766,1600,1504,1371, 
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1275,1165,1046,911,871,843; 8H(400 MHz) 7.59 (2H, d, J 8.6), 7.13 (2H, d, J 8.6), 
3.85 (6H, d, J 12.3), 2.31 (3H, s); 6c(67.5 MHz) 168.7 (C), 152.4 (C), 134.0 (d, 4Jcp 
2.4) (CH), 122.1 (CH), 116.7 (d, 3Jcp 4.9) (C), 99.0 (d, 2Jcp 52.2) (C), 77.0 (d, 1Jcp 
300.8) (C), 53.4 (d, 2Jcp 6.0) (CH3), 21.0 (CH3); 5p(161.98 MHz, CDC13) 
-1.7; m/z 
(ES) 269 (M++H, 100), 254 (2). 
(4-Methoxy-phenylethynyl)-phosphonic acid dimethyl ester 43. 
According to the general procedure A using Pd(OAc)2 (20 0 11 POCH33 
mg, 0.089 mmol) and dppf (93 mg, 0.17 mmol) in DMF (1 
H3CO ' mL), dibromo 36 (122 mg, 0.418 mmol) in DMF (1.5 mL), 
propylene oxide (88 µL, 1.26 mmol) and dimethyl phosphite (77 µL, 0.84 mmol) and 
after purification by column chromatography (AcOEt: Petroleum ether 1: 1) was 
obtained 43 (73 mg, 73%) as an orange oil; (Found (HRMS EI) M+, 240.0558, 
C11H1304P requires 240.0552); v,,,, /cm-1 2954,2184,1605,1459,1298,1276,1050, 
872; 8H(400 MHz) 7.48 (2H, d, J 8.8), 6.85 (2H, d, J 8.8), 3.81 (6H, d, J 12.3), 3.80 
(3H, s); ßc(100 MHz, C6D6) 161.6 (C), 134.6 (CH), 114.4 (CH), 111.7 (d, 3Jcp 5.7) 
(C), 99.8 (d, 2Jcp 53.1) (C), 78.0 (d, 'Jcp 299.9) (C), 54.8 (CH3), 52.7 (d, 2Jcp 5.3) 
(CH3); 6p(161.98 MHz) 
-0.9; m/z (EI) 240 (M+, 9), 181 (13), 169 (9), 132 (59), 131 
(52), 119 (23), 117 (13), 100 (11), 93 (14), 89 (21), 69 (100), 63 (10), 62 (10), 47 (13). 
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(4-Nitro-phenylethynyl)-phosphonic acid dimethyl ester 46 and ((E)-2-(4- 
nitrophenyl-vinyl)-phosphonic acid dimethyl ester 49. 
0 
11 0 POCH3 
\ P- 3 OCH3 
02N 
Iý 
02N\ý 
OIý3 
46 49 
According to the general procedure A 
using Pd(OAc)2 (18 mg, 0.080 mmol) 
and dppf (82 mg, 0.15 mmol) in DMF (1 
mL), dibromo 39 (113 mg, 0.368 mmol) in DMF (1.5 mL), propylene oxide (77 µL, 
1.10 mmol) and dimethyl phosphite (68 µL, 0.74 mmol) and after purification by 
column chromatography (AcOEt: Petroleum ether 1: 1) a separable mixture of 46 (25 
mg, 27%) and 49 (10 mg, 11%) was obtained. When Pd(OAc)2 (16 mg, 0.071 mmol) 
and TFP (65 mg, 0.28 mmol) in DMF (1 mL), dibromo 39 (102 mg, 0.332 mmol) in 
DMF (1.5 mL), propylene oxide (70 µL, 1.00 mmol) and dimethyl phosphite (61 µL, 
0.67 mmol) were used and after purification by column chromatography 
(AcOEt: Petroleum ether 1: 1) acetylene 46 (26 mg, 31%) was obtained. 
Data for 46: Orange crystals, mp 97-99°C; (Found: C, 47.2; H, 3.9; N, 5.4. 
C1OH10NO5P requires C, 47.1; H 4.0; N 5.5); (Found (HRMS EI) M++H, 256.0385, 
C10H1105NP requires 256.0375); vrax/cm'1 2955,2195,1596,1528,1488,1458,1348, 
1277,1047,871,857; 8d400 MHz) 8.28 (2H, d, J 8.7), 7.76 (2H, d, J 8.7), 3.90 (6H, 
d, J 12.3); 5ß(100 MHz) 148.8 (C), 133.7 (CH), 126.0 (d, 3Jcp 5.8) (C), 123.9 (CH), 
96.4 (d, 2Jcp 52.4) (C), 81.7 (d, 1Jcp 297.9) (C), 53.8 (d, 2Jcp 5.6) (CH3); SP(161.98 
MHz) 
-3.0; m/z (EI) 256 (M++H, 36), 154 (100), 138 (35), 137 (64), 136 (72), 107 
(25), 89 (21). 
Data for 49: White crystals, mp 102-104°C; (Found (HRMS EI) M+, 257.0457, 
C1OH12O5NP requires 257.0453); v X/cm 1 2955,2852,1596,1347,1110,1059, 
1042,987,859,838; 6H(400 MHz) 8.27 (2H, d, J 8.8), 7.66 (2H, d, J 8.8), 7.57 (1H, 
dd, J 22.3,17.6), 6.41 (1H, dd, J 17.5,16.4), 3.82 (6H, d, J 11.1); 8C(100 MHz) 149.0 
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(C), 146.9 (d, 2Jcp 6.5) (CH), 141.0 (d, 3Jcp 23.7) (C), 128.8 (CH), 124.6 (CH), 118.3 
(d, 'Jcp 191.2) (CH), 53.1 (d, 2Jcp 5.6) (CH3); äp(161.98 MHz) 21.3; m/z (EI) 257 
(M+, 30), 240 (17), 181 (11), 119 (19), 117 (11), 116 (100), 110 (48). 
Phenylethynyl-phosphonic acid dimethyl ester 45. 
According to the general procedure A using Pd(OAc)2 (19 mg, 
0 
11 P'OCg 3 0.085 mmol) and dppf (94 mg, 0.17 mmol) in DMF (1 mL), 
crýý 
dibromo 38 (113 mg, 0.431 mmol) in DMF (1.5 mL), propylene 
oxide (91 µL, 1.30 mmol) and dimethyl phosphite (79 µL, 0.86 mmol) and after 
purification by column chromatography (AcOEt: Petroleum ether 1: 1) 45 (57 mg, 
63%) was obtained as an orange oily solid; (Found (HRMS EI) M+, 210.0452, 
C10H1103P requires 210.0446); v,,.,, /cml 2995,2955,2854,2189,1490,1459,1273, 
1047,865,842,645; SH(400 MHz) 7.57 (2H, m), 7.45 (1H, m), 7.37 (2H, m), 3.85 
(6H, d, J 12.3); 8C(100 MHz, C6D6) 132.7 (d, 4JCp 1.4) (CH), 130.6 (CH), 128.6 (CH), 
119.8 (d, 3Jcp 5.3) (C), 99.1 (d, 2Jcp 52.0) (C), 79.0 (d, 'Jcp 296.9) (C), 52.8 (d, 2Jcp 
5.2) (CH3); 3p(161.98 MHz) 
-1.6; m/z (EI) 210 (M+, 13), 115 (47), 102 (100), 89 (27), 
86 (20), 84 (31), 63 (19), 49 (92), 47 (25). 
Furan-2-ylethynyl-phosphonic acid dimethyl ester 48 and ((Z)-1-Bromo-2-furyl- 
vinyl)-phosphonic acid dimethyl ester 52. 
According to the general procedure A using 0 
POCH3 3o P0 OCH Pd(OAc)2 (20 mg, 0.089 mmol) and df 96 mg, OCH33 PP ( 
or 
48 52 0.17 mmol) in DMF (1 mL), dibromo 41 (110 
mg, 0.437 mmol) in DMF (1.5 mL), propylene oxide (92 µL, 1.31 mmol) and 
dimethyl phosphite (80 µL, 0.87 mmol) and after purification by column 
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chromatography (AcOEt: Petroleum ether 1: 1) a mixture of 48 (22 mg, 18%) as a 
colourless oil and 52 (22 mg, 25%) as a colourless oil was obtained. When Pd(OAc)2 
(20 mg, 0.089 mmol) and TFP (82 mg, 0.35 mmol) in DMF (1 mL), dibromo 41 (112 
mg, 0.444 mmol) in DMF (1.5 mL), propylene oxide (94 µL, 1.34 mmol) and 
dimethyl phosphite (82 µL, 0.89 mmol) were used and after purification by column 
chromatography (AcOEt: Petroleum ether 1: 1) acetylene 48 (53 mg, 60%) was 
obtained. 
Data for 48: (Found (HRMS EI) M+, 200.0240, C8H904P requires 200.0239); v,,, a,, /cm 
1 2955,2854,2192,2177,1613,1458,1277,1048,964,942,886,842; 6u(400 MHz) 
7.47 (1H, d, J 1.6), 6.89 (1H, dd, J 3.5,0.5), 6.44 (1H, dd, J 3.5,1.8), 3.83 (6H, d, J 
12.3); Sc(100 MHz, C6D6) 145.8 (CH), 134.9 (d, 3Jcp 6.4) (C), 120.2 (CH), 111.3 
(CH), 88.5 (d, 2Jcp 52.5) (C), 84.3 (d, 1Jcp 292.6) (C), 52.8 (d, 2Jcp 5.3) (CH3); 
äp(161.98 MHz) 
-2.2; m/z (EI) 200 (M+, 14), 92 (100), 77 (12), 64 (16), 63 (37), 62 
(11), 51 (19), 47 (28). 
Data for 52: (Found (HRMS EI) M+, 279.9506, C8H10O4PBr requires 279.9500); 
vnu,, /cm'' 2986,2955,2853,1614,1574,1462,1266,1148,1045,964,947,908,886, 
839; SH(400 MHz) 8.00 (1H, d, J 16.3), 7.61 (1H, d, J 0.7), 7.37 (1H, d, J 3.5), 6.57 
(1H, dd, J 3.5,1.7), 3.83 (6H, d, J 11.4); ßc(67.5 MHz) 149.9 (d, 3Jcp 22.9) (C), 144.8 
(CH), 133.9 (d, 2Jcp 18.9) (CH), 116.4 (CH), 112.3 (CH), 104.3 (d, 'Jcp 211.7) (C), 
53.6 (d, 2Jcp 4.8) (CH3); SP(161.98 MHz) 15.0; m/z (EI) 280 (M+, 4), 282 (4), 280 (4), 
202 (8), 201 (100), 109 (45), 92 (23), 84 (6), 79 (12), 65 (9), 64 (18), 63 (40), 62 (12), 
52 (10), 51(8), 49 (12), 47 (28). 
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Non-1-ynyl-phosphonic acid dimethyl ester 42. 
According to the general procedure A using Pd(OAc)2 (18 mg, 
19 P OCHS 0.080 mmol) and dppf (81 mg, 0.15 mmol) in DMF (1 mL), OCH3 
n-hept 
dibromo 35 (105 mg, 0.370 mmol) in DMF (1.5 mL), propylene 
oxide (78 µL, 1.11 mmol) and dimethyl phosphite (68 µL, 0.74 mmol) and after 
purification by column chromatography (AcOEt: Petroleum ether 1: 1) 42 (57 mg, 
66%) was obtained as a pale yellow oil; (Found (HRMS ES) M++H, 233.1320, 
C11H2203P requires 233.1307); vna,, /cm 1 2954,2930,2856,2207,1459,1273,1048, 
841; 6H(400 MHz) 3.76 (6H, d, J 12.2), 2.34 (2H, m), 1.58 (2H, m), 1.38 (2H, m), 1.26 
(4H, m), 0.88 (3H, m); ßc(100 MHz) 104.3 (d, 2Jcp 53.2) (C), 69.1 (d, 'J p 305.6) (C), 
53.2 (d, 2Jcp 5.4) (CH3), 31.6 (CH2), 28.8 (CH2), 28.6 (CH2), 27.4 (CH2), 22.6 (CH2), 
19.2 (CH2), 14.1 (CH3); 6p(161.98 MHz) 
-1.7. 
(4-Cyano-phenylethynyl)-phosphonic acid dimethyl ester 47. 
According to the general procedure A using Pd(OAc)2 (19 mg, 
O 
11 POCH 3 0.085 mmol) and TFP (78 mg, 0.34 mmol) in DMF (1 mL), 
NC ' dibromo 40 (120 mg, 0.418 mmol) in DMF (1.5 mL), propylene 
oxide (88 µL, 1.26 mmol) and dimethyl phosphite (77 µl, 0.84 mmol) and after 
purification by column chromatography (AcOEt: Pentane 1: 1) 47 (28 mg, 29%) was 
obtained as white crystals, mp 77-79°C; (Found: C, 55.8; H, 4.6; N, 5.6. C11H10NO3P 
requires C, 56.2; H 4.3; N 6.0); (Found (HRMS FAB) M++H, 236.0488, CIIH1103NP 
requires 236.0477); v,,, a,, /cm'1 2955,2854,2232,2193,1605,1501,1459,1275,1046, 
865,841; 56(400 MHz) 7.68 (4H, s), 3.87 (6H, d, J 12.2); 8ß(100 MHz) 133.2 (CH), 
132.3 (CH), 124.1 (d, 3Jcp 5.5) (C), 117.8 (C), 114.4 (C), 96.8 (d, 2JJp 52.2) (C), 81.0 
(d, 1Jcp 298.1) (C) 53.7 (d, 2Jcp 5.4) (CH3); äp(161.98 MHz) 
-2.8; m/z (FAB) 236 
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(M++H, 30), 154 (30), 137 (18), 136 (24), 109 (16), 107 (13), 97 (26), 95 (35), 93 (15), 
91 (18), 85 (25), 83 (42), 81 (48), 79 (16), 77 (12), 71 (48), 69 (80), 67 (33), 57 (100), 
55 (92). 
5'-O-(tert-Butyldimethylsilyl)-3'-O-(tent-butyldiphenylsilyl)methyl-alkynyl 
phosphonate T*T dimer 63. 
According to the general procedure A using Pd(OAc)2 (11 mg, 
0.049 mmol) and dppf (54 mg, 0.097 mmol) in DMF (0.6 mL), 
dibromo 6 (144 mg, 0.370 mmol) in DMF (1.5 mL), propylene 
oxide (48 µL, 0.69 mmol) and H-phosphonate 62 (137 mg, 
0.316 mmol) and after purification by column chromatography 
(AcOEt: Pentane: MeOH 10: 10: 1) 63 (105 mg, 51%) was 
obtained as a separable 1: 1 mixture of diastereoisomers. 
Data for the least polar diastereomer: Yellow solid, mp 112-114°C; (Found (HRMS 
ES) M++H, 907.3546, C44H6oO11N4PSi2 requires 907.3535); vmax/cni 1 3392,2954, 
2932,2896,2859,2205,1693,1463,1363,1293,1275,1128,1104,1049,1006,979, 
956,908,838,611; 611(400 MHz) 8.46 (1H, br s), 8.28 (1H, br s), 7.64 (4H, m), 7.46 
(6H, m), 6.56 (1H, dd, J 8.5,5.8), 6.32 (1H, dd, J 9.2,5.1), 5.05 (1H, app t, J 6.9), 
4.68(1H, d, J3.4), 4.61 (1H, d, J4.6), 4.22(1H, d, J1.2), 3.88(1H, dd, J11.5,2.1), 
3.83 (IH, dd, J 11.5,2.1), 3.74 (3H, d, J 12.5), 2.48 (2H, m), 2.16-2.01 (2H, m), 1.93 
(6H, s), 1.10 (9H, s), 0.92 (9H, s), 0.12 (3H, s), 0.11 (3H, s); Sß(100 MHz) 163.4 (C), 
150.2 (C), 135.9 (CH), 135.3 (CH), 134.8 (CH), 132.5 (C), 132.3 (C), 130.8 (CH), 
128.5 (CH), 111.9 (C), 111.4 (C), 96.8 (d, 2Jcp 50.0) (C), 87.2 (CH), 86.0 (CH), 84.6 
(CH), 78.8 (CH), 78.2 (CH), (doublet corresponding to the quaternary Ca to P was 
occluded by the CDC13), 76.4 (CH), 63.2 (CH2), 53.7 (d, 2Jcp 5.4) (CH3), 40.2 (CH2), 
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39.2 (CH2), 27.0 (3x CH3), 26.0 (3 x CH3), 19.1 (C), 18.4 (C), 12.7 (CH3), 12.6 (CH3), 
-5.3 (CH3)9 -5.4 (CH3); 6p(161.98 MHz) -5.8; m/z (ES) 907 (M++H, 43), 569 (8), 340 
(8), 339 (100). 
Data for the most polar diastereomer: Yellow solid, mp 108-110°C; (Found (HRMS 
ES) M++H, 907.3521, C44H60O11N4PSi2 requires 907.3535); Vmax/cm'1 3390,2954, 
2932,2204,1692,1463,1363,1274,1105,1063,979; 6H(400 MHz) 8.57 (1H, br s), 
7.65 (4H, m), 7.45 (6H, m), 6.58 (1H, dd, J 8.6,5.7), 6.36 (1H, dd, J 9.2,5.2), 5.06 
(1H, appt, J7.1), 4.66(1H, d, J3.3), 4.60(1H, d, J4.5), 4.23(1H, d, 1.3), 3.86(1H, 
dd, J 11.5,2.1), 3.80 (1H, dd, J 11.5,2.1), 3.77 (3H, d, J 12.5), 2.48 (2H, m), 2.16- 
2.01 (2H, m), 1.93 (6H, s), 1.10 (9H, s), 0.91 (9H, s), 0.12 (3H, s), 0.11 (3H, s); 
8ß(100 MHz) 163.6 (C), 163.4 (C) 150.3 (C), 135.7 (CH), 135.0 (CH), 134.8 (CH), 
132.4 (C), 132.2 (C), 130.5 (CH), 128.2 (CH), 112.0 (C), 111.4 (C), 96.6 (d, 2Jcp 50.3) 
(C), 87.0 (CH), 85.7 (d, 3Jcp 5.0) (CH), 84.7 (CH), 78.6 (d, 3Jcp 4.9) (CH), 78.1 (CH), 
(doublet corresponding to the quaternary Ca to P was occluded by the CDC13), 76.3 
(CH), 63.2 (CH2), 53.8 (d, 2Jcp 5.5) (CH3), 40.1 (CH2), 39.4 (CH2), 26.8 (3 x CH3), 
26.0 (3 x CH3), 19.1 (C), 18.4 (C), 12.6 (CH3), 12.6 (CH3), 
-5.3 (CH3), 
-5.4 (CH3); 
8p(161.98 MHz) 
-5.8; m/z (ES) 907 (M++H, 33), 709 (10), 576 (20), 339 (38). 
Alkene 65. 
A solution of n-butyllithium in hexanes (2.22 M, 2.70 mL, 5.99 mmol) 0 
N-{"" was dropwise added to a stirred suspension of meth l-triph =1, 
,ºoY enyl- 
TBDPSä phosphonium bromide in THE (10 mL) at 0°C under nitrogen. This 
mixture was stirred for 20 min and then added dropwise to a stirred solution of 
aldehyde 5 (715 mg, 1.49 mmol) in THE (10 mL) at 0°C under nitrogen. The mixture 
was then stirred for 18 h during which it was allowed to come to RT. Sat ammonium 
chloride solution (25 mL) was added and the mixture was stirred for a further 5 min. 
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The mixture was extracted with DCM (3 x 40 mL), the combined organic phase was 
dried, the solvent removed in vacuo and the residue was purified by column 
chromatography to give 65 (174 mg, 24%) as a pale yellow solid, mp 54-56°C; (Found 
(HRMS FAB) M++H, 477.2183, C27H3304N2Si requires 477.2210); vmax/cm'1 3392, 
2932,2860,1690,1464,1363,1272,1113,1053,997,895; 6H(400 MHz) 8.08 (1H, br 
s), 7.67-7.63 (4H, m), 7.49-7.38 (6H, m), 7.05 (1H, q, J 1.2), 6.37 (1H, dd, J 7.4,6.0), 
5.58 (1H, ddd, J 17.0,10.5,6.4), 5.15 (2H, m), 4.38 (1H, m), 4.20 (1H, dt, J 6.5,3.4), 
2.35 (1H, ddd, J 13.6,6.0,3.4), 1.88 (3H, d, J 1.2), 1.82 (1H, ddd, J 13.6,7.5,6.1), 
1.10 (9H, s); Sß(100 MHz) 164.1 (C), 150.5 (C), 135.8 (CH), 135.7 (CH), 135.1 (CH), 
135.0 (CH), 133.0 (C), 133.0 (C), 130.0 (CH), 127.8 (CH), 127.8 (CH), 117.9 (CH2), 
111.0 (C), 87.4 (CH), 85.0 (CH), 76.2 (CH), 40.0 (CH2), 26.8 (3 x CH3), 19.0 (C), 
12.6 (CH3); m/i (FAB) 477 (M++H, 8), 267 (14), 247 (21), 239 (9), 199 (28), 197 
(43), 189 (9), 183 (17), 181 (9), 176 (11), 165 (10), 155 (15), 154 (20), 149 (13), 145 
(14), 139 (12), 137 (36), 136 (39), 135 (100), 127 (66), 121 (15), 117 (11), 115 (13), 
107 (18), 105 (17), 95 (38), 93 (12), 91 (31), 90 (11), 89 (28), 83 (16), 81 (22), 79 
(15), 77 (24), 75 (20), 73 (50), 71 (15), 69 (35), 67 (22), 57 (40), 55 (47). 
Vinylphosphonate 66. 
A 4.5 mL screw cap reaction vial was charged with Pd(OAc)2 (0.019 g, /NH 
TBSO A! N-ý(o 0.085 mmol, 0.1 eq), Ph3P (0.044 g, 0.17 mmol, 0.2 eq), H- 
. 
M. 0-P1' phosphonate 62 (0.367 g, 0.846 mmol), vinylbromide (3.5 mL, 1.0 M 
soln in THF, 4.1 eq) and propylene oxide (1.0 mL, 14.3 mmol, 17 eq). The mixture 
was heated at 70°C (oil bath temperature) for 15 h. After cooling to RT, the volatiles 
were removed in vacuo and the residue was purified by column chromatography 
(AcOEt: MeOH 3: 1) to give 66 (0.248 g, 64%) as a 1: 1 mixture of diastereoisomers. 
NH 
rssoýN-ý(o  l,  ,  4  l,  , 
öo 
Me0-P1' honate  7  l), i l romide  ,  
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(Data given for the mixture of diastereomers): (Found (HRMS ES) M++Na, 483.1669, 
C19H33O7NZPSiNa requires 483.1692); vra,, /cm'13393,3186,2954,2930,2858,1694, 
1463,1400,1385,1363,1322,1292,1277,1128,1065,1050,1005,977,892,838; 
811(400 MHz) 9.96 (IH, br s), 7.42 (1H, s), 6.38-6.20 (2.5H, m), 6.13-5.95 (1.5H, m), 
5.02 (0.5H, app t, J 6.5), 4.96 (0.5H, app t, J 6.5), 4.22 (0.5H, m), 4.17 (0.5H, m), 3.84 
(0.5H, m), 3.82 (0.5H, m), 3.70 (1.5H, d, J 11.2), 3.69 (1.5H, d, J 11.3), 2.50 (0.5H, 
dd, J 13.8,6.3), 2.43 (0.5H, dd, J 13.8,6.3), 2.12-2.01 (1H, m), 1.86 (3H, s), 0.87 (9H, 
s), 0.07 (6H, s); Sc(100 MHz) 164.1 (C), 150.6 (C), 137.0/136.8 (CH2)2 134.9 (CH), 
124.9 (d, 'Jcp 185.2)/124.8 (d, 1Jcp 184.2)(CH), 111.1 (C), 86.0 (d, 2Jcp 3.2)/85.9 (d, 
2Jcp 4.8)(CH), 84.4 (CH), 76.6/76.5 (CH), 52.6 (d, 2Jcp 5.5)/52.4 (d, 2Jcp 5.5)(CH3), 
39.5 (d, 3Jcp 3.3)/39.4 (d, 3Jcp 4.6)(CH2), 25.8 (CH3), 18.2 (C), 12.4 (CH3), 
-5.5/-5.6 
(CH3); äp(161.98 MHz) 20.4/20.1. 
Vinylphosphonate 74. 
oA4.5 mL screw cap reaction vial was charged with Pd(OAc)2 
H 
TssoN- ' (0.025 g, 0.111 mmol, 0.1 eq), Ph3P (0.098 g, 0.374 mmol, 0.4 eq), 
10 H-phosphonate 73 (0.440 g, 0.930 mmol), vinylbromide (3.5 mL, 
1.0 M soln in THF, 4.1 eq) and propylene oxide (1.0 mL, 14.3 mmol, 15 eq) and the 
mixture was heated at 70°C (oil bath temperature) for 15 h. After cooling to RT, the 
volatiles were removed in vacuo and the residue was purified by column 
chromatography (AcOEt) to give 74 (0.115 g, 25%) as a 1: 1 mixture of diastereomers. 
(Data for the mixture of diastereomers): (Found (HRMS ES) M++Na, 522.1829, 
C21H34O7N3PSiNa requires 522.1801); vaX/cm 13393,3187,2954,2931,2859,2257, 
1694,1462,1400,1385,1363,1322,1292,1126,1075,978,905,838; 611(400 MHz) 
9.25 (0.5H, br s), 9.19 (0.5H, br s), 7.47 (0.5H, q, J 1.3), 7.46 (0.5H, q, J 1.2), 6.49- 
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6.30 (2.5H, m), 6.26-6.04 (1.5H, m), 5.08 (0.5H, app t, J 5.9), 5.05 (0.5H, app t, J 7.6), 
4.30-4.17 (3H, m), 3.90 (1H, m), 3.89 (0.5H, dd, J 11.5,2.3), 3.84 (0.5H, dd, J 11.5, 
2.3), 2.81-2.74 (2H, m), 2.58 (0.5H, dd, J 13.9,5.2), 2.50 (0.5H, dd, J 13.8,6.4), 2.20- 
2.06 (1H, m), 1.91 (3H, d, J 1.2), 0.92 (9H, s), 0.12 (3H, s), 0.12 (3H, s); Sc(100 MHz) 
163.8 (C), 150.5/150.5 (C), 138.1/137.7 (CH2), 134.9 (CH), 124.7 (d, 'Jcp 
185.5)/124.6 (d, 'Jcp 184.5)(CH), 116.5/116.5 (C), 111.3 (C), 86.0 (d, 2Jcp 3.5)/85.9 
(d, 2Jcp 5.2)(CH), 84.6 (CH), 77.3/77.2 (CH), 63.3/63.2 (CH2), 60.5 (d, 2Jcp 4.7)/60.3 
(d, 2Jcp 4.2)(CH2), 39.6 (d, 3Jcp 3.8)/39.5 (d, 3Jcp 4.6)(CH2), 26.0 (CH3), 20.0 (2 x 
CH2), 18.4 (C), 12.6 (CH3), 
-5.4/-5.4 (CH3); &p(161.98 MHz) 19.8/19.6. 
Alkenes 70 and 71. 
QTBDPS A flask charged with alkene 65 (0.046 g, 0.097 
Qý O 
/ý/ NH // NH mmol), catalyst 68 (0.017 g, 0.020 mmol) and 
HN 
-I \\O 
- 
N-0 
0 
O 
TBDPSO 1ßDPSß dichloromethane (2.0 mL) under an argon 
To 71 
atmosphere was heated at reflux for 14 h. The solvent was removed under reduced 
pressure and the residue purified by column chromatography (hexane: AcOEt 1: 1) to 
give 70 (0.032 g, 72%, E: Z 5: 1) and 71(0.010 g, 20%). 
Data for 70: (Found (HRMS FAB) M++Na, 947.3930, C52H60O8N4P2Si2Na requires 
947.3847); v., /cm" 3392,2932,2895,2859,1694,1463,1364,1276,1112,1051, 
990,908; Trans-isomer: 5H(400 MHz) 8.42 (2H, br s), 7.65-7.57 (8H, m), 7.45-7.30 
(12H, m), 6.92 (2H, br s), 6.32 (2H, app t, J 6.8), 5.19 (2H, dd, J 3.6,1.6), 4.18 (2H, 
m), 4.06 (2H, m), 2.32 (2H, ddd, J 13.3,5.8,2.6), 1.85 (2H, m), 1.81 (6H, s), 1.08 
(18H, s); 8ß(100 MHz) 163.3 (C), 150.1 (C), 135.9 (CH), 135.8 (CH), 135.2 (CH), 
133.1 (C), 133.0 (C), 130.3 (CH), 130.2 (CH), 128.0 (CH), 127.9 (CH), 111.3 (C), 
86.4 (CH), 85.3 (CH), 76.4 (CH), 39.6 (CH2), 26.9 (CH3), 19.1 (C), 12.6 (CH3); Cis- 
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isomer (where signals not occluded by the trans-isomer): SH(400 MHz) 6.13 (2H, app 
t, J 6.5), 5.44 (2H, m), 4.69 (2H, m). m/z (FAB) 947 (M++Na, 3), 307 (14), 199 (19), 
197 (39), 183 (12), 154 (14), 137 (22), 136 (28), 135 (100), 127 (13), 121 (11), 107 
(10), 91 (11), 77 (12), 73 (12), 69 (11), 57 (14), 55 (13). 
Data for 71: (Found (HRMS ES) M++Na, 575.2323, C33H36O4N2SiNa requires 
575.2342); vex/cm"13391,2932,2859,1690,1464,1364,1273,1112,1052,965,908; 
611(400 MHz) 8.29 (1H, br s), 7.66-7.63 (4H, m), 7.48-7.22 (11H, m), 7.07 (1H, s), 
6.45 (1H, d, J 15.8), 6.38 (1H, app t, J6.6), 5.84 (1H, dd, J 15.8,7.0), 4.51 (1H, ddd, J 
6.6,4.0,1.0), 4.27 (1H, m), 2.44 (1H, ddd, J 13.6,6.6,4.0), 1.93 (1H, app dt, J 13.6, 
6.7), 1.87 (3H, s), 1.10 (9H, s); 6(100 MHz) 163.4 (C), 150.1 (C), 136.0 (CH), 135.8 
(CH), 135.3 (CH), 133.5 (CH), 133.1 (C), 133.1 (C), 130.2 (CH), 130,2 (CH), 128.7 
(CH), 128.3 (CH), 128.0 (CH), 128.0 (CH), 126.6 (CH), 125.8 (CH), 111.1 (C), 87.4 
(CH), 85.0 (CH), 76.4 (CH), 40.2 (CH2), 26.9 (CH3), 19.1 (C), 12.7 (CH3). 
Vinylphosphonate 72. 
oA flask charged with the vinylphosphonate 66 (0.046 g, 0.100 mmol), 
TBSO N-ýNH catalyst 68 (0.016 g, 0.019 mmol) and dichloromethane (2.0 
ý. lo 
under an argon atmosphere was heated at reflux for 14 h. The Me0'P 
ib solvent was removed under reduced pressure and the residue was 
purified by column chromatography (AcOEt) to give 72 (0.011 g, 20%) as a 1: 1 
mixture of separable diastereomers. 
Data for the least polar diastereomer: (Found (HRMS FAB) M+H+, 537.2158, 
C25H38O7N2PSi requires 537.2186); vma,, /cm'1 3392,2954,2930,2858,1689,1615, 
1463,1353,1322,1275,1128,1049,1007,976,908,863,836; SH(400 MHz) 8.16 
(1H, br s), 7.61-7.41 (7H, m), 6.41 (1H, dd, J 9.1,5.3), 6.25 (1H, dd, J 17.7,17.7), 
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5.06 (1H, app t, J6.3), 4.33 (1H, m), 3.93 (2H, m), 3.78 (3H, d, J 11.3), 2.51 (1H, ddd, 
J 14.0,5.7,0.9), 2.12 (1H, m), 1.92 (3H, s), 0.92 (9H, s), 0.13 (3H, s), 0.13 (3H, s); 
Sc(100 MHz) 163.4 (C), 150.4 (CH, d, 2Jcp 7.0), 150.1 (C), 135.1 (CH), 134.5 (C, d, 
3JJp 23.8), 130.8 (CH), 129.1 (CH), 128.0 (CH), 112.6 (CH, d, 'Jcp 192.2), 111.2 (C), 
86.3 (CH, d, 2. J p 3.6), 84.7 (CH), 76.6 (CH), 63.3 (CH2)9 52.6 (CH3, d, 2Jcp 5.6), 39.7 
(CH2, d, 3Jcp 4.8), 26.0 (CH3), 18.4 (CH3), 12.6 (CH3), 
-5.3 (CH3), -5.4 (CH3); 
8p(161.98 MHz) 22.9. m/z (FAB) 537 (M++H, 21), 339 (29), 307 (13), 199 (57), 176 
(15), 155 (29), 154 (83), 139 (18), 138 (33), 137 (58), 136 (68), 127 (13), 123 (11), 
121 (17), 120 (13), 119 (15), 115 (15), 111 (14), 109 (23), 107 (38), 106 (11), 105 
(20), 97 (34), 95 (43), 93 (20), 91 (33), 90 (18), 89 (52), 85 (24), 83 (47), 81 (86), 79 
(28), 78 (14), 77 (32), 75 (12), 73 (64), 71 (46), 69 (82), 67 (46), 65 (13), 57 (97), 55 
(100), 53 (13). 
Data for the most polar diastereomer: (Found (HRMS ES) M++Na, 559.2022, 
C25H37O7N2PSiNa requires 559.2005); Vmax/cm'13392,2954,2930,2858,1689,1616, 
1463,1362,1322,1276,1128,1064,1048,1006,976,908,864,838; SH(400 MHz) 
8.28 (1H, br s), 7.71-7.40 (7H, m), 6.41 (1H, dd, J 8.9,5.3), 6.25 (1H, dd, J 18.0, 
18.0), 5.11 (1H, m), 4.26 (1H, m), 3.89 (1H, dd, J 11.4,2.1), 3.85 (1H, dd, J 11.4,2.1), 
3.79 (3H, d, J 11.2), 2.60 (1H, ddd, J 14.3,5.3,1.0), 2.16 (1H, m), 1.93 (3H, s), 0.91 
(9H, s), 0.11 (3H, s), 0.11 (3H, s); 6c(100 MHz) 163.4 (C), 150.2 (C), 150.1 (CH, d, 
2Jcp 7.7), 135.1 (CH), 134.5 (C, d, 3Jcp 23.3), 130.8 (CH), 129.1 (CH), 127.9 (CH), 
112.7 (CH, d, 'Jcp 193.4), 111.2 (C), 86.2 (CH), 84.7 (CH), 76.7 (CH), 63.3 (CH2), 
52.7 (CH3, d, 2Jcp 5.2), 39.8 (CH2, d, 3Jcp 3.8), 26.0 (CH3), 18.4 (CH3), 12.6 (CH3), 
- 
5.3 (CH3), 
-5.4 (CH3); 6p(161.98 MHz) 22.7. 
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Vinyl iodide 78. 
A solution of iodoborabicyclononane in hexanes (1.0 M, 2.0 mL, 
`h(o 2.0 mmol) was added dropwise to a stirred solution of 77 (352 mg, 
1.55 mmol) in DCM (11 mL) at 
-10°C under nitrogen. The reaction was stirred at this 
temperature for Ih and acetic acid (1.35 mL, 23.6 mmol) was dropwise added. The 
mixture was stirred for a further 1h and a mixture of 3M NaOH (16 mL) and 30% 
hydrogen peroxide (2.7 mL) was added dropwise and then the mixture stirred for 30 
min. DCM (100 mL) and water (80 mL) were added and after vigorous stirring for 5 
min the layers were separated and the aqueous layer extracted with DCM (2 x 50 mL). 
The combined organic phase was washed with sat sodium thiosulphate (150 mL), 
water (100 mL), sat sodium hydrogencarbonate (100 mL) and brine (100 mL), then 
dried and the solvent removed in vacuo to give a residue which was purified by 
column chromatography (AcOEt: Petroleum ether 1: 4) to afford 78 (179 mg, 33%) as a 
pale yellow solid, mp 40-42°C; (Found: (HRMS FAB) M++H 356.0139, C14H15N02I 
requires 356.0148); Vmax/em 1 3307,2940,2862,1770,1713,1616,1468,1397,1374, 
1153,1088,1039,898; SH(400 MHz) 7.83 (2H, dd, J 5.7,3.1), 7.71 (2H, dd, J 5.5, 
2.9), 6.03 (1H, app q, J 1.4), 5.68 (1H, m), 3.69 (2H, t, J 7.0), 2.42 (2H, dt J 7.3,0.9), 
1.67 (2H, m), 1.56 (2H, m); 8ß(100 MHz) 168.4 (C), 134.0 (CH), 132.1 (C), 126.0 
(CH2), 123.2 (CH), 111.6 (C), 44.5 (CH2), 37.6 (CH2), 27.0 (CH2), 26.2 (CH2); m/z 
(FAB) 356 (M++H, 3), 154 (15), 136 (10), 123 (13), 111(17), 109 (25), 107 (14), 97 
(35), 95 (42), 93 (17), 91 (21), 85 (27), 83 (49), 81 (50), 79 (21), 77 (15), 73 (16), 71 
(46), 69 (77), 67 (42), 57 (90), 55 (100). 
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Vinyl phosphonate 79. 
oA mixture of Pd(OAc)2 (8 mg, 0.04 mmol) and dppf (31 mg, ýHINH 
0.056 mmol) in THE 0.5 mL) was flushed with nitrogen and 
-jýO i( dry TBSO ff 
stirred at RT for 20 min. A solution of 78 (90 mg, 0.25 mmol) and 
°.., o Me0P 
H-phosphonate 62 (180 mg, 0.41 mmol) in THE (2.5 mL) and 
ON 
o propylene oxide (53 µL, 0.76 mmol) were added and the mixture 
was heated at 70°C (bath temperature) for 15 h and then cooled to 
RT. Removal of the solvent in vacuo left a residue which was purified by column 
chromatography (AcOEt) to give 79 (73 mg, 43%) as a 1: 1 mixture of diastereomers. 
(Data given for the mixture of diastereomers): (Found (HRMS ES) M++Na, 684.2442, 
C31H44O9N3PSiNa requires 684.2482); Vmax/cm" 3668,3392,2952,2931,2859,1770, 
1713,1463,1397,1363,1322,1292,1276,1128,1065,1046,1004,974,908,838; 
54400 MHz) 8.51 (0.5H, br s), 8.47 (0.5H, br s), 7.84 (2H, dd, J 5.4,3.1), 7.71 (2H, 
dd, J 5.5,3.0), 7.49 (0.5H, d, J 1.2), 7.48 (0.5H, d, J 1.2), 6.37 (0.5H, dd, J 8.9,5.3), 
6.36 (0.5H, dd, J 9.1,5.2), 6.10 (1H, dd, J 23.5,11.3), 5.91 (0.5H, dd, J 10.1,1.3), 
5.79 (0.5H, dd, J 10.1,1.3), 5.05 (0.5H, app t, J 4.8), 4.98 (0.5H, app t, J 6.5), 4.28 
(0.5H, m), 4.22 (0.5H, m), 3.89 (1H, t, J 2.1), 3.89 (0.5H, dd, J 11.6,2.0), 3.84 (0.5H, 
dd, J 11.6,2.1), 3.72 (2H, obscured t), 3.72 (1.5H, d, J 11.2), 3.71 (1.5H, d, J 11.1), 
2.55 (0.5H, ddd, J 14.3,6.3,1.0), 2.46 (0.5H, ddd, J 12.9,5.4,1.1), 2.30 (2H, app 
quint, J 7.7), 2.11 (1H, m), 1.92 (3H, s), 1.70 (2H, m), 1.60 (2H, m), 0.92 (4.5H, s), 
0.92 (4.5H, s), 0.13 (1.5H, s), 0.12 (1.5H, s), 0.12 (1.5H, s), 0.12 (1.5H, s); 8c(100 
MHz) 168.5 (C), 163.6 (C), 150.2 (C), 137.9 (d, 'Jcp 171.8)1137.8 (d, 1Jcp 170.9) (C), 
135.1 (CH), 134.0 (CH), 132.2 (C), 131.2 (d, 2Jcp 9.7)/130.8 (d, 2Jcp 9.7) (CH2), 123.3 
(CH), 111.2/111.2 (C), 86.3 (d, 3Jcp 3.2)/86.0 (d, 3JcP 4.8) (CH), 84.7/84.6 (CH), 76.7 
(d, 2Jcp 5.8)/76.6 (d, 2J p 5.2) (CH), 63.3/63.2 (CH2), 52.7 (d, 2Jcp 5.5)/52.5 (d, 2Jcp 
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5.6) (CH3), 39.8 (d, 3Jcp 3.3)/39.5 (d, 3J p 4.9) (CH2), 37.6 (CH2), 31.7 (d, 2Jcp 
3.7)/31.5 (d, 2Jcp 3.6) (CH2), 28.1 (CH2), 26.0 (3 x CH3), 25.2 (d, 3Jcp 4.7)/25.2 (d, 
3. Jcp 4.5) (CH2), 18.4 (C), 12.6 (CH3), 
-5.3 (CH3), -5.4 (CH3); ßp(161.98 MHz) 
22.7/22.4. 
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Attempts to determine the stereochemistry at phosphorus of H-phosphonates 
17(fast) and 17(slow) 
Growing crystal experiments using slow evaporation or diffusion methods have been 
performed with the solvent systems presented in Table 3 and the compounds shown in 
Figure 25. 
Method 
Slow evaporation Diffusion 
Compound Solvent Solvent in Solvent out 
18 DCM, AcOEt DCM Ether 
21 DCM, AcOEt DCM Ether 
83 DCM / MeOH, * 
'PrOH 
DCM / MeOH* Ether 
84 DCM / MeOH* 
'PrOH 
DCM / MeOH* Ether 
25 DCM, AcOEt DCM 
AcOEt 
Ether 
Ether 
85 DCM, AcOEt 
- - 
86 DCM, AcOEt 
- - 
Table 3. Different conditions used in the growing crystal experiments. * Mixture of solvents. 
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Figure 25. Different compounds used in the growing crystal experiments. 
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